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SYNOPSIS 
The present thesis comprises three main parts: one theoretical and two experimental. 
The first part, composed of two chapters, will introduce the clinical and 
neuropathological features underlying parkinsonian disorders, namely in Parkinson’s 
disease (PD) as well as in atypical parkinsonisms — multiple system atrophy (MSA) and 
progressive supranuclear palsy (PSP) (Chapter 1). In this regard, PD and MSA are defined 
as synucleinopathies due to the presence of synuclein aggregates; while PSP that is 
characterized by tau protein accumulations, is part of tauopathies. Further, Chapter 2 will 
provide an overview of the cognitive dysfunctions characterizing these disorders, as well as 
evidence on the biological mechanisms and structural changes underlying cognitive 
alterations. 
The second and third parts are composed by studies I conducted during my doctoral 
research. 
Namely, in Chapter 3, I report results of my studies on cognitive screening instruments 
most sensitive in detecting cognitive alterations in atypical parkinsonisms compared to PD.  
In the following study, I characterized the progression of cognitive decline in these 
disorders (Chapter 4). 
Finally, I investigated with magnetic resonance imaging the structural changes 
underlying cognitive alterations in PD (Chapter 5), and MSA (Chapter 6). I conclude this 
thesis by discussing the clinical consequences of these cognitive and imaging findings 
(Chapter 7).  
 
 
PART I - Theoretical background 
 
Chapter 1: Parkinsonian disorders 
Parkinsonian disorders are characterized by different underlying pathologies.  In PD and 
MSA there are synuclein aggregates respectively in dopamine neurons or in glial cells, while 
PSP patients present pathological aggregation of the tau-protein, resulting in neurofibrillary 
tangles formation (Daniel, de Bruin, & Lees, 1995; Dickson, 1999). 
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Clinical manifestations depend by the characteristics of protein aggregation and by the 
extent of disease spread to cortical and subcortical regions (Halliday, Holton, Revesz, & 
Dickson, 2011). 
Thus, the present chapter will overview the underlying pathology of PD, MSA and PSP; 
and it will describe the different clinical features; and lastly review the most recent 
diagnostic criteria (e.g., Gelb, Oliver, & Gilman, 1999; Gilman et al., 2008; Höglinger et al., 
2017). 
 
Chapter 2: Cognitive features and their underlying mechanisms in parkinsonian 
disorders 
 
Non-motor symptoms represent a crucial part of the parkinsonian disorders spectrum; 
and cognitive dysfunctions, including dementia, are probably the most relevant, since they 
affect functional independence of patients, increase caregiver burden as well as wield a 
considerable socioeconomic impact (Keranen et al., 2003; McCrone et al., 2011; Vossius, 
Larsen, Janvin, & Aarsland, 2011). 
The first part of this chapter will provide an overview on cognitive dysfunctions in PD, 
MSA, and PSP. Moreover, the clinical criteria for the diagnosis of mild cognitive 
impairment and dementia in PD will be reported (Dubois et al., 2007; Emre et al., 2007; 
Litvan et al., 2012), while so far there are no available criteria to assess cognitive syndromes 
in PSP and MSA. 
Lastly, the second and third parts of this chapter will review the evidence on biological 
mechanisms and structural changes underlying cognitive alterations in these disorders. 
 
 
PART II - Studies on cognitive manifestations in parkinsonian disorders 
 
Chapter 3: Montreal Cognitive Assessment and Mini-Mental State Examination 
performance in progressive supranuclear palsy, multiple system atrophy and 
Parkinson’s disease 
 
Synopsis 
 
  11 
There is general agreement that cognitive dysfunctions are common in PD as well as in 
other parkinsonian disorders (Aarsland et al., 2017; Brown et al., 2010; Gerstenecker, 
2017).  
Brief screening cognitive scales can be adopted in routine care, to support the clinician 
in the diagnostic process (Marras, Troster, Kulisevsky, & Stebbins, 2014). The Mini-Mental 
State Examination (MMSE) is the most widely used (Folstein, Folstein, & McHugh, 1975) 
although MMSE is relatively insensitive in detecting cognitive deficits in parkinsonian 
disorders mainly because it does not investigate the fronto-executive domain (Hoops et al., 
2009). Conversely, the Montreal Cognitive Assessment (MoCA), another brief cognitive 
screening tool widely used with PD patients (Nasreddine et al., 2005), showed high 
sensitivity and specificity in the assessment of cognitive dysfunctions in PD (Gill, 
Freshman, Blender, & Ravina, 2008; Hoops et al., 2009; Zadikoff et al., 2008), as well as 
also in several neurodegenerative conditions such as Alzheimer’s disease, dementia with 
Lewy bodies (DLB) and Huntington’s disease (Biundo et al., 2016b; Hoops et al., 2009; 
Nasreddine et al., 2005; Videnovic et al., 2010). However, MoCA has been poorly 
investigated in atypical parkinsonisms — especially in PSP and MSA (Kawahara et al., 
2015). 
Thus, this study’s main aim was to determine if MoCA is more sensitive than the 
commonly used MMSE in detecting cognitive abnormalities in patients with probable PSP 
and MSA, compared to PD.  
In this multicenter study across three European institutions, MMSE and MoCA were 
administered to 130 patients: 35 MSA, 30 PSP and 65 age, and education and sex matched-
PD. 
We assessed between-group differences for MMSE, MoCA, and their subitems and 
calculated receiver operating characteristic (ROC) curves.  
Our results show that the mean MMSE is higher than the mean MoCA score in each 
patient group: MSA (27.7 ± 2.4 vs. 22.9 ± 3.0, p<0.0001), PSP (26.0 ± 2.9 vs. 18.2 ± 3.9, 
p<0.0001), and PD (27.3 ± 2.0 vs. 22.3 ± 3.5, p<0.0001). Furthermore, MoCA total score 
as well as its letter fluency subitem differentiates PSP from MSA and PD with high 
specificity and moderate sensitivity. Namely, a cut-off score of seven words or less per 
minute would support a diagnosis of PSP (PSP vs. PD: 86% specificity, 70% sensitivity; 
PSP vs. MSA: 71% specificity, 70% sensitivity). On the contrary, MMSE presented a ceiling 
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effect for most subitems, except for the ‘bisecting pentagons’, with PSP performing worse 
than MSA and PD patients.  
These findings suggest that PSP and MSA, similar to PD patients, may present normal 
performance on MMSE, but reduced performance on MoCA. To conclude, MoCA is more 
sensitive than MMSE in detecting cognitive dysfunctions in atypical parkinsonisms, and 
together with its verbal fluency subitem can be a valuable test to support PSP diagnosis. 
 
 
Chapter 4: Prospective assessment of cognitive dysfunctions in parkinsonian 
disorders 
 
 Clinical and research evidence suggests cognitive impairments in parkinsonian disorders 
are progressive. However, there are only a few longitudinal studies in the literature that 
investigated cognitive progression in PSP and MSA compared to PD (Dubois & Pillon, 
2005; Rittman et al., 2013; Soliveri, 2000). In addition, previous studies are based on brief 
cognitive screening scales or on neuropsychological assessments that do not extensively 
investigate the full spectrum of cognitive abilities across the five cognitive domains (i.e., 
attention/working-memory, executive, memory, visuospatial and language).  
Furthermore, even though clinical criteria for mild cognitive impairment (MCI) and 
dementia in PD have been formulated (Dubois et al., 2007; Litvan et al., 2012), it remains 
to be investigated whether similar criteria might be applied also for atypical parkinsonisms 
(Marras et al., 2014).  
Based on these observations, the aims of the present study were to: i) assess the severity 
of cognitive dysfunctions in PSP and MSA patients using PD-criteria for cognitive statuses 
(i.e., MCI or dementia); ii) investigate the sensitivity of two widely used cognitive screening 
instruments, the MMSE and MoCA, in differentiating MSA, PSP and PD global cognitive 
profile; iii) characterize the progression of cognitive decline on the five cognitive domains 
and behavioral features; and to compare the 15-month follow-up profile across the 
parkinsonian diseases. 
Our sample included 18 patients with PSP, 12 MSA; and 30 PD patients, matched for 
age, education and sex. They were evaluated at baseline and at a mean of 15-month follow-
up. 
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Demographic and clinical variables were collected. From the cognitive standpoint, I 
selected a comprehensive neuropsychological battery specifically designed to target 
cognitive deficits in PD, according to Level II criteria (Dubois et al., 2007; Litvan et al., 
2012; Marras et al., 2014). Thus, I applied these criteria also to MSA and PSP since there 
are no published criteria for atypical parkinsonisms. Statistical non-parametric analyses 
were used. 
I found PSP patients had more severe cognitive decline compared to PD and MSA. 
Namely, after 15-month follow-up, we noted a marked decline in the executive and 
language domains in the PSP group. Baseline and follow-up evaluations agreed, showing 
that PSP had a worse performance than PD and MSA patients: especially, in the Stroop 
test, verbal fluencies (semantic and phonemic) and MoCA.  
Assessing the severity of cognitive deficits, I found different percentages of cognitive 
status (i.e., normal cognition vs. MCI vs. dementia) among the three groups. In particular, 
the percentage of patients with dementia was higher in PSP compared to MSA (33% vs. no 
patients with dementia) even if disease duration was similar. Among MSA and PSP patients 
with multidomain MCI at baseline only PSP converted to dementia at follow-up. Then, 
although the disease duration was longer for PD patients compared with PSP, the 
proportion of patients who converted to dementia was lower in the PD group compared to 
PSP (7% vs. 16%), despite both groups having had similar baseline severity of MCI. 
Overall, these results suggest more rapid and severe cognitive decline in PSP while MSA 
patients generally have milder deficits.  
MoCA showed higher sensitivity than MMSE in detecting cognitive changes, especially 
in PSP. But MoCA was less sensitive than MMSE in detecting cognitive decline at 15-
month in PD, suggesting that MMSE is better if one wants to track cognitive changes in 
PD. 
Neuropsychiatric features are more common in PSP than PD patients, especially apathy 
with accompanying low levels of anxiety and depression. 
Lastly, analysis of subitems revealed that PSP patients had a ‘clinically significant’ 
worsening after 15-month in the attentive/executive subitems (Trial Making Test part B 
and Clock drawing). But it has been observed that some patients also improved in specific 
subtasks at the follow-up. This improvement could be related to their higher medication 
dose (although the dopaminergic treatment was not significantly different between the 
baseline and follow-up). However, noteworthy alterations in performance have been seen 
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for subitems sensitive to motor conditions (such as drawing figures and linking circles with 
a pen), which could affect cognitive outcome, leading to higher performance at follow-up. 
These limits of MoCA and MMSE scale have already been reported in PD patients (Biundo 
et al., 2016b; Hu et al., 2014), and maybe are more pronounced in atypical parkinsonisms.   
Taken together, these findings show that PSP patients were markedly impaired in 
comparison to the other parkinsonian disorders (MSA and PD) and six years after first 
symptoms, 33 percent of patients have dementia. This severe progression is possibly 
associated with the distribution of tau pathology that involves also cortical structures. On 
the contrary, the pattern of cognitive impairment in MSA is less severe, possibly due to the 
predominance of subcortical pathology with cortical involvement occurring only secondary 
to these abnormalities. 
Thus, these findings recommend using cognitive assessment to help differential 
diagnosis in atypical parkinsonisms, and to monitor disease progression. 
 
 
PART III - Neuroimaging studies of synucleinopathies 
 
Chapter 5: Amyloid depositions affect cognitive and motor manifestations in 
Parkinson’s disease 
 
 Cognitive deficits, particularly executive problems, can be observed early in PD 
(Aarsland, Bronnick, Larsen, Tysnes, & Alves, 2009). Dysfunction of the frontostriatal 
dopaminergic system may influence the presence of executive and attention problems 
(Bruck, Aalto, Nurmi, Bergman, & Rinne, 2005), but so far, evidence from dopamine 
transporter (DAT) imaging are inconsistent (Delgado-Alvarado, Gago, Navalpotro-Gomez, 
Jimenez-Urbieta, & Rodriguez-Oroz, 2016). 
In this regard, the neuropathology underlying cognitive impairment in PD is 
heterogeneous (Irwin, Lee, & Trojanowski, 2013; Kehagia, Barker, & Robbins, 2010) and 
amyloid deposit involvement with synuclein pathology remains poorly defined, particularly 
in the disease’s early stages. 
Thus, this study’s aims were to investigate the interplay between amyloid depositions in 
frontostriatal pathways, striatal dopaminergic deficit and brain atrophy rates; and their 
contribution to cognitive defects (i.e., fronto-executive functions) in early-PD. 
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A multicenter cohort of 33 PD patients from the Parkinson's Progression Markers 
Initiative underwent [18F]florbetaben positron emission tomography (PET) amyloid, 
[123I]FP-CIT (see Abbreviations List) single-photon emission computed tomography 
(SPECT), structural magnetic resonance imaging (MRI), clinical and selective cognitive 
evaluations. 
Our results showed that high amyloid levels were associated with reduced dopaminergic 
deficits in the dorsal striatum (as compared to low amyloid levels), increased brain atrophy 
in frontal and occipital regions and a tendency to show more frequent cognitive 
impairment in global cognition (as assessed by MoCA) and fronto-executive tests. 
Of note, amyloid depositions in frontostriatal regions were inversely correlated with 
cognitive performance.  
Overall, our findings suggest that early-PD patients with amyloid burden have higher 
brain atrophy rates and may experience more cognitive dysfunctions (i.e., executive) and 
motor impairment as compared to amyloid negative subjects. 
In this regard, our results seem to be aligned with a recent neuropathological hypothesis 
that considers synaptic axonal damage and dysfunction as the PD key feature (Tagliaferro 
& Burke, 2016). Indeed, dopaminergic system neurons are particularly vulnerable to 
synuclein pathology due to their axonal characteristics — long, thin and unmyelinated. This 
is also confirmed by imaging studies with DAT-binding PET (Caminiti et al., 2017), 
suggesting that synuclein aggregations in PD can affect synaptic function, and thus signal 
transmission from the disease’s very early stages. 
Our findings suggested a possible interaction between synuclein and the coincident 
amyloid pathology, wherein amyloid burden may facilitate the spread of synuclein (i.e., 
Lewy bodies) (Toledo et al., 2016), and we speculate that this interaction can further 
contribute to axonal vulnerability. 
Thus, consistently with this hypothesis, we conclude that possibly amyloid depositions 
act synergistically with synuclein pathology and affect PD clinical manifestations. 
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Chapter 6: Brain structural profile of multiple system atrophy patients with 
cognitive impairment 
 
 In contrast to other synucleinopathies (e.g., PD and DLB), presence of dementia is 
considered a non-supporting feature for MSA diagnosis (Gilman et al., 2008), however 
there is growing evidence that MSA patients can experience cognitive impairment ranging 
from executive dysfunctions to multiple-domain cognitive deficits, and in a few cases, also 
dementia (Gerstenecker, 2017). 
MMSE is a commonly used global cognitive scale and recently a large multicenter study 
has suggested using a cutoff score below 27 to increase the MMSE sensitivity in identifying 
cognitive dysfunctions in MSA (Auzou et al., 2015). 
Underlying mechanisms of cognitive impairment in MSA are still not understood, and in 
this regard evidence from MRI studies suggested a discrete cortical and subcortical 
contribution to explain cognitive deficits (Kim et al., 2015; Lee et al., 2016a), even though 
these findings were based on a relatively small number of patients at various disease stages 
as well as being single-center. 
Thus, the aim of our multicenter study was to better characterize the anatomical 
changes associated with cognitive impairment in MSA and to further investigate the cortical 
and subcortical structural differences in comparison to a sample of healthy subjects.  
We examined retrospectively 72 probable MSA patients and based on the MMSE 
threshold below 27, we defined 50 MSA as cognitively normal (MSA-NC) and 22 with 
cognitive impairment (MSA-CI). We directly compared the MSA subgroup, and further 
compared them to 36 healthy subjects using gray- and white-matter voxel-based 
morphometry and fully automated subcortical segmentation. Compared to healthy subjects, 
MSA patients showed widespread cortical (i.e., bilateral frontal, occipito-temporal, and 
parietal areas), subcortical, and white matter alterations. However, the direct comparison 
MSA-CI showed only focal volume reduction in the left dorsolateral prefrontal cortex 
compared with MSA-NC. These findings suggest only a marginal contribution of cortical 
pathology to cognitive deficits in MSA. Hence, we suggest that cognitive alterations are 
driven by focal frontostriatal degeneration that is in line with the concept of ‘subcortical 
cognitive impairment’. 
 
 
Sinossi 
 
 17 
SINOSSI 
La presente tesi è formata da tre parti principali: la prima teorica mentre le due seguenti 
sono sperimentali. 
La prima parte, composta di due capitoli, introdurrà le caratteristiche cliniche e 
neuropatologiche sottostanti ai disturbi parkinsoniani, in particolare nella malattia di 
Parkinson (PD) e nei parkinsonismi atipici — atrofia multisistemica (MSA) e paralisi 
progressiva sopranucleare (PSP) (Capitolo 1). Nello specifico, PD ed MSA sono definite 
come sinucleinopatie per la presenza di aggregati di sinucleina, mentre la PSP che è 
caratterizzata dall’accumulo di proteina tau rientra a far parte delle tauopatie. 
Invece, il Capitolo 2 fornirà una panoramica delle disfunzioni cognitive che 
caratterizzano questi disturbi e fornirà inoltre evidenze circa i meccanismi biologici e i 
cambiamenti strutturali che sono alla base delle alterazioni cognitive. 
Nella seconda e la terza parte sono riportati alcuni studi che ho condotto durante il 
dottorato di ricerca. In particolare, nel Capitolo 3 riporto i risultati dei miei studi sugli 
strumenti di screening cognitivo più sensibili nel rilevare alterazioni cognitive nei 
parkinsonismi atipici rispetto ai pazienti con PD. Nel successivo studio invece ho 
investigato la progressione del declino cognitivo in questi disturbi (Capitolo 4). 
Infine, ho investigato con studi di risonanza magnetica i cambiamenti strutturali che 
sottendono le alterazioni cognitive nel PD (Capitolo 5) e nella MSA (Capitolo 6). 
Seguiranno le conclusioni generali, in cui discuto le conseguenze cliniche dei risultati 
ottenuti negli studi cognitivi e di imaging (Capitolo 7). 
 
 
PARTE I – Background teorico 
 
Capitolo 1: I disturbi parkinsoniani 
I disturbi parkinsoniani sono caratterizzati da una diversa patologia sottostante. Nel PD 
ed MSA ci sono aggregati di sinucleina rispettivamente nei neuroni dopaminergici o nelle 
cellule gliali, mentre i pazienti con PSP presentano delle aggregazioni di proteina tau che 
determina la formazione di ammassi neurofibrillari (Daniel, de Bruin, & Lees, 1995; 
Dickson, 1999). Le manifestazioni cliniche dipendono dalle caratteristiche di aggregati 
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proteici e dall’entità di diffusione della malattia nelle regioni corticali e sottocorticali 
(Halliday, Holton, Revesz, & Dickson, 2011). 
Quindi, il presente capitolo illustrerà la patologia sottostante nel PD, MSA e PSP, 
saranno poi descritte le diverse caratteristiche cliniche ed infine, saranno presentati i più 
recenti criteri diagnostici di questi disturbi (e.g., Gelb, Oliver, & Gilman, 1999; Gilman et 
al., 2008; Höglinger et al., 2017). 
 
Capitolo 2: Caratteristiche cognitive e i sottostanti meccanismi nei disturbi 
parkinsoniani 
 
I sintomi non-motori rappresentano una parte cruciale dello spettro dei disturbi 
parkinsoniani, in particolare le disfunzioni cognitive, inclusa la demenza, sono 
probabilmente tra i sintomi non-motori più rilevanti, in quanto influenzano l'autonomia 
funzionale dei pazienti, incrementano il carico di gestione del caregiver ed hanno un 
notevole impatto socioeconomico (Keranen et al., 2003; McCrone et al., 2011; Vossius, 
Larsen, Janvin, & Aarsland, 2011).  
La prima parte di questo capitolo fornirà una panoramica sulle disfunzioni cognitive nel 
PD, MSA e PSP. Saranno inoltre riportati i criteri clinici per la diagnosi di declino cognitivo 
lieve e di demenza nel PD (Dubois et al., 2007; Emre et al., 2007; Litvan et al., 2012), al 
contrario invece non esistono al momento criteri disponibili per valutare le sindromi 
cognitive in PSP e MSA. 
Infine, la seconda e la terza parte di questo capitolo forniranno evidenze sui meccanismi 
biologici e sui cambiamenti strutturali sottostanti alle alterazioni cognitive in questi disturbi. 
 
 
PARTE II - Studi sulle manifestazioni cognitive nei disturbi parkinsoniani 
 
Capitolo 3: Performance al Montreal Cognitive Assessment e Mini-Mental State 
Examination nella paralisi sopranucleare progresiva, atrofia multisistemica e 
malattia di Parkinson 
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Vi è un generale consenso nel riconoscere che le alterazioni cognitive siano frequenti nei 
PD e negli altri disturbi parkinsoniani (Aarsland et al., 2017; Brown et al., 2010; 
Gerstenecker, 2017). 
Pertanto, nella pratica clinica possono essere adottate delle scale brevi di screening 
cognitivo, per supportare il clinico nel processo diagnostico (Marras, Troster, Kulisevsky, & 
Stebbins, 2014). Il Mini-Mental State Examination (MMSE) è la scala più utilizzata 
(Folstein, Folstein, & McHugh, 1975), anche se MMSE è relativamente insensibile 
nell’identificare rilevare disfunzioni cognitive nei disturbi parkinsoniani principalmente 
perché non indaga il dominio fronto-esecutivo (Hoops et al., 2009). Al contrario, il 
Montreal Cognitive Assessment (MoCA), un altro strumento di screening cognitivo 
ampiamente utilizzato nei pazienti con PD (Nasreddine et al., 2005), ha mostrato un’elevata 
sensibilità e specificità nell’identificazione di alterazioni cognitive nei PD (Gill, Freshman, 
Blender, & Ravina, 2008; Hoops et al., 2009; Zadikoff et al., 2008), come anche in altre 
malattie neurodegenerative come l’Alzheimer, la demenza da corpi di Lewy (DLB) e la 
malattia di Huntington (Biundo et al., 2016b; Hoops et al., 2009; Nasreddine et al., 2005; 
Videnovic et al., 2010). Tuttavia, vi sono poche evidenze sull’uso del MoCA nei 
parkinsonismi atipici, in particolare nella PSP ed MSA (Kawahara et al., 2015). 
Pertanto, lo scopo del presente studio era di determinare se il MoCA fosse più sensibile 
del comunemente utilizzato MMSE nel rilevare alterazioni cognitive nei pazienti con 
probabile PSP e MSA, rispetto al PD. 
In questo studio multicentrico, che ha coinvolto altri tre centri europei, sono state 
somministrate le scale MMSE e MoCA a 130 pazienti: 35 MSA, 30 PSP e 65 pazienti PD 
appaiati per età, scolarità e sesso. 
Sono state valutate le differenze tra i gruppi per MMSE, MoCA, e i loro subitem; infine 
sono state calcolate le curve ROC (Receiver-Operating Characteristic). 
Dai risultati emerge che la media del MMSE è superiore al punteggio medio del MoCA 
in ogni gruppo di pazienti: MSA (27.7 ± 2.4 vs. 22.9 ± 3.0, p<0.0001), PSP (26.0 ± 2.9 vs. 
18.2 ± 3.9, p<0.0001), e PD (27.3 ± 2.0 vs. 22.3 ± 3.5, p<0.0001). Inoltre, il punteggio 
totale MoCA così come il suo subitem di fluenza fonemica è in grado di differenziare la 
PSP da MSA e PD con un’alta specificità e moderata sensibilità. Specificamente, un 
punteggio uguale o inferiore a sette parole al minuto sembra supportare una diagnosi di 
PSP (PSP vs PD: 86% specificità, sensibilità al 70%, PSP vs MSA: 71% specificità, 
sensibilità al 70%). Al contrario, nel MMSE è stato possibile osservare un ‘effetto-soffitto’ 
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per la maggior parte dei subitem, ad eccezione del subitem dei ‘due pentagoni’, in cui i 
pazienti con PSP hanno una prestazione peggiore rispetto a MSA e PD. 
I nostri risultati suggeriscono che PSP ed MSA, similmente al PD, possono presentare 
una prestazione normale al MMSE ma deficitaria al MoCA. 
In conclusione, il MoCA è più sensibile del MMSE nel rilevare disfunzioni cognitive nei 
parkinsonismi atipici ed insieme al suo subitem di fluenza verbale sembra essere un valido 
test per supportare una diagnosi di PSP. 
 
 
Capitolo 4: Valutazione prospettica delle disfunzioni cognitive nei disturbi 
parkinsoniani 
 
 Evidenze in ambito clinico e di ricerca suggeriscono che le disfunzioni cognitive nei 
disturbi parkinsoniani siano progressive. Tuttavia, in letteratura vi sono pochi studi 
longitudinali che indagano la progressione cognitiva in pazienti con PSP ed MSA rispetto a 
pazienti PD (Dubois & Pillon, 2005; Rittman et al., 2013; Soliveri, 2000). In particolare, i 
precedenti studi si basano solo su scale globali di screening cognitivo, oppure su valutazioni 
neuropsicologiche parziali che non esaminano l'intero spettro delle abilità cognitive nei 
cinque domini (i.e., attenzione/memoria di lavoro, esecutivo, mnesico, visuospaziale e del 
linguaggio). Inoltre, sebbene siano stati formulati criteri clinici per la diagnosi di declino 
cognitivo lieve (MCI) e di demenza in pazienti PD (Dubois et al., 2007; Litvan et al., 2012), 
rimane ancora da investigare se tali criteri possano essere applicati anche nei parkinsonismi 
atipici (Marras et al., 2014). 
Date tali premesse, gli obiettivi del presente studio sono stati: i) valutare la severità delle 
alterazioni cognitive in pazienti PSP ed MSA utilizzando i criteri validati nei pazienti PD, 
per identificare gli stati cognitivi (i.e., MCI o demenza); ii) esaminare la sensibilità di due 
strumenti di screening cognitivo ampiamente utilizzati, (i.e., MMSE e MoCA), nel 
differenziare il profilo cognitivo globale di pazienti MSA, PSP e PD; iii) caratterizzare la 
progressione del declino cognitivo nei cinque domini, il profilo comportamentale e infine 
confrontare il profilo cognitivo al follow-up tra i vari disturbi parkinsoniani. Il nostro 
campione includeva 18 pazienti con PSP, 12 MSA e 30 pazienti con PD appaiati per età, 
scolarità e sesso, che sono stati valutati alla baseline e al follow-up a 15 mesi. Sono stati 
raccolti dati demografici e clinici; inoltre dal punto di vista cognitivo è stata selezionata una 
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batteria di test neuropsicologici completa, specifica per l’identificazione di deficit cognitivi 
in pazienti PD, secondo i criteri pubblicati di ‘Livello II’ (Dubois et al., 2007; Litvan et al., 
2012; Marras et al., 2014). Abbiamo quindi applicato tali criteri anche a pazienti MSA e 
PSP, dato che non esistono criteri pubblicati per i parkinsonismi atipici. Infine, sono state 
utilizzate analisi statistiche di tipo non-parametrico. 
Dai nostri risultati emerge che i pazienti con PSP hanno un declino cognitivo più severo 
rispetto a pazienti PD ed MSA. Nello specifico, al follow-up è stato possibile osservare un 
marcato declino a carico del dominio esecutivo e del linguaggio nel gruppo con PSP. Le 
valutazioni cognitive alla baseline e al follow-up erano concordanti, ed entrambe 
confermano che i pazienti PSP hanno una prestazione peggiore rispetto ai pazienti PD ed 
MSA: in particolare, nello Stroop test, nelle fluenze verbali (semantica e fonematica) e nel 
MoCA. 
Valutando la severità dei deficit cognitivi, abbiamo inoltre trovato diverse percentuali di 
diagnosi cognitive (i.e., profilo nella norma, MCI vs. demenza) tra i tre gruppi. In 
particolare, la percentuale più elevata di pazienti con demenza era nel gruppo con PSP 
rispetto ai pazienti MSA (i.e., 33% vs. nessun paziente con demenza), anche se la durata di 
malattia era simile. Inoltre, tra i pazienti MSA e PSP con un profilo MCI-multidominio alla 
baseline, solo pazienti con PSP passano ad una diagnosi di demenza al follow-up. 
Infine nel gruppo di pazienti PD, nonostante avessero una durata di malattia più lunga, 
la percentuale di soggetti che passano ad una diagnosi di demenza era inferiore rispetto al 
gruppo con PSP (7% vs. 16%), nonostante entrambi i gruppi avessero una gravità di MCI 
simile alla baseline. Complessivamente questi risultati suggeriscono un più rapido e severo 
declino cognitivo in soggetti PSP, mentre i pazienti MSA mostrano generalmente deficit 
più limitati. 
La scala globale MoCA sembra essere maggiormente sensibile, rispetto al MMSE, nel 
rilevare cambiamenti cognitivi, in particolare nella PSP. Tuttavia il MoCA mostra una 
sensibilità inferiore rispetto al MMSE nell’identificare un declino cognitivo al follow-up in 
pazienti PD; quindi il MMSE sembra essere uno strumento migliore per monitorare 
longitudinalmente cambiamenti cognitivi in pazienti PD. 
Riguardo al profilo comportamentale, i pazienti PSP riportano più comunemente 
rispetto ai pazienti PD: apatia, ansia e depressione. 
Infine, l'analisi dei subitem rivela che i pazienti PSP mostrano un peggioramento 
‘clinicamente significativo’ dopo 15 mesi soprattutto nei subitem attentivo-esecutivi (Trial 
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Making Test parte B e il disegno di un orologio). Tuttavia è stato possibile osservare che 
alcuni pazienti hanno anche un miglioramento in specifici subitem al follow-up. Questo 
miglioramento potrebbe essere attribuibile ad una più elevata dose farmacologica 
(nonostante il trattamento dopaminergico alla baseline non fosse significativamente diverso 
al follow-up). Tuttavia, è importante notare che tali alterazioni erano presenti soprattutto in 
subitem sensibili alle problematiche motorie (i.e., disegno di figure e collegamento di cerchi 
con una penna) che quindi potrebbero aver alterato la performance. Questi limiti della scala 
MoCA e MMSE sono già stati osservati in precedenza nei pazienti con PD (Biundo et al., 
2016b; Hu et al., 2014), e possibilmente sono ancora più pronunciati nei parkinsonismi 
atipici. 
In conclusione i nostri risultati rivelano che i pazienti PSP hanno una performance 
notevolmente alterata rispetto agli altri disturbi parkinsoniani (MSA e PD), e dopo circa 6 
anni di durata di malattia, il 33% dei pazienti PSP ha una diagnosi di demenza. Questa 
severa progressione è probabilmente associata ad una diffusione di aggregati tau che 
coinvolge anche strutture corticali. Al contrario, il pattern di compromissione cognitiva in 
pazienti con MSA è meno severo, e probabilmente è associato ad una predominanza 
sottocorticale della patologia, con un coinvolgimento corticale solo secondario alle 
alterazioni sottocorticali. Pertanto, i nostri risultati suggeriscono che la valutazione 
neuropsicologica può essere utile nella differenziazione dei profili cognitivi nei 
parkinsonismi atipici e per monitorare la progressione della malattia. 
 
PARTE III – Studi di neuroimmagine sulle sinucleinopatie 
 
Capitolo 5: Effetti dei depositi di amiloide sulle manifestazioni cognitive e motorie 
nella malattia di Parkinson 
 
 Alterazioni cognitive, in particolare deficit esecutivi, possono essere osservati anche 
nelle prime fasi del PD (Aarsland, Bronnick, Larsen, Tysnes & Alves, 2009). La disfunzione 
frontostriatale del sistema dopaminergico può influenzare la presenza di problemi esecutivi 
ed attentivi (Bruck, Aalto, Nurmi, Bergman, & Rinne, 2005), tuttavia al momento le 
evidenze relative al trasportatore striatale di dopamina (DAT) sono inconsistenti (Delgado-
Alvarado, Gago, Navalpotro-Gomez, Jimenez-Urbieta, & Rodriguez-Oroz, 2016). 
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I meccanismi neuropatologici che stanno alla base delle alterazioni cognitive nei PD 
sono eterogenei (Irwin, Lee, & Trojanowski, 2013; Kehagia, Barker & Robbins, 2010), ed il 
contributo del deposito di amiloide in aggiunta alla sinucleinopatia rimane ancora poco 
definito, soprattutto nelle prime fasi della malattia. 
Pertanto, lo scopo del presente studio è stato quello di indagare l'interazione tra depositi 
di amiloide nel circuito frontostriatale, deficit dopaminergico striatale, grado di atrofia 
cerebrale ed il loro contributo nelle alterazioni cognitive (i.e., funzioni fronto-esecutive) 
nelle prime fasi del PD. 
Una coorte multicentrica di 33 pazienti con PD ricavata dal ‘Parkinson's Progression 
Markers Initiative’ è stata sottoposta a una tomografia ad emissione di positroni (PET) con 
radiofarmaco [18F]florbetaben, tomografia ad emissione di fotone singolo (SPECT) con  
radiofarmaco [123I]FP-CIT, risonanza magnetica (MRI) strutturale, valutazione clinica e 
cognitiva. 
Dai nostri risultati emerge che elevati livelli di depositi di amiloide erano associati ad una 
riduzione del deficit dopaminergico nello striato dorsale (rispetto ai bassi livelli di depositi 
di amiloide), ad un aumento dell’atrofia cerebrale in regioni frontali ed occipitali, e ad una 
tendenza a manifestare più frequentemente alterazioni cognitive globali (come valutato dal 
MoCA), ed in test fronto-esecutivi. 
Inoltre, le deposizioni di amiloide nelle regioni frontostriatali erano inversamente 
correlate alla performance cognitiva. 
Nel complesso i nostri risultati suggeriscono che pazienti con PD in fase iniziale di 
malattia e amiloidosi hanno un più elevato grado di atrofia cerebrale e possono esperire 
maggiori deficit cognitivi (i.e., disfunzioni esecutive) e alterazioni motorie rispetto a soggetti 
negativi all’amiloide. 
I nostri risultati sembrano essere in linea con una recente ipotesi neuropatologica che 
considera il danno e disfunzione assonale a livello sinaptico come un elemento 
caratteristico del PD (Tagliaferro & Burke, 2016). Infatti, i neuroni del sistema 
dopaminergico sono particolarmente vulnerabili alla sinucleinopatia a causa delle loro 
caratteristiche assonali: gli assoni sono lunghi, sottili e non mielinizzati. Questa ipotesi è 
confermata anche da studi di neuroimmagine PET con traccianti che si legano al DAT 
(Caminiti et al., 2017), suggerendo che le aggregazioni di sinucleina nel PD possono 
influenzare la funzione sinaptica e la trasmissione di segnale sin dalle prime fasi della 
malattia. 
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I nostri risultati suggeriscono quindi una possibile interazione tra depositi di amiloide e 
sinucleinopatia, in cui la presenza di amiloide può facilitare la diffusione di sinucleina (i.e., 
corpi di Lewy) (Toledo et al., 2016), pertanto questa interazione può contribuire 
ulteriormente alla vulnerabilità assonale. 
In linea con questa ipotesi, i nostri risultati sembrano confermare che le deposizioni di 
amiloide agiscono sinergicamente con la sinucleinopatia, influenzando le manifestazioni 
cliniche del PD. 
 
 
Capitolo 6: Profilo neurostrutturale dell’atrofia multisistemica con alterazioni 
cognitive  
 
 A differenza di altre sinucleinopatie (e.g., PD e DLB), la presenza di demenza è 
considerata un criterio di esclusione nella diagnosi di MSA (Gilman et al., 2008), tuttavia vi 
è una crescente evidenza che pazienti affetti da MSA possano manifestare alterazioni 
cognitive, che includono disfunzioni esecutive ma anche deficit cognitivi multidominio, e in 
alcuni casi anche demenza (Gerstenecker, 2017). 
Il MMSE è una scala cognitiva globale comunemente utilizzata nella pratica clinica, e 
recentemente uno studio multicentrico ha suggerito l’utilizzo di un cutoff <27 per 
aumentare la sensibilità di tale scala nell'identificare alterazioni cognitive in pazienti MSA 
(Auzou et al., 2015). 
I meccanismi che sottendono le disfunzioni cognitive in soggetti MSA non sono ancora 
stati identificati ed evidenze da studi di MRI suggeriscono un discreto contributo corticale e 
sottocorticale per spiegare tali alterazioni cognitive (Kim et al., 2015; Lee et al., 2016a). 
Tuttavia questi risultati sono basati su un numero relativamente piccolo di pazienti e in vari 
stadi di malattia, inoltre sono studi basati su singoli centri. 
Pertanto, lo scopo del nostro studio multicentrico è stato quello caratterizzare i 
cambiamenti anatomici associati ad alterazioni cognitive in pazienti MSA e di investigare le 
differenze strutturali corticali e sottocorticali rispetto ad un campione di soggetti sani. 
Abbiamo quindi esaminato retrospettivamente 72 pazienti MSA, e definito 50 MSA 
come cognitivamente normali (MSA-NC) e 22 con alterazioni cognitive (MSA-CI) 
utilizzando il cutoff del MMSE <27. Abbiamo inoltre confrontato direttamente i due 
sottogruppi di MSA, e comparato l’intero gruppo di MSA ad un campione di 36 controlli 
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sani (HC) utilizzando un’analisi di ‘morfometria basata sui voxel’ che analizzava la sostanza 
grigia e bianca. Inoltre, abbiamo applicato anche una segmentazione automatizzata dei 
volumi sottocorticali.  
Dai nostri risultati emerge che i pazienti MSA, rispetto a soggetti sani, hanno una diffusa 
atrofia corticale (i.e., che coinvolge bilateralmente aree frontali, occipito-temporali e 
parietali), sottocorticale ed alterazioni alla sostanza bianca. Tuttavia, nel confronto diretto, i 
soggetti MSA-CI mostrano solo una focale riduzione del volume a carico della corteccia 
prefrontale dorsolaterale sinistra rispetto a pazienti MSA-NC.  
Tali risultati suggeriscono che la patologia corticale abbia un effetto marginale sulle 
alterazioni cognitive nei pazienti MSA. Suggeriamo quindi che le alterazioni cognitive siano 
piuttosto determinate da una degenerazione frontostriatale focale, che sembra essere in 
linea con il concetto di ‘alterazioni cognitive sottocorticali’. 
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CHAPTER 1 
PARKINSONIAN DISORDERS 
 
Two hundred years ago, in 1817, James Parkinson described for the first time some 
patients with movement disorders who showed the so-called “shaking palsy”, altered 
posture and sense of weakness (Parkinson, 2002). Remarkably, in An Essay on the Shaking 
Palsy, motor aspects as well as non-motor features (i.e., behavioral, sleep, and autonomic 
dysfunctions) were reported, and a few decades later this disease was recognized by Jean-
Martin Charcot as a complex disorder, defined as Parkinson's disease (PD) (Goetz, 2011).  
PD is a common and disabling disorder that affects people in a wide age range, namely 
with a prevalence of about 1−2 percent in the population older than 60 to 65 years, or 0.3 
percent in the general population. Indeed, PD is the second most common 
neurodegenerative disorder after Alzheimer’s disease (AD) (De Lau & Breteler, 2006).  
The etiology of PD remains unknown, since it is extremely difficult to disentangle the 
complex interactions between genetic causes and environmental agents. Several risk factors 
have been identified, including intoxications or familial history; although age remains the 
most significant factor so far (De Lau & Breteler, 2006); and since life expectancy is 
growing, the disease’s prevalence is expected to dramatically increase, leading to health care 
issues (Dorsey et al., 2007). 
From the motor standpoint, PD is characterized by a clinical manifestation known as 
parkinsonism, indicating a combination of four features: rigidity, tremor, slowing down of 
movements (bradykinesia), postural and gait dysfunctions. Initially, parkinsonism was 
considered specific to PD, however these symptoms were observed also in other 
neurodegenerative disorders, defined as atypical parkinsonisms. These include multiple 
system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD) and dementia with Lewy bodies (DLB).  
However, PD is by far the most common cause of parkinsonism accounting for up to 
85 percent of the cases (Figure 1.1) (Colosimo, Riley, & Wenning, 2011). 
As parkinsonism may occur in several clinical conditions, it is challenging to identify and 
distinguish these conditions from idiopathic PD. Although specific clinical diagnostic 
criteria are available to differentiate PD from other forms of atypical parkinsonism (Gilman 
et al., 2008; Höglinger et al., 2017), so far most of the available clinical features are 
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characterized by a poor sensitivity, leading to a high rate of misdiagnosis (Joutsa, Gardberg, 
Röyttä, & Kaasinen, 2014).  
 
 
Figure 1.1 Summary of primary and secondary parkinsonian disorders. As primary and atypical 
parkinsonism are reported: progressive supranuclear palsy (PSP), multiple system atrophy (MSA), 
corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB). Modified from Schapira, 
Hartmann and Agid (2009). 
 
Indeed, approximately 10 percent of patients, who were initially diagnosed as PD, 
ultimately are identified as atypical parkinsonisms, especially because of the significantly 
reduced (or absent) response to dopaminergic treatment, due to the degeneration of striatal 
neurons and thus the absence of postsynaptic dopaminergic receptors (Schapira, Hartmann 
& Agid, 2009). Making the distinction between PD and atypical parkinsonism is crucial for 
both clinical practice and research, as the prognosis and treatment of patients with atypical 
parkinsonism differ from PD, namely atypical parkinsonian disorders have a shorter 
survival time, more clinical complications since the early stage of the disease and in general 
a more severe prognosis (Litvan, 2005).  
The present chapter will provide an overview of the current status of PD as well as of 
atypical parkinsonian disorders from a clinical and neuropathological viewpoint, in order to 
subsequently better understand the research work illustrated in this thesis.  
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1.1 CLINICAL AND NEUROPATHOLOGICAL FEATURES 
An alternative classification of parkinsonian disorders is based on the underlying 
pathology; namely the aggregated proteins in the brain lesions, and thus it is possible to 
classify the disorders as synucleinopathies and tauopathies.  
This classification comprises several neurodegenerative disorders, but the present thesis 
will focus only on PD and MSA as synucleinopathies, and on PSP as tauopathy.   
 
 1.1.1 Synucleinopathies: Parkinson’s disease and multiple system atrophy 
Synuclein is a 140-amino-acid protein that forms abnormal aggregates in PD, MSA and 
DLB. 
The main pathological inclusions observed in the synucleinopathies are Lewy bodies 
(LB), Lewy neuritis (LN) and oligodendroglia cytoplasmic inclusions (Halliday et al., 2011; 
Spillantini & Goedert, 2000). Since these disorders have abnormal inclusions of synuclein, 
they are defined as synucleinopathies. 
Of note, even though the common factor is synuclein, there are some features that can 
impact differently the clinical symptoms — the most important factor is the location of 
synuclein aggregates that will determine the clinical phenotype (Halliday et al., 2011). 
 
Parkinson’s disease 
PD is characterized by the degeneration of nerve cells, in several brain regions 
particularly in the substantia nigra, due to filamentous inclusions in the form of LB and 
LN, whose major component is synuclein (Spillantini & Goedert, 2000).  
Motor symptoms that characterize PD patients arise from the loss of nigrostriatal 
neurons that use dopamine as neurotransmitter to communicate within the striatal network.  
According to the diagnostic criteria, PD diagnosis can be defined as: definite (i.e., 
assessed with postmortem autopsy), probable or possible. At present, only the criteria for 
the probable diagnosis will be briefly described since these are the diagnostic criteria 
subsequently used in the experimental studies (the detailed criteria are reported in the 
Appendices, page 199). For a probable diagnosis of PD, three of four cardinal symptoms 
should be observed (i.e., resting tremor, bradykinesia, rigidity and asymmetric onset) for at 
least three years and substantial response to levodopa therapy should be documented (Gelb 
et al., 1999). However, it has been demonstrated that motor symptoms are also 
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accompanied by non-motor symptoms, such as cognitive impairments, sleep disturbances 
and depression. Notably, it has been observed that non-motor problems can appear in the 
preclinical phase of the disease, before motor symptoms (Chaudhuri & Schapira, 2009). 
The staging of LB distribution across the PD brain has been proposed by Braak and 
colleagues, receiving considerable attention (Braak et al., 2003; Braak, Ghebremedhin, Rub, 
Bratzke, & Del Tredici, 2004). This staging provides an explanation of the motor as well as 
non-motor symptoms based on the topographical distribution and extent of LB lesions. 
According to this staging LB and LN seem to start at specific sites, and subsequently 
follow a predictable topographical sequence (Figure 1.2).  
 
 
 
Figure 1.2 Pathological staging scheme for Parkinson’s disease according to the theory of Braak 
and colleagues. RBD, rapid eye movement behavior disorder. From Schapira, Hartmann and Agid 
(2009). 
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Braak stage I and II are defined as the presymptomatic, wherein the LB depositions are 
located mainly in the olfactory regions and anterior olfactory nucleus; and then in stage II 
the progression of pathology involves also the lower brainstem (dorsal motor nucleus of 
the vagus nerve and locus coeruleus). PD patients during these phases are characterized by 
mainly autonomic disturbances and non-motor symptoms (i.e., olfactory dysfunction, sleep 
disturbances, such as rapid eye movement (REM) sleep behavior disorder, restless legs 
syndrome). These symptoms usually precede the diagnosis of the disease, and can possibly 
occur also during the other phases of the disease. 
Of note, typical PD motor symptoms (i.e., bradykinesia, rest tremor and rigidity) appear 
during Braak stages III and IV, implicated by the extension of synuclein pathology to the 
substantia nigra pars compacta, the basal forebrain and entorhinal cortex, leading to 
neurodegenerative processes associated with neural loss (and not only presence of LB 
depositions). 
Finally, in Braak stages V and VI the presence of LB affects limbic regions and the 
neocortex (i.e., temporal, frontal and parietal). Thus in these phases PD patients can 
eventually experience cognitive impairments (including frank dementia), neuropsychiatric 
alterations (i.e., depression and apathy), and visual hallucinations, as consequence of the 
diffuse spread of synuclein pathology to the cerebral cortex. 
This model of Braak and colleagues, is still object of debate and raised criticisms (Burke, 
Dauer, & Vonsattel, 2008; Jellinger, 2009), in light of the fact that neuropathological 
evidence did not confirm the proposed ‘caudo-rostral progression pattern’ of synuclein 
pathology in 47 percent of PD cases (Kalaitzakis, Graeber, Gentleman, & Pearce, 2008), 
and at autopsy patients had variable degrees of LB in several regions of the nervous system. 
Overall, the major criticisms are related to the fact that the Braak staging scheme is valid 
only to describe some of the PD clinical phenotypes.  
In this regard, PD is a heterogeneous disease and can present with different clinical 
features, motor and non-motor manifestations, even though the clinical definition of PD is 
based on motor signs. The diverse clinical manifestations suggest the existence of different 
PD subtypes.  
Indeed, a recent systematic review has identified four PD subtypes using a cluster 
analysis, considering motor as well as non-motor characteristics (i.e., age of onset, severity 
and type of motor impairments, rate of progression, and presence or absence of significant 
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cognitive impairment) (van Rooden et al., 2010). The four phenotypes were: early-onset, 
tremor dominant, postural instability and gait dominant, and old onset phenotype. 
Interestingly, a model has been proposed that was able to combine the Braak PD 
staging with the four PD subtypes (Halliday et al., 2011), based on neuropathological 
evidence.  
As shown in Figure 1.3, it has been demonstrated that the LB pathology distribution 
was similar for the ‘early-onset’ and ‘tremor dominant’ subtypes, suggesting that possibly 
the amount of LB depositions was different according to disease onset (i.e., early vs. late 
onset) (Halliday et al., 2011). Indeed, in patients with ‘postural instability and gait’ dominant 
as well as ‘late onset’ phenotype, there was a significantly broader distribution of cortical 
LB depositions with concomitant amyloid pathology compared to the other two 
phenotypes (e.g., tremor dominant and early onset) (Halliday et al., 2011; Selikhova et al., 
2009). 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic of the progression of pathology in the four main phenotypes of Parkinson’s 
disease with Lewy body pathology (i.e., early onset PD, tremor dominant, postural instability and 
gait and old age onset). PD, Parkinson’s disease. From Halliday et al. (2011). 
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The phenotype with the older onset had a higher rate of cortical LB depositions as well 
as amyloid pathology, suggesting that a faster rate of LB depositions is possibly associated 
with comorbid pathologies (i.e., amyloid-β). 
This is aligned also with the recent evidence considering synaptic axonal damage and 
dysfunction as the key features of PD (Tagliaferro & Burke, 2016), supported by the fact 
that synuclein pathology affects dopaminergic neurons due to their vulnerability because of 
their axonal characteristics (i.e., long, thin and unmyelinated) (Braak et al., 2004). Axon 
damage can lead to protein accumulation, including amyloid precursor protein, which can 
be cleaved to form amyloid-β (Johnson, Stewart, & Smith, 2010; Stokin et al., 2005). In 
addition, interaction between synuclein and the coincident amyloid pathology has been 
suggested and this interaction can possibly facilitate the spreading of synuclein (Toledo et 
al., 2016). 
 
Multiple system atrophy 
MSA is a sporadic, adult onset, progressive neurodegenerative disease characterized by 
poorly levodopa-responsive parkinsonism, cerebellar ataxia, autonomic dysfunction and 
pyramidal signs (Gilman et al., 2008). Historically, three cardinal presentations were 
recognized — including patients with predominantly parkinsonian symptoms considered to 
be striatonigral degeneration (SND), patients with cerebellar symptoms considered to be 
sporadic olivopontocerebellar atrophy (OPCA), and patients with mainly autonomic 
dysfunctions considered to be Shy−Drager syndrome. However in 1969, the 
clinicopathological overlap of these disorders had been recognized and MSA had been 
proposed as an umbrella term (Graham & Oppenheimer, 1969). Subsequently, ubiquitin-
positive glia cytoplasmic inclusions (GCIs) were discovered to be the common pathological 
hallmark of MSA, and thus MSA was defined as a member of the group of synucleinopathy 
(Papp, Kahn, & Lantos, 1989). 
Clinical diagnostic criteria for the diagnosis of probable and possible MSA during life 
have been published, and include autonomic dysfunction, parkinsonism with poor 
response to levodopa therapy, pyramidal signs and cerebellar syndrome (Gilman et al., 
2008). A definite diagnosis is provided post-mortem on a neuropathological basis, based on 
the presence of GCIs with concomitant neurodegenerative changes (striatonigral or 
olivopontocerebellar), which are the main constituents of MSA (Spillantini et al., 1998).  
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In the present chapter, only the criteria for the probable diagnosis will be briefly described 
since these are the diagnostic criteria subsequently used in the experimental studies (the 
detailed criteria are reported in the Appendices, page 199). 
In the current criteria, probable MSA is defined as sporadic, progressive, adult-onset (> 
30 years) characterized by autonomic failure of urogenital type (i.e., with erectile 
dysfunction in men), or of cardiovascular type (i.e., orthostatic reduction in blood pressure 
falls ≥30 mmHg systolic or ≥15 mmHg diastolic) in a context of a poor levodopa-
responsive parkinsonism or cerebellar syndrome. 
In addition, patients with predominant parkinsonism at first evaluation are defined as 
MSA with predominant parkinsonism symptoms (MSA-P) (with striatonigral involvement), 
while patients with a cerebellar syndrome are recognized as MSA-C (with 
olivopontocerebellar involvement). Even though it is acknowledged that with disease 
progression, these distinguishing features can both be present (Gilman et al., 2008). 
Interestingly, the distribution of the phenotypes shows some ethnic variations: namely, in 
Europe, 58 percent usually are MSA-P and the remaining are classified as MSA-C — on the 
contrary, in Japan the most frequent phenotype is represented by MSA-C, accounting for 
84 percent (Geser et al., 2006; Yabe et al., 2006). 
MSA, has an equal distribution in both genders, and usually its disease duration varies 
from seven to nine years. The mean age at onset is approximately 60 years; instead, the 
prevalence rate is about 4.4 per 100,000 (Schrag, Ben-Shlomo, & Quinn, 1999; Schrag, 
Wenning, Quinn, & Ben-Shlomo, 2008).  
Due to the high variability in disease severity and in the regional distribution of the MSA 
pathology (i.e., regarding both neural loss and GCIs), Wenning, Seppi, Tison, and Jellinger 
(2002) proposed a disease staging system. 
This model (specific for SND) suggested that at grade I, neural loss was restricted to the 
substantia nigra, then extending to the putamen (grade II), and finally affecting the caudate 
nucleus and globus pallidus at grade III. The present classification was able to interpret the 
spread of MSA pathology, but it did not take into account the OPCA (Wenning & 
Fanciulli, 2013).  
Another classification was proposed by Halliday et al. (2011), wherein both the MSA 
variants (MSA-P an MSA-C) have been illustrated (Figure 1.4). It is possible to note that 
although patients may present with a predominant SND or OPCA degenerative pattern, 
then at autopsy, synuclein pathology and neuronal loss are usually widespread and are not 
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confined to striatonigral nor olivopontocerebellar regions respectively. Hence, usually there 
is an overlap of these two conditions.  
 
Figure 1.4 Schematic of the amount and progression of pathology in the two major clinical 
phenotypes of MSA with oligodendroglial cytoplasmic inclusions (GCIs). MSA-P, multiple system 
atrophy parkinsonian variant; MSA-C, multiple system atrophy cerebellar variant. From Halliday et 
al. (2011). 
 
 
In agreement with this observation, a study that included 100 MSA confirmed cases 
from the Parkinson's UK Brain Bank showed that in the grading of neuronal loss, 34 
percent was affected mostly on striatonigral regions, while 17 percent on 
olivopontocerebellar regions and the remaining half of the cases were equally affected in 
both regions (Ozawa et al., 2004). 
In another neuropathological study that included 203 cases, the severity of gliosis and 
neurodegeneration in the substantia nigra, globus pallidus and putamen was associated with 
akinesia, while rigidity correlated only with neuronal loss in the putamen. On the contrary, 
limb and gait ataxia were more associated with Purkinje cell depletion, inferior olives and 
pontine nuclei (Wenning, Tison, Ben Shlomo, Daniel, & Quinn, 1997). Interestingly, 
patients with less changes in the putamen were more responsive to the levodopa treatment. 
Thus, it seems conceivable that in general a poor response to treatment in MSA is due to 
an extensive putaminal degeneration (Fearnley & Lees, 1990).  
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It is also of note that the density of GCIs and the degree of neural loss are positively 
associated (Ozawa et al., 2004). This suggests that GCIs have an important role in the 
neurodegenerative process in MSA, although this relationship was previously object of 
debate (Papp & Lantos, 1994).  
Finally, autonomic dysfunctions — a prominent clinical feature that can also precede 
motor symptoms — seem to be associated with pathological changes in components of the 
autonomic system (e.g., parasympathetic preganglionic nuclei in Onuf’s nucleus and in the 
inferior intermediolateral nucleus of sacral spinal cord) (Ozawa, 2007). 
However, in order to develop a MSA staging scheme similar to the Braak staging 
proposed for PD, further studies are needed with larger cohorts to establish the earliest site 
of involvement to develop MSA (Wenning & Fanciulli, 2013).  
 
1.1.2 Tauopathy: Progressive supranuclear palsy 
Different neurodegenerative diseases (e.g., PSP, AD, CBD, Pick’s disease) are denoted 
by the presence of tau protein accumulation. Tau is a phosphoprotein, which is involved in 
the regulation of tubulin assembly and is an intracellular accumulation. So far, six tau 
isoforms have been identified that can include three or four of the repetitive patterns (i.e., 
3R or 4R tau) (Goedert, Wischik, Crowther, Walker, & Klug, 1988). PSP is characterized by 
4R tau isoform; and this thesis will focus only on PSP among the tauopathies. 
 
Progressive supranuclear palsy 
The first detailed description of PSP came from J.C. Steel, J.C. Richardson and J. 
Olszewski in the 1960s, to denote ‘a heterogeneous degeneration involving brain stem, 
basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia 
and dementia’ (Steele, 1964). In this article, they described nine cases that now are defined 
as PSP Richardson’s syndrome (PSP-RS) phenotype. So far, many phenotypes have been 
described, and after PSP-RS, the second most common is PSP-parkinsonism (PSP-P), in 
which the disease duration is longer (Respondek et al., 2014; Williams et al., 2005). 
The prevalence of PSP is approximately five per 100,000 and accounts for five percent 
of all parkinsonian disorders (Nath et al., 2001); PSP affects both genders with a slight 
predominance in males. Clinical symptoms commonly begin in the seventh decade and the 
median age is about 63 years. The most frequent symptom reported at the onset is postural 
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instability, characterized by frequent falls, and followed by cognitive impairment, bulbar 
and visual deficits (Nath et al., 2001).  The disease can be easily recognized when all the 
clinical features are present — vertical supranuclear gaze palsy, history of falls, postural 
instability, symmetrical bradykinesia, axial rigidity, dysarthria, dysphagia and dysexecutive 
syndrome. Although, patients usually present with atypical symptoms, leading to difficulties 
in the diagnostic process.  
In this regard, the International Parkinson and Movement Disorder Society (MDS) PSP 
study group has recently revised the diagnostic criteria for PSP (Höglinger et al., 2017), 
wherein the main aim was to optimize the sensitivity and specificity of PSP diagnosis. Since 
the previous criteria, proposed by the National Institute of Neurological Disorders and 
Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) (Litvan et al., 
1996a), did not take into account all the variants of PSP syndrome and were focused only 
on the PSP-RS variant. 
According to the diagnostic criteria, PSP diagnosis can be defined as: definite, probable 
or possible. Also the new diagnostic criteria require neuropathological confirmation to 
establish a PSP definite diagnosis, where the appropriateness of the definition is based on 
unique neuropathological features: namely, presence of intracellular aggregates of 
microtubule-associated protein tau (4R-tau) in neurofibrillary tangles, oligodendrocytic coils 
and astrocytic tufts (Dickson, 1999; Höglinger et al., 2017; Kovacs, 2015). 
The mandatory features are: a sporadic occurrence, minimum age at onset of the first 
symptoms at 40 years and gradual progression of PSP-related symptoms.  
In the present chapter, only the criteria for probable diagnosis will be briefly described 
since these are the diagnostic criteria subsequently used in the experimental studies (the 
detailed criteria are reported in the Appendices, page 199). 
The core clinical features for a probable diagnosis require the presence of a combination 
of these symptoms: ocular motor dysfunction (i.e., clear limitation of voluntary gaze range 
especially in the vertical plane), postural instability (i.e., spontaneous loss of balance while 
standing and history of more than one unprovoked falls, within 3 years), akinesia (i.e., 
sudden and transient motor block, within 3 years) and cognitive dysfunctions (i.e., defined 
as speech/language disorders or frontal cognitive deficits). 
Interestingly, PSP with the previous diagnostic NINDS-SPSP criteria was 
underdiagnosed (Respondek et al., 2017), as the criteria did not identify variants other than 
PSP-RS. Thus, the actual criteria included also other variants of PSP manifestation.  
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For instance, the ‘probable’ diagnostic criteria distinguish between PSP-RS, PSP-P, PSP 
with progressive gait freezing (PAGF) and PSP with predominant frontal presentation 
(Höglinger et al., 2017). 
A recent study by Williams et al. (2005) has tried to correlate the heterogeneity of 
clinical features (in PSP-RS, PSP-P and PAGF) with the pathological variations, based on 
regional differences in tau load or in the type of tau lesions. Thus, the neurofibrillary 
tangles, coiled, tufted astrocytes bodies and thread pathology were quantified, and a grading 
system was established accordingly for each region (Dickson, 1999) (Figure 1.5).  
The substantia nigra, subthalamic nucleus and globus pallidus were the regions most 
affected by tau pathology. Of note, tau severity was higher in PSP-RS compared to PSP-P 
and PAGF in all brain regions. 
The PSP-tau score (as the sum of the coiled bodies and the thread pathology in the 
substantia nigra, caudate and dentate nucleus) was a valuable marker for pathological 
disease progression (Williams et al., 2007).  
The examined cases were then grouped according to the PSP-tau score. Namely, the 
involvement was: with a score of 0–1, limited to the striatum and premotor cortex (Figure 
1.5B); scores of 2–3, moderate in the basal ganglia, pontine nuclei and dentate nucleus and 
absent in parietal lobe (Figure 1.5C); scores 4–5: severe in the basal ganglia and dentate 
nucleus and moderate in the frontal and parietal lobes (Figure 1.5D); scores 6–7: 
moderately severe in the basal ganglia, pontine nuclei, parietal and frontal lobes (Figure 
1.5E); score >7: severe in the subthalamic nucleus, substantia nigra, internal globus pallidus 
as well as neocortical areas, pontine nuclei and cerebellar structures (Figure 1.5F) (Williams 
et al., 2007). 
Overall, PSP-RS had a significantly higher PSP-tau score compared to PSP-P cases, and 
no PSP-P had a score higher than 5, suggesting that PSP-P had also a topographically 
restricted distribution of tau-pathology.  
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To summarize, tau pathology was more widespread in PSP-RS variant compared to the 
other variant (PSP-P), and this is aligned also with the clinical symptoms and cognitive 
dysfunctions (Bigio, Brown, & White, 1999; Josephs et al., 2006) (see also Section 2.1.3).  
 
 
Figure 1.5 Distribution of median coiled body plus thread tau pathology, according to PSP-tau 
score. Color/median grade per PSP-tau score: pink/grade 1; purple/grade 2; red/grade 3; 
brown/grade 4. A=legend; B = PSP-tau scores 0-1; C=PSP-tau scores 2-3; D=PSP-tau scores 4-5; 
E=PSP-tau scores 6-7; F=PSP-tau scores >7. Modified from Williams et al. (2007). 
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CHAPTER 2 
COGNITIVE FEATURES AND THEIR UNDERLYING MECHANISMS 
IN PARKINSONIAN DISORDERS 
 
As introduced in Chapter 1, atypical parkinsonisms (MSA and PSP) are characterized by 
rapid disease progression, poor response to dopaminergic treatment, and the presence of 
features that are atypical for PD (e.g., severe autonomic dysfunctions, cerebellar or 
pyramidal signs, early postural instability, or dementia in the early phase of the disease). 
Overall, the survival time is shorter and motor complications occur in the earlier stages of 
the disease and with higher degree of severity than in PD patients (Colosimo et al., 2011; 
Litvan, 2007; Muller et al., 2000).  
Recently, it has been recognized that also non-motor symptoms in movement disorders 
represent a crucial part of the parkinsonian disorders spectrum. Of note, non-motor 
symptoms include psychiatric symptoms (i.e., depression, anxiety, apathy); cognitive 
impairment; sleep disorders (i.e., restless leg syndrome, REM sleep behavior disorder, 
daytime somnolence); sensory and other symptoms (i.e., pain, fatigue) (Chaudhuri, Healy, 
& Schapira, 2006; Schapira et al., 2009). These symptoms, which can also appear early or 
even precede characteristic parkinsonian motor symptoms, are the ones that frequently 
trouble patients and caregivers the most, contributing significantly to quality of life 
(Colosimo et al., 2010; Duncan et al., 2014; Martinez-Martin, Rodriguez-Blazquez, Kurtis, 
Chaudhuri, & Group, 2011; Schapira et al., 2009). 
Thus, the present chapter will provide an overview on the state of the art regarding 
cognitive dysfunctions in parkinsonian disorders (namely, in PD, MSA, and PSP). Further, 
evidence on the biological mechanisms and structural changes underlying cognitive 
alterations in these disorders will be provided.  
2.1 COGNITIVE PROFILING  
Among the non-motor symptoms in parkinsonian disorders, perhaps cognitive deficits 
are probably the most relevant, since they can potentially predict dementia, which affects 
significantly patients’ autonomy, caregivers’ burden, as well as wields a considerable 
socioeconomic impact (Keranen et al., 2003; McCrone et al., 2011; Vossius et al., 2011).  
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In addition, assessing cognitive dysfunctions could help the diagnostic process, since 
distinct and specific neuropsychological profiles can be useful in defining the clinical 
picture in the diagnostic work up (Pillon, Dubois, & Agid, 1996). In this regard, in the early 
stage of the disease when motor symptoms are mild and not sufficiently evident, it could 
be challenging to differentiate parkinsonian disorders and establish the correct diagnosis. 
Indeed, misdiagnoses are not infrequent (Joutsa et al., 2014).  
As shown in Table 2.1, the cognitive profiles seem to be characteristic enough to 
differentiate cognitive impairment observed in PD from that found in PSP, or to 
distinguish MSA from PSP or PD with dementia (PDD). However, this is not the case 
when comparing MSA and PD, since their cognitive pattern is almost identical, as well as 
PSP versus PDD (Schapira et al., 2009). 
Hence, the following paragraphs will focus on cognitive features characterizing these 
three parkinsonian disorders: PD, MSA and PSP, respectively. 
 
Table 2.1 Neuropsychological profile in patients with movement disorders 
  PD PDD MSA PSP 
Dementia     
          Global impairment − + − + 
          Fluctuations − − − − 
Memory     
          Storage disorders − − − − 
          Recall disorders + ++ + ++ 
Instrumental disorders     
          Linguistic − ± − ± 
          Praxic − ± − ± 
Executive disorders     
          Planning + ++ + ++ 
          Behavior ± + ± ++ 
 
Note. Abbreviations: PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; MSA, 
multiple system atrophy; PSP, progressive supranuclear palsy; − = absent; ± = mild or discussed; + 
= moderate or present in a proportion of patients; ++ = severe and present in a majority of 
patients. The double crosses underline the neuropsychological characteristics of each disease. 
Adapted from Pillon et al. (1996). 
Cognitive features and their underlying mechanisms in parkinsonian disorders 
 45 
2.1.1 Parkinson’s disease  
Despite an initial controversy in 1817, about the existence of cognitive dysfunctions in 
PD (Parkinson, 2002), Dr. Jean-Martin Charcot, who named this disorder, conversely, 
underlined that in PD ‘the mind becomes clouded and the memory is lost’ (Charcot, 1889). 
Today, cognitive impairment and dementia are well recognized as the most prevalent 
and invalidating non-motor symptoms in PD. Robust evidence showed that compared to 
age-matched healthy subjects, PD patients experience more severe cognitive changes in 
several domains — namely, executive, attentive, visuospatial and also memory domains 
(Aarsland et al., 2017).  
Early PD patients are twofold more likely to develop mild cognitive impairment (MCI) 
than are healthy elderly (Aarsland et al., 2009; Foltynie, Brayne, Robbins, & Barker, 2004), 
and between the 20−57 percent of patients will experience MCI within the first five years 
of the disease (Janvin, Larsen, Aarsland, & Hugdahl, 2006; Williams-Gray, Foltynie, Brayne, 
Robbins, & Barker, 2007).  
Indeed, cognitive deficits in PD are defined as a heterogeneous entity, as they vary in 
severity from ‘subjective cognitive decline’, to MCI (i.e., insufficient to affect daily 
functioning), and to frank dementia (Marras et al., 2014). While severe cognitive deficits are 
observed in the advanced stage of the disease, mild cognitive changes are more common in 
the early phase of PD, affecting mostly the fronto-executive functions (Schapira et al., 
2009). 
Regarding fronto-executive dysfunctions, usually experienced by early-PD, untreated 
patients or even by the prodromal phase PD (Goldman, Williams-Gray, Barker, Duda, & 
Galvin, 2014; Santangelo et al., 2015), these dysfunctions mirror the deficits usually 
observed in patients with frontal lesions — as assessed by the Tower of London test, 
Wisconsin Card Sorting Test, and Odd-Man-Out Reaction Time test that evaluate 
planning, working memory, switching and concept formation (Kehagia et al., 2010; Morris 
et al., 1988; Owen et al., 1992; Taylor & Saint-Cyr, 1995). In line with these findings, PD 
has been considered as a frontostriatal syndrome (Kehagia et al., 2010); and in agreement 
with this observation, the first studies on dopaminergic treatment reported beneficial drug-
effects on cognition (i.e., on fronto-executive tasks) (Taylor & Saint-Cyr, 1995). Although 
dopaminergic treatment showed no effect on other cognitive functions (e.g., attentive set-
shifting, verbal memory, associative learning and spatial recognition memory), and further 
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showed a detrimental effect on another group of cognitive abilities (e.g., reversal learning, 
decision making and gambling) (Cools, Barker, Sahakian, & Robbins, 2003; Kehagia et al., 
2010). These findings explained the non-linear effect of dopaminergic treatment on 
cognition and are in line with the hypothesis of ‘dopamine overdose’ (Biundo, Weis, & 
Antonini, 2016a). Dopaminergic drugs, while improving motor symptoms (through dorsal 
striatum), can eventually overdose the ventral striatum and consequently the orbitofrontal 
cortex, leading to side effects on cognitive functions associated with this network 
(Swainson et al., 2000). 
Since dopaminergic treatment restores only a proportion of PD cognitive deficits, it is 
evident not all-cognitive dysfunctions are dopamine-related. Indeed, neurotransmitter 
systems such as acetylcholine, noradrenaline and serotonin are involved in cognition, 
leading to a heterogeneous picture (Biundo et al., 2016a; Kehagia et al., 2010) (see Section 
2.2.1 for a description). 
 
Mild cognitive impairment and dementia diagnostic criteria  
In this regard, cognitive deficits deserve attention from early disease stages, as they can 
possibly precede cognitive decline.  
Recently, considerable interest has been shown for ‘subjective cognitive complaints’ — 
initial cognitive deficits perceived by the patient or caregiver in a context of a normal 
performance at the cognitive evaluation. Of note, subjective cognitive complaints have 
been reported in patients with PD, and evidence showed these can possibly herald further 
cognitive alterations (Erro et al., 2014). 
The full ‘spectrum of cognitive statuses’ can be observed in PD, from normal cognition 
to PD with MCI (PD-MCI) and PDD. In recent decades, attention has focused particularly 
on PD-MCI, denoting a status of impaired cognition (as compared to a ‘normal’ age-
matched sample) suggesting a transitional status within a continuum from normal cognitive 
functions to dementia (Figure 2.1).  
Among patients with PD, approximately 25 to 30 percent are PD-MCI, and MCI 
syndrome is present at diagnosis in 10 to 20 percent (Svenningsson, Westman, Ballard, & 
Aarsland, 2012). Thus, PD-MCI seems to be associated with a shorter time (and so a higher 
risk) to develop dementia, even though considerable variability could be observed, and 
some patients can possibly revert to normal cognition (Pedersen, Larsen, Tysnes, & Alves, 
2013); or remaining stable as PD-MCI or PD cognitively normal (Figure 2.1). 
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Figure 2.1 Parkinson’s disease cognitive impairment spectrum. Although potential modifiers can 
contribute to progression, stability or reversion across the PD cognitive categories: demographic 
data, biological data (i.e., gene susceptibility, environmental factors, neuropathology), and clinical 
data (i.e., neuropsychological patterns or PD-MCI subtypes, cognitive tests performance, other 
neuropsychiatric features such as depression, apathy, sleepiness etc.), medical treatments (e.g., for 
motor, cognitive or other symptoms). MCI, mild cognitive impairment; PD, Parkinson’s disease. 
Adapted from Goldman et al. (2014). 
 
 
The concept of PD-MCI has been developed and defined in the Diagnostic and 
Assessment Guidelines of MDS, in order to: i) clinically characterize the earliest stage of 
PD cognitive impairment; ii) identify the predictors that better explain the conversion from 
PD-MCI to PDD; iii) determine to which extent PD-MCI influences quality of life and 
functional autonomy; iv) identify the more suitable patients for interventions that can 
possibly reduce cognitive decline; and iv) help clinicians in clinical practice and research 
(Litvan et al., 2012).  
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According to the MDS criteria, PD-MCI syndrome can be evaluated with an 
abbreviated assessment (Level I) or with a comprehensive neuropsychological assessment 
(Level II). Namely, according to: 
 
●  Level I: PD patients should be impaired on global cognitive abilities or impaired 
on at least two tests of a limited neuropsychological battery (i.e., if the battery 
included less than two tests per cognitive domain, or assessed less than five 
cognitive domains); and 
● Level II: PD patients should be impaired on two tests within each of the five 
cognitive domains (i.e., attention and working memory, executive, language, 
memory and visuospatial) or impaired on two tests within one cognitive domain. 
 
According to these criteria, the cutoff values for impairment are set between 1.0 and 
2.0 standard deviation (SD) below the appropriate norms. Furthermore, PD-MCI can be 
classified in two subtypes (only by means of Level II assessment): namely, as MCI-single 
domain, when the deficits are within a single domain; or MCI-multiple domain, when 
abnormalities are based on at least one test in two or more domains (Litvan et al., 2012) 
(the detailed criteria are reported in the Appendices, page 199). 
Several studies applied these standardized criteria, but the PD-MCI prevalence estimates 
remain highly variable (ranging from 20−62%) (Goldman et al., 2014). This high variability 
is possibly due to the different applied methodologies: indeed, there is still no consensus on 
which and how many cognitive tests are needed in the neuropsychological battery as well as 
which is the best cutoff value to define the impairment (1.0 or 1.5 or 2.0 SD) (Biundo et al., 
2016a). 
However, although the current criteria seem to have some weaknesses, a recent 
validation study supported their predictive validity and demonstrated that PD-MCI 
syndrome (as assessed by Level II) is highly related to the risk of turning into dementia 
(Hoogland et al., 2017). More specifically, the risk to develop dementia was 3.5-fold higher 
as compared to healthy subjects, and this effect was comparable to an age increase of 14 
years and increased PD severity of 37 points at the motor part of the MDS Unified 
Parkinson’s Disease Rating Scales (MDS-UPDRS III). This is aligned also with previous 
findings reporting that PD-MCI is at risk of developing dementia (Janvin et al., 2006; 
Pedersen et al., 2013). 
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Overall according to this evidence, PD-MCI syndrome seems to be not a ‘static entity’, 
but a ‘transitional status’, with a high risk for developing PD dementia.  
Diagnostic criteria for the diagnosis of PDD have been also recommended by the MDS 
Task Force (Dubois et al., 2007; Emre et al., 2007), and the diagnostic procedures for the 
PDD diagnosis have been established, by means of two series of tests. Namely, Level I, a 
practical test that requires no specific expertise in neuropsychology and can be used also at 
bedside; and Level II that is more comprehensive and reliable (the detailed criteria are 
reported in the Appendices, page 199). Specifically, according to: 
 
● Level I: patients should develop Parkinson before the onset of dementia; the Mini-
Mental State Examination (MMSE) should be below 26 (Folstein et al., 1975); 
cognitive severity should be severe enough to impair functional autonomy (as 
assessed by the caregiver interview or the Pill Questionnaire); impairment should be 
present in at least two of the following tests:  
● Months reversed, or Seven backward (MMSE) 
● Lexical fluency, or Clock drawing 
● MMSE Pentagons 
● 3-Word recall (MMSE) 
As supporting features, at least also one behavioral symptom should be present (i.e., 
among hallucinations, anxious or depressed mood, excessive daytime sleepiness, 
apathy, and delusions). 
● Level II: this assessment should follow the Level I, in order to better characterize 
the impaired components of PDD. Cognitive deficits include impairment in at least 
two of the four core cognitive domains and the presence of at least one behavioral 
symptom. Four areas will be investigated: global cognitive efficacy, subcortico-
frontal functions (i.e., executive functions, long-term memory process and retrieval 
ability), instrumental cortically mediated functions (i.e., language and complex 
visual-functions), and neuropsychiatric features. 
 
Objectively demonstrated cognitive deficits are the core features of these criteria, 
although another primary aspect to establish presence of dementia is that cognitive deficits 
must be severe enough to interfere and impair functional independence (i.e., personal care, 
social and occupational functioning), independently of the impairment related to motor or 
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autonomic symptoms (Emre et al., 2007). In this regard, measuring the specific impact of 
cognitive decline in patients with PD, minimizing the impact of the disease motor 
symptoms, is challenging and requires elements of clinical judgment (Aarsland et al., 2017; 
Marras et al., 2014). 
Furthermore, the lack of valid instruments capable of measuring the specific cognitive 
impact on functional independence, made this evaluation even more complex (Marras et 
al., 2014).  
Recent MDS PDD criteria suggest using the Pill Questionnaire to assess functional 
autonomy — however previous evidence reported its low sensitivity and specificity 
(Reginold et al., 2012). But now, there are two newer PD-specific instruments: the Brief 
Penn Daily Activities Questionnaire (Weintraub et al., 2013) and the PD-Cognitive 
Function Rating Scale (PD-CFRS) (Kulisevsky et al., 2013). 
These tools need to be validated across countries, but can possibly be useful in 
identifying alterations in the instrumental activities of daily living (IADL) due to cognitive 
deficits.  
 
Mild cognitive impairment and the risk of turning into PD dementia  
In the recent literature, there is great interest in the identification of biomarkers for the 
conversion from PD-MCI to dementia. However, the association between the first 
cognitive symptoms and the subsequent development of dementia has not been clearly 
determined. 
Of note, recently detailed characterization of patients with PD-MCI has led to the 
recognition that PD-MCI is more heterogeneous than what was previously expected, and 
this provides another point of confusion (Goldman et al., 2015). Namely within the ‘PD-
MCI classification’ there are several types of MCI patients (i.e., closer to the normal 
cognition vs. closer to dementia syndrome), and so far the current criteria are unable to 
assess and operationalize this heterogeneity within the PD-MCI definition (Biundo et al., 
2016a). 
This clinical heterogeneity can possibly reflect also a range of different pathologies, and 
combining all PD-MCI together into a single entity can create confusion in the research as 
well as the clinical and pathophysiological field (Goldman et al., 2015) (for further detail see 
Section 1.1.1).  
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The point-prevalence of dementia in PD is approximately 30 percent (Aarsland, Zaccai, 
& Brayne, 2005; Emre et al., 2007), and approximately 80 percent of PD patients 
progressed to dementia after 15 to 20 years from the beginning of the disease (Figure 2.2) 
(Aarsland & Kurz, 2010; Halliday, Hely, Reid, & Morris, 2008; Hely, Reid, Adena, Halliday, 
& Morris, 2008). 
 
Figure 2.2 Kaplan−Meier plot of time (years of disease duration) to presence of dementia and 
hallucinations. From Hely et al. (2008). 
 
The average rate of cognitive decline in PDD is about 2.3 points per year on the 
MMSE, similar to the decline observed in patients with AD, while in non-demented PD is 
about one point per year (Aarsland et al., 2004; Burn et al., 2006). Typically, patients with 
PD are characterized by a time period with a minimal decline, followed by an ‘inflection 
point’ after which a more severe decline is observed and interestingly the time of this 
inflection can vary a lot between patients (Aarsland, Muniz, & Matthews, 2011) (Figure 
2.3). 
Figure 2.3 Estimated mean Mini-Mental State examination trajectory. From Aarsland et 
al. (2011). 
Chapter 2 
 52 
 
Thus, defining whether a specific cognitive or motor pattern can predict the progression 
to dementia has been widely investigated, but this is still unclear (Troster, 2008, 2011). 
In this regard, some studies demonstrate that there are some distinct types of PD-MCI 
with different prognostic implications. 
A longitudinal study on PD motor-subtypes demonstrated that patients characterized by 
older-age, severe parkinsonism, as well as ‘postural instability and gait difficulty’ were 
associated with a higher risk to develop dementia, compared to the tremor-dominant type 
(Alves, Larsen, Emre, Wentzel-Larsen, & Aarsland, 2006). This is also aligned with the 
neuropathological evidence reported in the previous chapter (for further details see Section 
1.1.1). 
Interestingly, another study by Aarsland, Andersen, Larsen, Lolk, and Kragh-Sorensen 
(2003a) found an association between the presence of hallucinations and an akinetic-
dominant phenotype and the further turning into dementia (at 8 years of follow-up). In this 
regard, another study confirmed these results, demonstrating that hallucination increased 
the hazard of developing dementia at 4 to 5 years follow-up (Anang et al., 2014).  
With regard to the cognitive profile, clinical evidence from the CamPaIGN cohort 
showed two phenotypes of PD-MCI patients — the former, an executive 
dysfunction/frontostriatal type; while the latter, a posterior-cortical type with visuospatial 
(intersecting pentagon copying) and semantic naming deficits (Williams-Gray et al., 2009; 
Williams-Gray et al., 2013); and they found that the posterior-cortical phenotype was 
probably more associated with dementia. In agreement with these findings, a recent study 
showed that only PDD patients were impaired on executive and visuospatial tasks (Biundo 
et al., 2014). 
Another longitudinal study (5-year follow-up) observed that older PD-MCI with deficits 
in episodic memory, category fluency and mental flexibility tasks were more likely to 
develop dementia (Domellof, Ekman, Forsgren, & Elgh, 2015). 
These findings seem to be aligned with the so called ‘dual syndrome hypothesis’ 
(Kehagia, Barker, & Robbins, 2013), which identified two cognitive syndromes in PD — 
the ‘executive syndrome’ related to frontostriatal dysfunctions secondary to dopaminergic 
deficits, and the ‘posterior syndrome’ associated with cortical alterations and thus with 
mainly visuospatial and semantic deficits. According to this model the ‘posterior syndrome’ 
and thus cortical abnormalities can possibly herald a further progression to dementia.  
Cognitive features and their underlying mechanisms in parkinsonian disorders 
 53 
Coversely, another recent study demonstrated that frontal dysfunctions were associated 
with the conversion from PD-MCI syndrome to PDD (Lee et al., 2014) 
A further study of Besser et al. (2016), reported distinct cognitive and clinical 
characteristics in PD–MCI compared to MCI patients with AD, wherein PD-MCI are 
characterized by slower decline and different cognitive profiles; suggesting the need to use 
different instruments to monitor disease progression as well as for diagnostic purposes.  
Taken together, these findings seem to suggest that both the ‘dysexecutive’ and 
‘posterior’ syndromes can be a harbinger of PDD; but while the ‘dysexecutive’ syndrome is 
possibly a long-range predictor, the posterior cortical syndrome indicates a more imminent 
turning to dementia (Biundo, Weis, Fiorenzato, & Antonini, 2017). 
 
2.1.2 Multiple system atrophy 
According to a current consensus statement on the diagnosis of MSA (Gilman et al., 
2008), dementia is listed among the nonsupporting features.  
In the original paper of Quinn (1989), dementia has been reported as an exclusion 
criterion for ‘practical purposes’ as MSA patients usually showed a ‘preservation of 
intellect’ compared to the motor and autonomic dysfunctions. It was recognized that AD 
pathology could occur also in MSA, but amyloid depositions rates were not higher than in 
healthy subjects.  
In addition, few cases showing parkinsonism and dementia, presented cortical and 
diffuse LB at autopsy, suggesting not a diagnosis of MSA. Thus, dementia was listed as an 
exclusion criterion to not avoid misdiagnoses (Quinn, 1989).  
While there has been some reluctance to recognize cognitive deficits in MSA patients in 
previous clinical criteria, there is now abundant evidence that cognitive disorder can be 
early in the course of MSA (Kitayama, Wada-Isoe, Irizawa, & Nakashima, 2009; Konagaya, 
Sakai, Matsuoka, Konagaya, & Hashizume, 1999; Wakabayashi, Ikeuchi, Ishikawa, & 
Takahashi, 1998), and also cognitive disorders can precede motor symptoms (Kitayama et 
al., 2009).  
In the literature, the debate about the existence and severity of this cognitive decline is 
ongoing (Gerstenecker, 2017), however listing dementia as an exclusion criterion has been 
demonstrated to lead to misdiagnoses — MSA patients with cognitive impairment tended 
to be misdiagnosed as other neurodegenerative disorders (i.e., PSP, PD and DLB) (Koga et 
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al., 2015; Koga et al., 2016). As reported in a study by Kitayama et al. (2009), a subgroup of 
MSA patients with cognitive disorders preceding motor symptoms were misdiagnosed as 
AD during life. 
Increasing evidence suggests that the presence of cognitive dysfunctions is frequent, and 
this varies from 22 to 37 percent in MSA (with autoptic confirmation) (Homma, 
Mochizuki, Komori, & Isozaki, 2016; Wenning et al., 1997). Although so far the cognitive 
impairment in MSA remains poorly characterized (Stankovic et al., 2014).  
Furthermore, previous studies reported that motor severity is a predictor of cognitive 
decline (Brown et al., 2010; Kawamura et al., 2010), while controversial findings are 
reported for disease duration (Balas, Balash, Giladi, & Gurevich, 2010; Chang et al., 2009; 
Kawamura et al., 2010).  
Among patients who survived at least 8-year, the point prevalence of cognitive deficits 
was approximately 50 percent (Brown et al., 2010), as assessed with a score below the fifth 
percentile on the Mattis Dementia Rating Scale (DRS) (Mattis, 1988). While the interval 
between disease onset and the presence of significant cognitive deficits was about 6.5 years 
(O'Sullivan et al., 2008), the deficits were defined as interfering with the ability to perform 
tasks of daily living as described in Diagnostic and Statistical Manual of Mental Disorders 
(DSM) Fourth Edition criteria (APA, 1994). MSA patients with longer disease duration 
reported dementia after 13.5 to 17 years (Petrovic et al., 2012).  
Overall, these findings seem to suggest that dementia could be observed among the 
MSA clinical symptoms. This is in agreement also with PD cognitive decline, wherein 
dementia appears at an advanced disease stage (see also Figure 2.2, in Section 2.1.1) (Hely 
et al., 2008).  
Thus, possibly the majority of MSA patients did not experience dementia due to the 
short time of survival (indeed the disease duration is of approximately 7-9 years; for further 
details see Section 1.1.1) (Stankovic et al., 2014). 
Notably, previous studies assessed the presence of dementia in MSA using PD dementia 
criteria (Auzou et al., 2015; Kim et al., 2013), DSM-IV criteria (Kim et al., 2013; Kitayama 
et al., 2009; O'Sullivan et al., 2008), cut-off values of the Clinical Dementia Rating Scale 
(Chang et al., 2009; Kitayama et al., 2009), DRS (Brown et al., 2010), using a threshold of 
MMSE ≤ 24 (Kitayama et al., 2009), or of MMSE below 26 (Kim et al., 2013).  
On the basis of this heterogeneity on the assessment of dementia in MSA, comparing 
the findings of previous studies seems difficult. Dementia was defined with different 
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clinical criteria, and frequently also with a ‘combination of criteria’. However, varying the 
thresholds, and the applied methods can possibly affect the frequencies as well as the 
clinical profiles of dementia.  
This heterogeneity on the methods used is due to the fact that criteria for the diagnosis 
of MCI and dementia in atypical parkinsonisms have not been formulated; hence, few 
studies tried to apply the MDS PD criteria for the diagnosis of MCI or dementia (Emre et 
al., 2007; Litvan et al., 2012) (for further details see also Section 2.1.1). However, it remains 
unclear whether these criteria can be applied also in atypical parkinsonisms.  
Interestingly, some studies also used the DSM-IV criteria for the diagnosis of dementia. 
These criteria specify that memory deficits must be present, but it is well recognized that 
MSA patients exhibited more fronto-executive deficits (Brown et al., 2010; Gerstenecker, 
2017). Thus, the DSM-IV criteria for the diagnosis of dementia are probably not the most 
feasible to use in this population. Conversely, the latest criteria for dementia of DSM-5 (i.e., 
defined as major-neurocognitive disorder) did not require memory deficits (APA, 2012), 
but still it remains unclear whether it is better to apply the MDS PD criteria or the DSM-5 
in atypical parkinsonisms. 
Another important issue is that to assess the presence of dementia, the cognitive deficits 
should ‘significantly’ affect functional performance. However, the assessment of dementia 
in MSA is challenging as activities of daily living (ADL) and IADL are usually impaired due 
to motor dysfunctions from the disease’s first stages, and isolating the cognitive 
component of already impaired functional tasks requires elements of clinical judgment. 
Hence, if clinicians do not consider properly the motor impact of the disease on 
functional independence, there could be an overestimation of the extent to which cognitive 
dysfunctions are contributing to functional tasks (Feldman et al., 2001; Marras et al., 2014).  
Cognitive impairment in MSA covers a wide spectrum, and even though the executive 
dysfunctions are prominent, also alterations in the other cognitive domains have been 
observed (Gerstenecker, 2017; Stankovic et al., 2014) 
Regarding fronto-executive dysfunctions, up to 69 percent of MSA showed executive 
deficits (Auzou et al., 2015; Brown et al., 2010; Koga et al., 2016; Lyoo et al., 2008; Siri et 
al., 2013). Namely, over 40 percent had an impaired performance on verbal fluency tasks 
(phonemic and category fluencies) (Dujardin, Defebvre, Krystkowiak, Degreef, & Destee, 
2003; Kawai et al., 2008; Soliveri, 2000). Interestingly, category fluency was more impaired 
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than the phonemic fluency in some cases (Bak, Crawford, Hearn, Mathuranath, & Hodges, 
2005a; Kao et al., 2009).   
Further, also impairment in response inhibition tasks (as assessed by Stroop tests) 
(Meco, Gasparini, & Doricchi, 1996), mental flexibility, planning and problem solving were 
observed (Dujardin et al., 2003; Kao et al., 2009; Robbins et al., 1994). When comparing 
the performance of MSA-P versus MSA-C, the latter (MSA-C) were slower than the former 
(Chang et al., 2009). 
Also, deficits on the attentive/working-memory domain were observed, as assessed by 
Trail Making Test part B (TMT-B) (Chang et al., 2009; Kao et al., 2009). Instead, regarding 
working-memory tasks, MSA patients showed a similar performance to the other 
parkinsonisms (Kao et al., 2009; Stankovic et al., 2014), but another study demonstrated 
that MSA patients were able to apply some effective strategies in working-memory tasks 
(Gerstenecker, 2017; Robbins et al., 1994). 
In addition, also memory disorders were reported, namely up to 16 percent of MSA 
patients showed an altered performance on learning and long-term verbal memory task 
(Siri et al., 2013), also delayed and immediate recall (Brown et al., 2010; Kim et al., 2013; 
Lyoo et al., 2008). In the direct comparison of the two subtypes, MSA-C showed a worse 
performance than MSA-P on immediate as well as delayed recall (Balas et al., 2010; Chang 
et al., 2009). 
Regarding visuospatial abilities, there is inconsistent evidence in the literature, since 
some studies reported that visuospatial abilities were preserved in MSA (Bak, Caine, Hearn, 
& Hodges, 2006; Brown et al., 2010; Burk, Daum, & Rub, 2006); while a worse 
performance compared to healthy controls in visuospatial and visuo-constructive was also 
observed (Kawai et al., 2008; Kim et al., 2013; Lyoo et al., 2008).  
Language skills seem to be not consistently impaired in MSA (Gerstenecker, 2017; Kao 
et al., 2009), with the exclusion of verbal fluencies that are listed among the executive tasks 
in the majority of the studies. However, Kim et al. (2013) reported an altered performance 
in naming tasks in MSA with dementia compared with MSA without cognitive defects. 
Furthermore, studies investigating differences of cognitive performance in the MSA 
subtypes found controversial results. Evidence reported that MSA-P and MSA-C were 
compromised to a similar extent in executive and memory tasks (Burk et al., 2006; Siri et 
al., 2013); while Chang et al. (2009), examining the same cognitive domains, reported a 
worse performance in MSA-C patients. Another study reported that MSA-P patients were 
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cognitively more impaired than MSA-C, specifically the former reported multidomain 
deficits and the latter only visuospatial dysfunctions (Kawai et al., 2008).  
Recently, Koga and others (2016) observed that cognitive impairment was more evident 
on the comprehensive neuropsychological assessment rather than on the brief screening 
cognitive tests; thus the authors suggest to assess cognition extensively if MSA patients 
reported subjective complaints on cognition (Koga et al., 2016).  
Hence, if comprehensive assessments will be used in future studies, probably these will 
be useful to better define the MSA cognitive profile, as in the literature there are still 
inconsistent findings. 
Overall, executive dysfunction, followed by memory, attention and visuospatial deficits 
are observed in the cognitive profile of MSA with cognitive alterations (Wenning & 
Fanciulli, 2013); although according to the controversial results, no specific deficits were 
observed in the two MSA variants (i.e., MSA-P and MSA-C).  
Notably, the cognitive pattern of MSA patients seems to overlap the PD profile, 
characterized by mild impairment especially in executive functions as expression of the 
subcortical degeneration (Pillon et al., 1996; Pillon et al., 1995), resulting in a more severe 
profile only with the progression of the disease. In support of this observation, so far there 
is no neuropsychological testing able to differentiate the two synucleinopathies, while 
considerable differences have been observed compared to PSP (Pillon et al., 1995; 
Stankovic et al., 2014).  
 
2.1.3 Progressive supranuclear palsy 
Severe cognitive dysfunctions were reported in the first cases of PSP (Steele, 1964); ten 
years later, Albert, Feldman, and Willis (1974) described the cognitive and behavioral 
changes of seven patients with PSP and defined this specific pattern as ‘subcortical 
dementia’. Of note, this subcortical pattern was different from the one observed in patients 
with AD, while the observed deficits were more similar to those of patients with frontal 
lobe damage (Albert, 2005; Bak et al., 2005a).  
‘Subcortical dementia’ is a syndrome characterized primarily by slowness of thought 
(bradyphrenia), executive dysfunctions, impaired memory retrieval and behavioral changes 
(i.e., apathy, irritability); in the absence of aphasia, agnosia, and apraxia.  
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Thus, clinically different from ‘cortical dementia’ syndrome characterized by memory, 
language, perception and praxis disorders (Albert, 2005; Cummings, 1986). 
Cognitive and behavioral changes occur in the early stages of PSP, and bradyphrenia has 
been observed in 52 percent of patients in the first year of the disease (Dubois & Pillon, 
2005). Furthermore, approximately 70 percent will progress to dementia during the 
disease’s course (Daniel, de Bruin, & Lees, 1995; Pillon, Dubois, Ploska, & Agid, 1991). 
Evidence showed that cognitive dysfunctions rapidly progressed, namely in a sample of 24 
PSP, where 38 percent reported cognitive deficit at their first evaluation, while after 15-
month, this percentage significantly increased to 70 percent (Dubois & Pillon, 2005).  
It is worth noting, as previously mentioned for the MSA population that criteria for the 
diagnosis of MCI and dementia in atypical parkinsonisms have not been formulated (for 
further details see also Section 2.1.2).  
Previous studies on PSP defined dementia profiles with different clinical criteria: 
namely, using the DSM-IV (APA, 1994), as well as trying to apply the MDS PD criteria for 
the diagnosis of dementia (Emre et al., 2007) (for further details see also Section 2.1.1). 
Varying the methods can possibly affect the frequencies as well as the clinical profiles of 
dementia in PSP. Hence, there also is a strong need to define specific criteria for the 
diagnosis of dementia and MCI for PSP patients. 
Executive dysfunctions are the most common cognitive defect in PSP (Gerstenecker et 
al., 2013; Lee, Williams, & Anderson, 2016b; O'Keeffe et al., 2007) and are more severe 
than those observed in the other parkinsonian disorders (Dubois & Pillon, 2005). 
Bradyphrenia appears evident in PSP, who slowly answer questions as well as need 
more time to solve simple problems; this is also confirmed from the neuropsychological 
assessment, wherein PSP had an impaired performance on the Tower of London test 
(planning and problem-solving task) (Robbins et al., 1994). PSP patients also performed 
poorly in other executive tasks (i.e., Wisconsin Card Sorting Test that requires shifting and 
concept formation abilities), where a tendency to perseverate was observed (Pillon et al., 
1991). 
Cognitive slowing is not related to motor dysfunctions, but is a ‘genuine’ slowing of 
cognitive processes also observed in reaction time tasks (Dubois & Pillon, 2005; Dubois, 
Pillon, Legault, Agid, & Lhermitte, 1988); indeed, bradyphrenia can possibly also contribute 
to poor performance on verbal fluency tasks, which are more severely impaired in PSP 
compared to other parkinsonian disorders (PD and MSA). 
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This deficit has been reported in phonemic and category fluencies (Grafman, Litvan, & 
Stark, 1995; Soliveri, 2000). 
However, it is worth noting that especially phonemic fluency is severely impaired in PSP 
(Bensimon et al., 2009; Brown et al., 2010; Burrell, Hodges, & Rowe, 2014; O'Keeffe et al., 
2007; Pillon et al., 1991). 
Interestingly, Donker Kaat et al. (2007) reported that 50 percent of PSP named less than 
three words per minute beginning with a given letter, and 80 percent less than five, and 85 
percent less than nine words. 
In addition, a recent work demonstrated that phonemic fluency was able to differentiate 
PSP from PD patients with high specificity and sensitivity (0.85 and 0.83, respectively), at 
early PSP stage (3-year of disease duration). Seven or less words per minute suggests a 
diagnosis of PSP instead of PD and MSA; while the differentiation was slightly poorer 
when combining category and phonemic fluency (i.e., combined fluency) (Figure 2.4) 
(Rittman et al., 2013).  
 
Figure 2.4 Verbal fluency is very sensitive in differentiating PSP from PD. On the left side, 
phonemic fluency and on the right side, combined fluency (phonemic and category fluency).  Here, 
receiver operating characteristics curves are reported distinguishing between PSP versus PD in 
verbal fluencies (both subscores of ACE-R). Thresholds were chosen by means of a ‘top left 
corner’ algorithm. Confidence intervals are shown for sensitivity and specificity in parenthesis. 
ACE-R, Addenbrooke’s Cognitive Examination Revised; AUC, area under the curve; PD, 
Parkinson’s disease; PSP, progressive supranuclear palsy. Adapted from Rittman et al. (2013). 
 
Fluency deficits are not entirely associated with motor deficits, since motor involvement 
is quite minimal (Rittman et al., 2013). Possibly this is more associated with bradyphrenia 
that characterized PSP patients; namely the impaired performance is related to difficulties 
Phonemic and Combined Fluency 
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in words recalled rather than motor deficits.  In support of this observation, Rittman et al. 
(2013) noted PSP patients tend to generate a small number of ‘low frequency words’ (e.g., 
‘perambulator’), instead of ‘high frequency words’ (i.e., ‘people’, ‘phone’, etc.). 
These findings suggest that easy and brief tests such as phonemic and category fluency 
can also be used in clinical practice with a diagnostic purpose.  
Of note, several brief cognitive scales include verbal fluency: such as the Montreal 
Cognitive Assessment (MoCA)(Nasreddine et al., 2005), the Frontal Assessment Battery 
(FAB) (Dubois, Slachevsky, Litvan, & Pillon, 2000), the Addenbrooke’s Cognitive 
Examination-Revised (ACE-R) (Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006), 
suggesting that these scales are valuable tools to briefly assess cognitive functioning of PSP 
patients (Burrell et al., 2014). Conversely, MMSE seem to be very insensitive to PSP’s most 
impaired domains (i.e., executive and attentive) (Bak et al., 2005b; Bensimon et al., 2009; 
Lagarde et al., 2013). 
Regarding memory domain, one third of patients reported memory deficits — in long 
and short-term memory (Pillon et al., 1994; Robbins et al., 1994). Notably, it was observed 
that performance on memory retrieval tasks improved significantly when facilitations were 
presented (i.e., cueing or recognition) (Dubois & Pillon, 2005), suggesting memory deficits 
in PSP are not a ‘poor amnesia’, but the retrieval processes are possibly the most impaired 
(Pillon et al., 1994). Further, this would be aligned with the ‘subcortical’ memory profile, 
wherein retrieval deficits are frequently observed (Cummings, 1986). 
However, findings on memory domain are still controversial, since Aarsland et al. 
(2003b) found that PSP patients had no deficits in the memory subtest of the DRS (Mattis, 
1988). But these results are based on a subtest of a brief cognitive scale, thus possibly they 
are less reliable than the more complex memory measures used in previous studies (Pillon 
et al., 1994; Robbins et al., 1994). 
With regard to attention and working-memory domain, patients with PSP performed 
poorly on TMT-B as well as on other measures of attentional set-shifting (Grafman et al., 
1995; Paviour et al., 2005; Robbins et al., 1994).  
In addition, at 21-month follow-up, PSP patients showed a significant decline in 
attentive tasks (Soliveri, 2000). 
Evidence on visuospatial domain is also still uncertain, as PSP patients performed worse 
than MSA and PSP at Benton’s Judgment of Line Orientation Test (JLO) (Soliveri, 2000), 
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while showing no impairment in other visuospatial tasks of the Visual Object and Space 
Perception Battery (VOSP) (Bak et al., 2006). 
Also language deficits were observed in PSP patients (in naming tasks), however further 
studies need to verify this finding (Cotelli et al., 2006).  
Other features worth mentioning are the behavioral aspects that can be strictly 
connected with neuropsychological assessment as well as interfere with it (Bak, Crawford, 
Berrios, & Hodges, 2010; Brown et al., 2010).  
In this regard, PSP patients usually exhibit profound apathy that is among the 
supporting features of the PSP diagnosis. Apathy is observed in PSP almost as a rule — in 
up to 91 percent of cases (Litvan, Mega, Cummings, & Fairbanks, 1996b) and often it is 
one of the earliest symptoms (Burrell et al., 2014). Along with apathy severity, PSP patients 
usually develop disinhibited behaviors, impulsivity and show poor judgment (Litvan et al., 
1996b). This can be easily evaluated by means of the ‘clapping sign’: namely, when asked to 
clap their hands three times consecutively, usually PSP patients tend to clap more (i.e., four 
or five times) (Dubois & Pillon, 2005). 
Overall, this neuropsychological evidence was observed in the PSP-RS variant, 
suggesting that cognitive changes are more frequent in PSP-RS rather than PSP-P 
phenotype, in which fewer cognitive defects have been observed (Burrell et al., 2014).  
Tröster and Browner (2013) have proposed some guidelines and modifications that 
should be applied to the standard administration of the neuropsychological evaluation. 
Indeed, PSP patients are characterized by more severe motor dysfunctions than PD 
patients (i.e., vertical gaze palsy) that can hamper the cognitive evaluation. Thus, to not 
overestimate the cognitive deficits due to motor symptoms, some modifications should be 
applied to the standard administrations. For instance, it has been recommended to present 
the tests at about 45 cm from a patient’s face, due to downward gaze palsy impairments 
(Marras et al., 2014).  
To summarize, PSP striatocortical dysfunctions are so severe, they frequently lead to 
considerable executive dysfunctions (i.e., planning, monitoring) and recall deficits, followed 
by attention and visuospatial disorders and finally evolving toward dementia (Pillon et al., 
1996). 
Diffuse cortical changes probably secondary to subcortical alterations can produce 
composite pictures. Further, other factors (i.e., age at onset and disease duration) can 
possibly alter the neuropsychological profile at different time-point. 
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However, specific neuropsychological batteries, tailored for PSP patients and atypical 
parkinsonisms, can be a useful method not only for diagnosis work up, but also to better 
understand the underlying pathology and neuronal pathways affected by the disease 
(Dubois & Pillon, 2005). 
 
 
2.2 BIOLOGICAL MECHANISMS UNDERLYING COGNITIVE DEFICITS 
A large body of evidence recognized the heterogeneity of cognitive impairment in PD 
as well as in atypical parkinsonisms (for reviews see Gerstenecker, 2017 and Kehagia et al., 
2010; Pillon et al., 1996); and recently several studies aimed to identify the widespread 
pathological changes in the brain underpinning cognitive dysfunctions (Irwin et al., 2013; 
Kehagia et al., 2010). 
In this regard, understanding the nature of cognitive alterations and the interplay 
between cognitive, neurochemical and pathological entities, associated with cognitive 
deficits in parkinsonian disorders, is one of the major challenges. This will be crucial also 
for practical implications, such as advancing new treatments, as well as for prognostic 
purposes. Advances have been made in disentangling the neurochemical and 
neuropathological substrate of cognitive deficits in PD, and to a lesser extent, also in 
atypical parkinsonisms (MSA and PSP).  
Thus, the following paragraphs will provide a brief overview about the diverse 
biological mechanisms (i.e., neuropathological and neurochemical) underlying cognitive 
impairments in parkinsonian disorders. 
 
 
2.2.1 Parkinson’s disease 
As reported in the previous Section (2.1.1), cognitive alterations, particularly in the 
form of executive dysfunctions, are common in early-stage PD — although there is not a 
universal or uniform profile, and variable risks as well as progression rates to dementia are 
observed (Kehagia et al., 2010). The cognitive profile of patients who eventually develop 
dementia can differ from the typical dysexecutive profile seen in early-PD. Specifically, the 
roles of visuospatial and language deficits have been emphasized in those patients at a 
higher risk to develop dementia (Williams-Gray et al., 2007).  
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This heterogeneous constellation of cognitive deficits (caused by PD) can be explained 
by a combination of biological mechanisms (Kehagia et al., 2013), such as uneven striatal 
dopaminergic loss (Lewis & Barker, 2009; Sawamoto et al., 2008), or by the deficits of 
other neurotransmitter systems (i.e., acetylcholine and norepinephrine) (Halliday, Leverenz, 
Schneider, & Adler, 2014; Kehagia et al., 2010) as well as neurodegenerative pathologies 
(i.e., cortical LB and other non-parkinsonian features as a consequence of aging) 
(Kempster, O'Sullivan, Holton, Revesz, & Lees, 2010). Together, these heterogeneous 
processes that include neural and multiple neurochemical alterations can possibly interact, 
leading to the complex cognitive picture that characterizes PD patients, from the disease’s 
early stage.  
Hence, this Section will briefly introduce the neurobiological basis underlying cognitive 
impairment in PD patients: first, the neurochemical changes will be presented, and 
subsequently the neuropathological degenerative processes. 
 
Neurotransmitter systems underlying cognitive impairment 
PD is characterized by various neurotransmitter dysfunctions that can possibly 
contribute to explain its cognitive impairment. Among the neurotransmitter systems that 
have been emphasized are the importance of the dopaminergic dysfunctions (that 
underlines the diagnosis of this disorder), and the noradrenergic and the cholinergic 
dysfunctions (Halliday et al., 2014). Also serotonergic dysfunctions can possibly be 
involved in cognitive processes, but these will not be described in the present Section, since 
evidence is still limited (Kerenyi et al., 2003; Švob Štrac, Pivac, & Mück-Šeler, 2016). 
Interestingly, Kehagia and others (2010) proposed a ‘model’ able to describe the PD 
neuropsychological profile and its underlying neurochemical mechanisms. According to 
this model, executive dysfunctions characterizing the neuropsychological profile of PD-
MCI in the early stage of the disease are associated mainly to frontostriatal dopaminergic 
dysfunctions (depicted as the blue pathway in Figure 2.5).  
Further, although it remains to be verified, noradrenergic dysfunctions possibly can be 
related with attentional set-shifting impairment that forms part of the PD dysexecutive 
syndrome (depicted as the green pathway in Figure 2.5). Finally, also some frontal cholinergic 
dysfunctions can be observed in the early stage of the disease that possibly compromise 
PD cognition (depicted as the red pathway in Figure 2.5). However, cholinergic 
abnormalities seem to have a crucial role in the progression to PDD. Indeed, even though 
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diffuse cortical degeneration has been observed in PDD patients, the presence of specific 
deficits in the visuospatial and memory domains suggests a cholinergic involvement. In 
support of this observation, it has been demonstrated that cholinesterase inhibitors 
improve cognitive performance in PDD (Rolinski, Fox, Maidment, & McShane, 2012) — 
by contrast anticholinergic treatments accelerate the onset of cognitive alterations (Ehrt, 
Broich, Larsen, Ballard, & Aarsland, 2010). Of note, as shown in Figure 2.5, 
neuropsychological deficits in PDD include dysexecutive alterations (associated with 
dopaminergic and noradrenergic changes) as well as marked acetylcholine-based 
visuospatial and memory deficits.  
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Figure 2.5 Neurochemical pathways possibly implicated in PD cognitive deficits. Cholinergic 
pathways extend from: 1) the pedunculopontine nucleus to the thalamus and 2) the basal nucleus of 
Meynert to the neocortex. Dopaminergic pathways are the 3) nigrostriatal, from the substantia nigra 
(pars compacta) to the striatum; 4) mesolimbic, from the ventral tegmental area to the nucleus 
accumbens; 5) mesocortical, from the ventral tegmental area to the frontal cortex and 6) 
tuberoinfundibular, from the hypothalamus to the pituitary gland. The noradrenergic pathways are 
from 7) the lateral tegmental nucleus to the amygdala and hippocampus and 8) the locus coeruleus 
to the hypothalamus, thalamus, amygdala, cortex, and cerebellum. WCST, Wisconsin Card Sorting 
Test; TOL, Tower of London test; EDS, extra-dimensional shifting. From Kehagia et al. (2010). 
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Among the pathways compromised by PD and implicated in its cognitive dysfunctions, 
there is the dopaminergic pathway (Figure 2.6) including the nigrostriatal system that 
projects from the substantia nigra (pars compacta) to the striatum; the mesolimbic system 
that projects from the ventral tegmental area to the nucleus accumbens (limbic regions), 
and the mesocortical system that projects from the ventral tegmental area to the frontal 
cortex (Halliday et al., 2014). The nigrostriatal pathway, which provides feedback to the 
striatum necessary to control actions and cognition; especially the projections to the 
putamen, degenerate early in PD, even before LB formation (Milber et al., 2012). Of note, 
nigrostriatal dopaminergic degeneration is almost identical in PD and PDD (Colloby et al., 
2005), and this is aligned also with evidence from neuroimaging studies in PD (Klein et al., 
2010; Pavese, Rivero-Bosch, Lewis, Whone, & Brooks, 2011). With regard to the mesolimbic 
pathway, greater degeneration is reported in PDD patients (Zweig, Cardillo, Cohen, Giere, 
& Hedreen, 1993); namely cognitive changes are possibly associated to cell loss in the 
caudate nucleus and ventral striatum (Mattila et al., 2001). In addition, this pathway plays a 
key role in behavioral features (e.g., impulsivity) (Reyes, Cottam, Kirik, Double, & Halliday, 
2013). 
Instead, the findings from functional imaging about the mesocortical pathway suggest a 
reduction in cortical dopamine in PDD patients (Ito et al., 2002), but the effects of 
dopaminergic treatment on mesocortical system are still not completely understood 
(Delgado-Alvarado et al., 2016). 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Dopaminergic pathways affected in PD and PDD: in red the substantia nigra (SN); in 
dotted red line the ventrolateral substantia nigra (VLa SN); in yellow the ventral tegmental area 
(VTA); in dotted orange the medial SN and VTA which give rise to mesolimbic projections 
affected in PDD. PDD, Parkinson’s disease with dementia; cp, cerebral peduncle; N.acc, nucleus 
accumbens; R, red nucleus. From Halliday et al. (2014). 
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The noradrenergic pathways extend from the lateral tegmental nucleus to the amygdala 
and hippocampus, and from the locus coeruleus to the hypothalamus, thalamus, amygdala, 
cortex, and cerebellum (Figure 2.7) (Halliday et al., 2014). Although there is less evidence 
about the noradrenergic effects on cognition in PD, it has been suggested that alterations 
of this pathway can contribute to another subset of higher-order cognitive flexibility 
deficits (i.e., attentional set-shifting) (Kehagia et al., 2010). In agreement with this 
observation, a pilot study demonstrated that a noradrenaline reuptake inhibitor improved 
executive functions, attention, and verbal memory in PD patients (Marsh, Biglan, 
Gerstenhaber, & Williams, 2009). Marked alterations of noradrenergic pathways are 
reported in PDD, but there is little evidence on its contribution to the progression of 
dementia (Del Tredici & Braak, 2013; Zweig et al., 1993). Furthermore, degeneration of 
this pathway is associated with alterations of cholinergic neurons in the basal nucleus of 
Meynert (Halliday et al., 2014; Zweig et al., 1993). 
 
Figure 2.7 Noradrenaline pathways affected in PD and PDD: noradrenergic neurons innervate 
most of the brain including the substantia nigra (SN) and thalamus, pathways affected in patients 
with PD, as well as the nucleus basalis of Meynert (NBM), cortical and limbic regions, pathways 
affected in PDD. N. acc=nucleus accumbens. From Halliday et al. (2014). 
 
 
Instead, the cholinergic pathways that are more involved in cognition extend from the 
pedunculopontine nucleus to the thalamus, and from the nucleus basalis of Meynert to the 
neocortex (Figure 2.8) (Halliday et al., 2014). Cholinergic deficits originated from changes 
in the basal forebrain (e.g., associated with degeneration as well as LB pathology) and 
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ascending cholinergic pathways affecting amygdala, hippocampus and cortical regions (i.e., 
frontal, parietal, and superior temporal cortex) that are more pronounced in PDD 
compared to non-demented PD and AD patients (Bohnen & Albin, 2011; Kuhl et al., 
1996). 
Neuropathological evidence showed that reduced choline acetyltransferase in the 
temporal cortex was associated with cognitive impairment (Mattila et al., 2001; Perry et al., 
1985), and progression to dementia correlated with the cholinergic degeneration of the 
basal forebrain (Ruberg, Rieger, Villageois, Bonnet, & Agid, 1986). Further, this agreed also 
with the findings from in-vivo neuroimaging studies, wherein PDD were characterized by a 
broad loss of cortical acetylcholine (Bohnen & Albin, 2011; Yarnall, Rochester, & Burn, 
2011). 
 
Figure 2.8 Acetylcholine pathways affected in PD and PDD: The two major acetylcholine nuclei 
with projections to the forebrain are the nucleus basalis of Meynert (NBM), and the 
pedunculopontine nucleus. The pedunculopontine nucleus projects to the thalamus (this is affected 
in PD), while the NBM projects to limbic regions and cortex (this is affected in PDD). 
Caud=caudate nucleus, GPe=external globus pallidus, GPi=internal globus pallidus, ic=internal 
capsule, OT=optic tract, Put=putamen, N. acc=nucleus accumbens. From Halliday et al. (2014). 
 
 
To summarize, heterogeneity of cognitive impairment in PD reflects the complexity of 
the neurodegenerative disease process that includes the interaction of the dopaminergic, 
noradrenergic and cholinergic systems. A recent model tried to explain this heterogeneity 
with the ‘dual syndrome hypothesis’, which distinguishes between a profile characterized by 
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frontostriatal deficits in PD/PD-MCI, and a profile characterized by a greater involvement 
of the cholinergic system in PDD — with distinctive cholinergic memory, visuospatial 
psychiatric deficits (Kehagia et al., 2013) (for further details see Section 2.1.1).  
Nevertheless, this hypothesis recognizes some degree of overlap and interaction 
between the two ‘syndromes’ and their underpinning systems; indeed, PDD could not exist 
without a significant disruption of the dopaminergic system, given nigrostriatal 
degeneration is the core feature of PD (Kehagia et al., 2013). 
Furthermore, mesolimbic and mesocortical dopamine dysfunctions contribute to 
executive deficits, but it is worth noting that these systems include also the parietal and 
temporal cortexes (De Keyser, Ebinger, & Vauquelin, 1989); thus, possibly also their 
involvement contributes to the ‘posterior’ deficits. By contrast, cholinergic deficits will 
probably also contribute to executive dysfunctions since their system also innervates some 
frontal regions (Kehagia et al., 2013). Although this model distinguished two specific 
‘syndromes’, it does consider the presence of underlying ‘interacting’ patterns of 
neurodegeneration — recognizing the complexity of the disease processes underpinning 
cognitive impairment heterogeneity. 
This agrees also with a recent model proposed by Gratwicke, Jahanshahi and Foltynie 
(2015), which provides a neural network approach to the mechanisms underlying cognitive 
features of PDD (see Figure 2.9 for further details). The authors hypothesized the 
involvement of specific brain networks (i.e., frontostriatal, mesocortical, cholinergic, 
fronto-parietal, medial temporal and noradrenergic networks), influenced by dopaminergic, 
noradrenergic and cholinergic deficits. Namely, executive dysfunction in PDD is mostly 
associated with disruption of the frontostriatal and mesocortical dopaminergic pathways, 
followed by dysfunction of the noradrenergic and cholinergic networks (Gratwicke et al., 
2015). Attention deficits, in particular ‘top-down’ executive control deficits are mediated by 
dysfunction of the fronto-parietal network, while ‘bottom-up’ orienting of attention deficits 
are associated with cholinergic and noradrenergic networks dysfunctions. Further, 
according to this model, memory deficits, in terms of memory storage and retrieval, are 
mediated by medial temporal lobe structures; whereas memory encoding as well as 
visuoperceptual deficits are associated with nucleus basalis of Meynert cholinergic network. 
Overall both Gratwicke’s neural network model (Gratwicke et al., 2015) and the ‘dual 
syndrome hypothesis’ (Kehagia et al., 2013) supported the predominance of cholinergic 
dysfunction as predictor of dementia in PD. Namely, the former model identified the 
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nucleus basalis of Meynert cholinergic network as involved in all cognitive domains 
dysfunction.  
 
 
 
 
Figure 2.9 Model of neural networks and neurotransmitter affected in PDD, and associated 
cognitive deficits. As shown in the legend, colored arrows correspond to the neural networks and 
neurotransmitter involved. Black crosses indicate dysfunction in the network, black dashed arrows 
associate the dysfunctional network with the cognitive deficits. Purple arrows show that cognitive 
deficit in a specific domain can contribute to deficits among other cognitive domains. The red 
dashed arrow indicates the connection between prefrontal areas to the nucleus basalis of Meynert. 
The frontostriatal, orbitofrontal, limbic and associative circuits correspond to the parallel 
organization linking basal ganglia and cortex by Alexander et al. (1986). Cx = cortex; DLPFC = 
dorsolateral prefrontal cortex; fx = function; GPi = globus pallidus (internus); NBM = nucleus 
basalis of Meynert; PPC = posterior parietal cortex; SN = substantia nigra; VLPFC = ventrolateral 
prefrontal cortex; VTA = ventral tegmental area. Modified from Gratwicke et al., 2015. 
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Neuropathology underlying cognitive impairment  
Also, the neuropathological substrate of cognitive alterations in PD appears 
heterogeneous in nature and includes mainly LB, AD pathology and cerebrovascular 
lesions (Halliday et al., 2014; Irwin et al., 2013).  
The majority of studies observed that PDD has higher levels of cortical synuclein 
pathology than PD (Apaydin, Ahlskog, Parisi, Boeve, & Dickson, 2002; Compta et al., 
2011; Irwin et al., 2012; Jellinger & Attems, 2008; Kempster et al., 2010). 
In this regard, the progression of synuclein pathology was inversely correlated with 
cognitive performance (on several cognitive measures) (Aarsland et al., 2003a; Kovari et al., 
2003; Mattila, Rinne, Helenius, Dickson, & Roytta, 2000). Notably, a large autopsy cohort 
of 48 non-demented PD and 92 PDD cases found that cortical and limbic LB and LN 
were the strongest predicators of dementia in PD (Irwin et al., 2012). 
However, overall, evidence from the literature suggests that cortical and limbic 
synuclein are not necessarily required for the development of PDD (Irwin et al., 2013) —
non-demented PD with marked burden of cortical and limbic synuclein pathology has been 
observed (Hurtig et al., 2000), as well as PDD with minimal cortical synuclein pathology at 
autopsy (Galvin, Pollack, & Morris, 2006; Irwin et al., 2012; Pletnikova, 2005). 
Thus, Irwin et al. (2013) suggested that PDD with reduced cortical and limbic synuclein 
pathology can possibly be associated with the presence of comorbid pathologies (i.e., 
amyloid-β pathology). 
Interestingly, there is evidence that disease progression in PDD is also faster in 
presence of comorbid amyloid pathology — in particular, without amyloid-β pathology the 
mean survival was about 10.1 years while it was about 4.5 years in presence of comorbid 
amyloid pathology (Jellinger, 2003; Jellinger, Seppi, Wenning, & Poewe, 2002). PDD with 
amyloid comorbidity was also associated with older age-at-onset of motor symptoms (Irwin 
et al., 2012; Jellinger et al., 2002; Sabbagh, 2009). 
In this regard, although the key role of synuclein pathology in PDD has been 
frequently demonstrated, some studies observed that also amyloid pathology burden as well 
as tau-neurofibrillary tangles were inversely associated with cognitive defect in PDD 
(Compta et al., 2011; Jellinger, 2007; Jellinger & Attems, 2008; Kovari et al., 2003). A recent 
study, wherein cortical synuclein and amyloid pathologies were quantitatively assessed, 
found that when combining both the two pathologies the correlation with PDD was higher 
(Compta et al., 2011). 
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PDD patients with amyloid- related pathology have higher levels of cortical and limbic 
synuclein compared to PDD patients without the comorbidity (Compta et al., 2011; 
Pletnikova, 2005). In addition, increased severity of amyloid pathology and tau-
neurofibrillary tangles correlated with a higher burden of cortical synuclein (Compta et al., 
2011; Harding & Halliday, 2001; Jellinger, 2007; Lashley, 2008), suggesting a possible 
interaction (Toledo et al., 2016). In agreement with this observation, recent evidence from 
neuropathological studies suggests coincident amyloid pathology may alter the spread of 
LB in PD (Toledo et al., 2016) 
To conclude, it seems very likely that there is a synergistic effect between age, synuclein 
and amyloid pathologies, which has been considered as the main trigger of cognitive 
decline in PD — as the presence of amyloid in PD patients can possibly lead to a PD-
subtype with an older-age of onset, which is characterized by a more ‘malignant prognosis’ 
(Compta et al., 2011; Halliday & McCann, 2010; Irwin et al., 2013). 
Lastly, recent evidence from neuroimaging studies confirmed these patterns of 
underlying pathologies associated with PD cognitive decline (Duncan, Firbank, O'Brien, & 
Burn, 2013),  
In this regard, a further Section will briefly overview the neuroimaging evidence 
assessing such structural changes underpinning cognitive deficits in PD (for further details 
see Section 2.3.1). 
 
 
2.2.2 Multiple system atrophy 
In MSA, pathological changes affect primarily subcortical structures, while cortical 
pathology is not a predominant feature of this disorder (Papp & Lantos, 1994) (for further 
details see Section 1.1.1). Namely, MSA is characterized by putaminal and nigral 
degeneration (Wenning et al., 1997), and by a disruption of striato–pallido–thalamocortical 
circuit possibly secondary to the subcortical degeneration (Stankovic et al., 2014).  
Furthermore, evidence from neuropsychological studies showed that executive 
dysfunctions are the prominent cognitive symptoms in MSA (Gerstenecker, 2017) (for 
further details see Section 2.1.2), thus it has been suggested that the concept of ‘subcortical 
dementia’ may partially explain cognitive features of MSA (Bak et al., 2005a; Cummings, 
1986; Stankovic et al., 2014). 
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Recently, a few studies investigated the underlying neuropathology of cognitive 
alterations in MSA, but the results are controversial, and the underlying mechanisms are 
still not completely understood. 
Notably, a neuropathological study reported no significant difference between 
cognitively impaired MSA and MSA without cognitive impairment — GCIs and neural 
cytoplasm inclusions in limbic or cortical regions as well as secondary pathological 
conditions (AD-related pathology) were not more severe in MSA with cognitive alterations 
(Asi et al., 2014). The authors noted that cognitive deficits in MSA are independent of AD-
pathology or other secondary pathologies, suggesting that cognitive impairment can be 
possibly intrinsic of the MSA disease process, but without being associated with GCIs or 
neural cytoplasm inclusions. 
By contrast, other studies demonstrated that neural cytoplasm inclusions in limbic or 
cortical regions (rather than GCIs) were related to cognitive dysfunctions in MSA 
(Cykowski et al., 2015; Homma et al., 2016; Koga et al., 2016). 
Recently, Koga et al. (2016) reported a greater burden of neural cytoplasm inclusions in 
the limbic regions (i.e., hippocampal dentate gyrus) that were associated with cognitive 
impairment in MSA. Although in this study, they did not identify any correlations between 
cognitive measures and the respective neuroanatomical regions: suggesting that MSA were 
characterized by a predominant fronto-subcortical pattern of cognitive dysfunction. 
Then, in another study, it was demonstrated that presence of LB-like inclusions in the 
neocortex was strongly associated with cognitive alterations, suggesting that neural 
pathology plays an important role both in cognition and disease progression (Cykowski et 
al., 2015). 
Finally, Homma and others (2016) reported that MSA with dementia was characterized 
by frequent globular neural cytoplasm inclusions in the medial temporal region (i.e., 
subiculum). Furthermore, they did not find any association between dementia and AD-
pathology (i.e., neurofibrillary tangles and senile plaques). Thus, the author suggested that 
neural cytoplasm inclusions in medial temporal regions are one of the most important 
features in MSA with dementia, also in a context of absent cortical atrophy. 
More recently, in a single-case study, an MSA patient with dementia showed numerous 
neural cytoplasm inclusions in the perirhinal cortex’s anterior portion, but without 
hippocampal involvement (Saito et al., 2017). 
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However, further neuropathological studies are still required to elucidate the underlying 
mechanism of cognitive impairment in MSA, in this regard also correlations of cognitive 
measures and the responsible neuroanatomical regions will be necessary (Koga & Dickson, 
2017). 
 
 
2.2.3 Progressive supranuclear palsy 
Neuropathology of PSP is widespread and comprises several structures; namely the 
substantia nigra, subthalamic and red nucleus, pontine tegmentum, striatum, oculomotor 
nucleus, medulla, and dentate nucleus (Litvan et al., 1996a) (for further details see Section 
1.1.2). 
Cognitive dysfunctions are a prominent feature of PSP patients, especially of PSP-RS 
phenotype (Gerstenecker, 2017; Gerstenecker et al., 2013) (for further details see Section 
2.1.3), and due to the prevalence of executive dysfunctions as well as bradyphrenia, their 
cognitive impairments profile has been described with the concept of ‘subcortical 
dementia’ (Albert, 2005; Albert et al., 1974; Bak et al., 2005a). In this regard, striatofrontal 
dysfunction is frequently severe and leads to dramatic monitoring, planning, and recall 
deficits, progressing toward dementia (Dubois & Pillon, 2005). 
Despite the lack of detailed neuropsychological studies in patients with pathological 
confirmed PSP, there is little neuropathological evidence that reported correlations 
between global cognitive performance and underlying pathology. 
In this regard, Cordato, Halliday, Harding, Hely, and Morris (2000) found that PSP 
patients had a greater frontal lobe atrophy (compared with PD and DLB patients) that 
correlated with clinical dementia. Furthermore, the authors reported significant frontal 
atrophy without clinical dementia, although overall, the most severe frontal atrophy 
correlated with dementia. Of note, hippocampal volumes were relatively well preserved in 
both demented as well as in non-demented PSP patients. 
Interestingly, a factorial analysis in a study by Verny, Duyckaerts, Agid, and Hauw 
(1996) was able to isolate the cortical from the subcortical factor. The results showed the 
extent of cortical pathology was not entirely determined by the severity of the subcortical 
changes, suggesting it possibly was due to an independent disease mechanism. 
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As mentioned above, dementia with predominant frontal features is common in PSP 
(Brown et al., 2010; Burrell et al., 2014). Since at first, the cortex was thought to be spared, 
Albert and others (1974) hypothesized a subcortical origin of cognitive symptoms — 
leading to the concept of ‘subcortical dementia’ (Albert, 2005; Albert et al., 1974; Verny et 
al., 1996), possibly due to the deafferentation from thalamus or reticular structure. 
However, correlations between dementia and lesions in the entorhinal region have been 
found (Braak, Jellinger, Braak, & Bohl, 1992); and further, the presence of neurofibrillary 
tangles in frontal regions leaves the possibility that some cognitive deficits are associated 
with these lesions (Verny et al., 1996).  
Clinicopathological studies that aim to explain the underlying pathology of cognitive 
impairment in PSP are still limited and further studies with autopsy-based correlates are 
necessary to elucidate the pathological mechanisms of dementia in PSP. 
 
 
2.3 STRUCTURAL NEUROIMAGING UNDERLYING COGNITIVE 
DEFICITS 
In recent decades, several neuroimaging techniques have considerably been used to 
advance our understanding of the complex mechanisms underpinning development of 
cognitive impairment as well as the potential progression to dementia in parkinsonian 
disorders (Aarsland et al., 2017; Biundo et al., 2016a; Delgado-Alvarado et al., 2016). 
Structural magnetic resonance imaging (MRI) can identify and localize differences in 
regional tissue volume (i.e., cortical and subcortical) between groups of individuals. 
The following Sections will overview the most recent literature on structural changes 
underlying cognitive dysfunctions in PD, MSA and PSP.  
 
 
2.3.1 Parkinson’s disease 
The major aim of neuroimaging studies in PD has been to identify potential biomarkers 
of the progression to dementia and MCI — despite the elevated number of studies, so far 
no explicit biomarker has been identified. A possible explanation for this is that the 
majority of these studies are based on the PD-MCI available criteria, leading to a very 
heterogeneous PD-MCI sample (for further details see Section 2.1.1) (Biundo et al., 2016a; 
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Litvan et al., 2012). Of note, also the inclusion of small samples as well as heterogeneous 
neuroimaging methodological approaches could also have increased variability (Biundo et 
al., 2016a). 
As expected, several cross-sectional studies have reported broader brain atrophy in 
PDD as compared to PD-MCI patients and PD with normal cognition (PD-NC) 
(Apostolova et al., 2012; Biundo et al., 2013; Compta et al., 2012; Delgado-Alvarado et al., 
2016; Melzer et al., 2012; Summerfield et al., 2005); namely in the parietal, occipital, 
temporal, and frontal areas, as well as in other specific regions (i.e., hippocampus, 
amygdala, caudate, putamen, thalamus, and substantia innominate) (Figure 2.10) (Delgado-
Alvarado et al., 2016).  
 
 
Figure 2.10 Summary of the potential biomarkers of PD with dementia (PDD) and PD with mild 
cognitive impairment (PD-MCI) found in studies of magnetic resonance imaging. Adapted from 
Delgado-Alvarado et al. (2016). 
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In this regard, PDD patients showed more cortical thickness than PD-MCI in the 
anterior cingulate and entorhinal and orbitofrontal cortices as well as in the 
parahippocampus, temporal pole, precuneus, and fusiform and lingual areas 
(Pagonabarraga et al., 2013). Furthermore, PDD also showed cortical volume reductions in 
several temporal and prefrontal areas (Song et al., 2011), including the amygdala compared 
to PD-MCI (Choi et al., 2012). 
Interestingly, evidence on PD-MCI reported cortical volume reduction in the frontal, 
parietal and posterior areas, as well as atrophy in the hippocampus, which correlated with 
memory deficits (Mak et al., 2015; Pereira et al., 2015). Further, longitudinal studies 
demonstrated that patients with PD-MCI showed a cortical thinning in frontal, temporal, 
parietal and occipital cortices, and loss of hippocampal volume that was related to cognitive 
decline (Hanganu et al., 2014; Mak et al., 2015). Hippocampal volume has also been 
identified as a predictor of the further conversion to PD-MCI (Kandiah et al., 2014), and 
other evidence using Bayesian network classifiers was aligned with this finding (Morales et 
al., 2013). Indeed, Morales et al. (2013) demonstrated that it was possible to classify PDD, 
PD-MCI and PD-NC with high sensitivity and specificity — PDD patients were identified 
by left hippocampal and right entorhinal cortex atrophy and by lateral ventricles 
enlargement, while PD-MCI patients were characterized by brain stem and left 
hippocampus atrophy. 
Another 2-year longitudinal study showed that atrophies in the caudate nuclei, 
prefrontal and insular cortex were associated with a further cognitive decline and thus 
turning into dementia (Lee et al., 2014). Lastly, another study identified volume reduction 
in the occipital cortex as able to differentiate PDD from PD without cognitive defects 
(Burton, McKeith, Burn, Williams, & O'Brien, 2004). 
To summarize, several studies reported a typical cortical thinning pattern that identified 
PDD. Specifically, this pattern is associated with gray matter loss in the frontal, temporal, 
parietal, occipital cortices; in conjunction with volume loss in the insula, hippocampus, 
parahippocampus, and cingulate gyrus, which is associated with cognitive decline (Hwang 
et al., 2013; Pagonabarraga et al., 2013; Rektorova et al., 2014; Zarei et al., 2013). 
Taken together these findings seem i) to suggest that reduced volume or thickness in 
several cortical areas as well as in the hippocampus appear to be associated with the further 
progression to PD-MCI or PDD; ii) to be aligned with the ‘dual syndrome hypothesis’. 
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Indeed, progressive thinning of ‘posterior’ regions together with ‘frontal’ atrophy can 
possibly herald a progression towards dementia. 
 
 
2.3.2 Multiple system atrophy 
In the literature, there is little evidence of structural MRI studies investigating the 
pattern underlying cognitive impairment in MSA. This is probably associated to the fact 
that cognitive deficits are still listed as an exclusion criterion among the MSA diagnostic 
criteria (Gilman et al., 2008), as well as due to the rare nature of this disease.  
 Several studies tried to identify a specific pattern underpinning MSA pathology — and 
indeed, a characteristic pattern was found — with cortical atrophies in the frontal, 
temporal, and parietal areas in MSA-P (Brenneis et al., 2007; Brenneis et al., 2003; 
Minnerop et al., 2007) and in MSA-C (Brenneis et al., 2006; Hauser et al., 2006; Specht et 
al., 2003; Specht, Minnerop, Müller-Hübenthal, & Klockgether, 2005).  
Interestingly, about the pattern underpinning cognitive alterations in MSA, Kim et al. 
(2013) found MSA with dementia was characterized by focal cortical atrophies on 
parahippocampal and lingual cortices compared to MSA without dementia, which was not, 
suggesting a pattern resembling those found in AD or PDD (even though more 
widespread in these two disorders).  
Instead, a previous study by Paviour, Price, Jahanshahi, Lees, and Fox (2006) found a 
correlation in MSA patients between pontine, midbrain, and cerebellar atrophy and 
impairment in attentive/executive domains as well as global cognition (i.e., FAB), 
advancing the hypothesis of cortical deafferentation secondary to subcortical regions 
alterations. In this regard, this hypothesis also was in agreement with another study 
demonstrating that short disease duration was associated with atrophy in the striatum, 
while longer disease duration was associated with increasing atrophy in the cortical and 
cerebellar areas (Brenneis et al., 2007). 
Interestingly, a study by Chang et al. (2009), wherein more cognitive domains were 
assessed (i.e., memory, attention and executive), noted that prefrontal atrophy correlated 
with the memory performance of MSA patients. Further, evidence from a functional study 
reported a dorsolateral prefrontal hypoperfusion associated with executive dysfunction in 
MSA-P (Kawai et al., 2008). Overall, these findings seem to suggest an important role of 
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frontal regions in understanding the underpinning mechanisms of cognitive deficits in 
MSA.  
Recently, another study on MSA-P demonstrated that cortical, cerebellar atrophy and 
striatal degeneration were associated with the presence of cognitive impairment (i.e., 
immediate and recall memory, and executive functions) in these patients (Kim et al., 2015). 
By contrast, Lee et al. (2016a) found that cortical thinning in the fronto-temporo-
parietal regions and volume reduction in subcortical structures were significantly correlated 
with attentional, executive and visuospatial dysfunctions in MSA-C patients: suggesting 
cognitive dysfunctions in MSA-C can possibly result from functional disruption of the 
corticostriatal and pontocerebellar circuit, mediated by primary cortical, cerebellar or 
thalamic pathology. 
To summarize, overall evidence from structural neuroimaging studies in MSA seem to 
suggest that both deafferentation from subcortical structures and intrinsic cortical 
pathology have a crucial role in cognitive decline, wherein cortical involvement is possibly 
secondary to a subcortical alteration (Stankovic et al., 2014). However, these hypotheses 
need to be verified by further studies applied in larger cohorts and with reliable cognitive 
measures, possibly not biased by motor dysfunctions.  
 
 
2.3.3 Progressive supranuclear palsy 
Although cognitive dysfunctions are widely recognized as a prominent feature of PSP 
(Brown et al., 2010), there is still little neuroimaging evidence in literature about the 
underlying structural deficits associated with cognitive impairment. 
Regarding the distribution of atrophy associated with the disorder, it has been noted 
that the pattern is less broad from neuroimaging evidence (i.e., voxel-based 
morphometry)(Cordato, Duggins, Halliday, Morris, & Pantelis, 2005; Ghosh et al., 2012; 
Josephs et al., 2008; Padovani et al., 2006), than in neuropathological studies (Schofield, 
Hodges, Bak, Xuereb, & Halliday, 2012): suggesting that maybe tau inclusions have only a 
weak correlation with the extensive cell loss that underpins atrophy detected by MRI 
studies (Burrell et al., 2014). 
Neuroanatomical changes underlying cognitive deficits were reported by Cordato et al. 
(2005), namely PSP presented symmetrical atrophies in the frontal cortex (i.e., orbitofrontal 
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and medial frontal cortex), subcortical nuclei (i.e., midbrain, caudate and thalamic) and 
periventricular white matter that correlated with cognitive measures (MMSE). 
Furthermore, Paviour et al. (2006) found that alterations in the brainstem and 
subcortical structures contribute to cognitive deficits in PSP, namely an association 
between increased midbrain atrophy and a worse performance on the FAB was observed. 
Interestingly, the association with the midbrain was even stronger than the frontal atrophy. 
In addition, they found a correlation between increasing lateral ventricles atrophy (possibly 
explained by changes at the lateral ventricle/caudate nucleus boundary) and decline at the 
FAB. Hence, the authors suggested that the atrophy in the caudate can possibly contribute 
to worsening of the subcortical dementia.  
Overall, the evidence about neuroanatomical changes associated with cognitive deficits 
in PSP is very limited; but these findings seem to be promising and in line with the concept 
of ‘subcortical dementia’ (Albert et al., 1974). 
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CHAPTER 3 
MONTREAL COGNITIVE ASSESSMENT AND MINI-MENTAL STATE 
EXAMINATION PERFORMANCE IN PROGRESSIVE 
SUPRANUCLEAR PALSY, MULTIPLE SYSTEM ATROPHY and 
PARKINSON’S DISEASE1 
 
 
3.1 Introduction  
Cognitive dysfunctions are frequently reported in PD as well as in atypical 
parkinsonisms — at early disease phase, absence of marked cognitive changes makes a 
diagnosis of PD and MSA more probable, while presence of dysexecutive symptoms are 
more suggestive of a diagnosis of PSP that is considered the typical form of ‘subcortical 
dementia’ (Bak et al., 2005a; Dubois & Pillon, 2005; Lee et al., 2012).  
However, the identification and magnitude of cognitive abnormalities are frequently not 
routinely assessed in most clinical settings, and performing a comprehensive 
neuropsychological assessment is impractical in most clinical settings (Marras et al., 2014). 
Thus, to make cognitive assessment more practical during routine care, brief screening 
cognitive scales can be adopted, to support the clinician in the diagnostic process.  
Indeed, brief cognitive scales have some advantages over extensive neuropsychological 
evaluation: brevity, low cost and higher patient acceptability (Bak et al., 2005a; Burrell et al., 
2014). Cognitive screening tools should be sensitive in detecting parkinsonism-related 
cognitive dysfunctions, possibly brief and easy to be administered.  
Among the generic screening tests adopted in PD cognitive assessment, MMSE is the 
most widely used (Folstein et al., 1975). Although MMSE was designed for assessing AD, it 
has been applied to several disorders also in PD populations, but MMSE was relatively 
insensitive in detecting MCI or dementia, mainly as it does not investigate the fronto-
executive domain (Hoops et al., 2009). 
                                                 
1 Published: Fiorenzato, E., Weis, L., Falup-Pecurariu, C., Diaconu, S., Siri, C., Reali, E., ... & Biundo, R. 
(2016). Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in 
progressive supranuclear palsy and multiple system atrophy. Journal of Neural Transmission, 123(12), 1435-1442. 
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On the contrary, the MoCA, another brief cognitive screening tool widely used in PD 
patients (Nasreddine et al., 2005), showed high sensitivity and specificity in the assessment 
of cognitive dysfunctions in PD (Gill et al., 2008; Hoops et al., 2009; Zadikoff et al., 2008).  
Indeed, previous evidence reported higher sensitivity and adequate psychometric 
properties with MoCA, when compared to MMSE in detecting cognitive changes, 
particularly in the general population (Luis, Keegan, & Mullan, 2009), and in several 
neurodegenerative conditions such as AD, DLB, and Huntington’s disease (HD) (Biundo 
et al., 2016b; Hoops et al., 2009; Nasreddine et al., 2005; Videnovic et al., 2010). 
However, MoCA has been poorly investigated in atypical parkinsonisms — especially in 
PSP and MSA (Kawahara et al., 2015). 
Thus, we hypothesize that as observed in PD, MoCA should have a higher sensitivity 
than MMSE also in atypical parkinsonisms due to the lack of ceiling effect and the more 
challenging attention-executive subitems (Hoops et al., 2009; Zadikoff et al., 2008). 
This present study’s objective was to investigate the sensitivity of MoCA and MMSE 
scales in detecting cognitive dysfunctions in atypical parkinsonisms, probable MSA and 
PSP, as compared to PD patients.  
 
3.2 Methods 
3.2.1 Study population and data collection 
One hundred thirty patients with parkinsonian disorders were evaluated. Namely, 35 
patients with MSA, 30 with PSP and 65 age, sex and education matched PD patients. Data 
were collected across three European centers specialized in movement disorders: San 
Camillo Hospital Foundation, Venice, Italy; Parkinson Institute, ASST G. Pini-CTO, 
Milan, Italy and at the Faculty of Medicine, Transilvania University, Brasov, Romania. All 
the patients fulfilled the clinical ‘probable’ level of the diagnostic criteria and the diagnoses 
were based on the more recent published criteria (Gelb et al., 1999; Gilman et al., 2008; 
Höglinger et al., 2017). Patients with PSP were all of Richardson’s syndrome phenotype.  
Ethical approval was obtained from the Venice Research Ethics Committee, Venice, 
Italy and before study enrolment, patients gave their written, informed consent. This study 
was conducted in accordance with the Declaration of Helsinki. 
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The two brief cognitive scales, MMSE and MoCA, were performed at each center on 
two separate occasions within five to seven days, in a random order and administered in 
the morning ON medication. 
Demographic variables (i.e., age, education, sex) and clinical characteristics (i.e., disease 
duration, age of onset) were collected; in addition, motor symptoms were assessed by 
means of the motor session of the MDS-UPDRS III administered by neurologists with 
experience in movement disorders.  
Exclusion criteria were presence of psychiatric and other neurological comorbidity, and 
surgical treatment with deep brain stimulation. 
Levodopa equivalent daily dose (LEDD) and dopamine agonist equivalent dose 
(DAED) were calculated accordingly to Tomlinson and others (2010).   
 
3.2.2 Statistical analyses 
All statistics were performed using SPSS version 20 (IBM SPSS, Chicago, IL). Statistical 
significance threshold was set at p < 0.05 and Bonferroni correction was used to control 
for multiple comparisons.  
One-way Analysis of Variance (ANOVA) was run to analyze the clinical and 
demographic data of the whole sample, while the Pearson’s chi-squared test was adopted to 
analyze categorical variables. To compare the mean difference in MMSE, MoCA and 
MoCA’s letter fluency task across the MSA, PSP and PD group, ANOVA was run. 
Further, if clinical and demographic variables differed among the groups, analysis of 
covariance (ANCOVA) was run to compare MMSE, MoCA and MoCA’s letter fluency 
scores controlling for the previously mentioned variables. Lastly, to evaluate the presence 
of ceiling or floor effects in MMSE and MoCA scales, we calculated the 25 to 75 percent 
percentiles for each group. To compare the MSA subgroups (MSA-P and MSA-C), we ran 
a non-parametric analysis due to the non-normal distribution of several outcome variables; 
the Kruskal-Wallis test was applied for the between-groups comparison.  
Backward linear regression analysis was also run to investigate if clinical or demographic 
characteristics explained the variance between the two scales. Thus, we set MMSE and 
MoCA scores as dependent variable; and age, education, disease duration, MDS-UPDRS 
III score, LEDD and DAED as independent variables. Pearson’s correlation coefficients 
were calculated between the scales in each group. 
Chapter 3 
 86 
Regarding the analysis of the subitems, first we normalized the subitems scoring 
differences in each scale, dividing the subitem’s obtained scores by the subitem’s maximum 
score, and then the ‘weighted subitems means’ were converted to percentage. Lastly, we ran 
Pearson’s chi-squared analyses to compare the performance on MMSE and MoCA 
subitems. Receiver Operating Characteristic (ROC) curves with Area Under the Curve 
(AUC) (95% CI) were also obtained. Then, for each scale’s total scores (MMSE and 
MoCA) and for the subitems reaching the significance, we calculated the AUCs, optimal 
cut-off, sensitivity, specificity, positive predictive value and negative predictive value. The 
optimal cut-off point was defined as the value optimizing the combination of sensitivity 
and specificity scores of each test by means of Youden’s J statistic (J) (Youden, 1950), and 
the difference in discriminative power (i.e., AUC) of each cut-off score for between-group 
comparisons was tested with DeLong’s method (DeLong, DeLong, & Clarke-Pearson, 
1988).  
 
3.3 Results 
3.3.1 Demographic and clinical features 
Table 3.1 shows the demographic and clinical data and the corresponding group 
comparisons. Data of MSA subtypes, MSA-P and MSA-C are presented in Table 3.2.
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Table 3.1 Demographic and clinical characteristics of MSA, PSP and PD groups 
 
MSA                                                                                                     
(n = 35)  
PSP                                                     
(n = 30)  
PD                                               
(n = 65)  
MSA 
vs.                                                                     
PSP 
PSP 
vs.
PD 
MSA 
vs.
PD 
 
Mean 
(SD) Mdn min max  
Mean 
(SD) Mdn min max  
Mean 
(SD) Mdn min max  p value 
                   
Age, y 64.5                   (6.1) 64.5 49 77  
69.8            
(7.4) 70.0 57 88  
67.5          
(7.5) 68.0 49 85  
*   
Sex 
(m/ f) 18/17     12/18     40/25     
   
Education, y 10.1      (4.1) 9.0 5 18  
9.0              
(3.2) 8.0 4 17  
9.6            
(4.2) 8.0 4 18  
   
Disease 
duration, y 
4.5        
(1.9) 4.0 1 10  
5.4              
(3.1) 4.5 2 14  
7.7            
(4.5) 7.0 0 22  
 * *** 
Age of onset, y 60.1      (5.9) 61.5 44 69  
64.4            
(7.5) 64.0 48 80  
59.7          
(8.7) 59.0 43 74  
 *  
MDS- 
UPDRS-III 
38.6      
(19.4) 35.5 11 93  
41.2          
(16.6) 37.5 16 73  
24.0        
(11.9) 22.0 4 68  
 ** ** 
LEDD 
602.1  
(340.0
) 
621 0 1340  476.1       (303.0) 500 0 1208  
897.3     
(552.3) 800 0 2511  
 ** * 
DAED 85.9    (96.9) 9 0 240   
53.0          
(84.7) 0 0 249   
143.3     
(108.3) 160 0 400   
  ** * 
 
 
Note. The p values were obtained by one-way analysis of variance. Chi-squared analyses were used for categorical 
variables. Significant difference Bonferroni-corrected for multiple comparison at: * = p < 0.05, ** = p < 0.001,  *** = p 
< 0.0001. MSA, multiple system atrophy; PSP, progressive supranuclear palsy; PD, Parkinson’s disease; Mdn, median; 
min, minimum; max, maximum; MDS-UPDRS III, Movement Disorder Society Unified Parkinson’s Disease Rating Scale 
III; LEDD, levodopa equivalent daily dose; DAED, dopamine agonist equivalent dose.  
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Table 3.2 Demographic data of the MSA sample (MSA-P and MSA-C subtypes) 
 
MSA-P                                                                                                    
(n = 26)   
MSA-C                                                             
(n = 9) 
MSA-P 
vs.                                                                     
PSP 
MSA-P 
vs.         
PD 
 Mean            (SD) Mdn min max   
Mean                 
(SD) Mdn min max p value 
            
Age, y 64.8           (5.3) 64.0 51 70  
63.8                
(8.2) 64.5 49 72   
Sex (m/ f) 13/13     5/4      
Education, y 9.9                 (4.0) 8.0 5 18  
10.6                 
(4.6) 10.0 5 18   
Disease duration, y 4.4              (1.7) 4.0 1 8  
4.7                       
(2.6) 4.0 2 10  * 
Age of onset, y 60.4            (5.3) 61.0 47 68  
59.2                 
(7.6) 62.0 44 67   
MDS-UPDRS III 39.8                (19.4) 40.0 15 93  
35.00                  
(20.2) 33.0 11 78  * 
LEDD 620.0              (350.1) 660.0 0 1340  
550.2                   
(319.2) 400.0 200 1338   
DAED 97.7            (95.4) 100.0 0 240  
52.0                      
(98.5) 0.0 0 240   
MMSE 27.7           (2.3) 28.0 21 30  
27.4                 
(2.7) 28.0 23 30   
MoCA 23.1                 (2.6) 23.0 18 28  
22.3                    
(4.2) 22.0 15 28 **  
MoCA                   
letter fluency 
10.1 
(4.9) 9.5 3 22   
11.8 
(4.7) 12.0 5 20   
 
Note. The p values were obtained by non-parametric Kruskal-Wallis test and Bonferroni post hoc test to compare groups. 
Chi squared analyses were used for nominal variables.  Comparison was considered significant at: * = p < 0.05, ** = p < 
0.001. No differences between MSA-C vs. MSA-P, MSA-C vs. PD, MSA-C vs. PSP. MSA, Multiple System Atrophy; 
MSA-P, MSA Parkinsonian type; MSA-C, Cerebellar type; PSP, Progressive Supranuclear Palsy; PD, Parkinson’s Disease; 
Mdn, median; Min, minimum score; Max, maximum score; MDS-UPDRS III, Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale III; LEDD, Levodopa Equivalent Daily Dose; DAED, Dopamine Agonist Equivalent 
Dose; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment. 
 
 
Patients with MSA were younger than PSP (p = 0.01), while the PD group agreed in age 
with PSP and MSA patients. No differences were found between-groups in terms of 
education and sex. The PD group had longer disease duration than PSP (p = 0.01) and 
MSA groups (p < 0.0001); and PSP patients were older at disease onset than PD (p = 0.02) 
but not older than MSA patients. 
We also noted that PD patients had lower motor severity (MDS-UPDRS III) than PSP 
(p = 0.00003) and MSA (p = 0.00004) as well as PD patients had higher LEDD and 
DAED than PSP (p = 0.0002; p = 0.0004 respectively) and MSA patients (p = 0.007; p = 
0.02 respectively). 
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3.3.2 Cognitive results 
MMSE mean total score was higher than the mean of MoCA in the whole group (27.05 
± 2.43 vs. 21.54 ± 3.93), as well as in PSP (26.0 ± 2.9 vs. 18.2 ± 3.9, p < 0.0001), MSA 
(27.7 ± 2.4 vs. 22.9 ± 3.0, p < 0.0001), and PD patients (27.3 ± 2.0 vs. 22.3 ± 3.5, p < 
0.0001). Correlation analysis showed that MMSE and MoCA total scores were highly 
correlated (PSP: r = 0.75, p < 0.0001, MSA: r = 0.63, p < 0.0001, and PD: r = 0.68, p < 
0.0001). Interestingly, MSA subtypes (MSA-P and MSA-C) had a similar performance on 
MoCA and MMSE scales and we found no significant differences when comparing their 
performances on both scales (Table 3.2). Thus in the present thesis, we decided to analyze 
all MSA subjects as a whole group without differentiating them according to their subtypes. 
To investigate a possible floor and ceiling effect of the scales, we ran some descriptive 
analyses and we noted that MMSE scores of 29 or 30 were found in 13 percent of PSP, 48 
percent of MSA and 28 percent of PD patients. Indeed, these higher scores corresponded 
with the 75th percentile (Figure 3.1, Table 3.3), while in MoCA the maximum scores did not 
correspond with the 75th percentile and overall MoCA scale showed a broader distribution. 
Figure 3.1. Between-group differences for MMSE and MoCA total scores. Box plots show the 
medians with upper (75th percentile) and lower quartiles (25th percentile). The T-bars (whiskers) that 
extend from the boxes indicate maximum and minimum values. The p values were obtained by one-
way analysis of variance. Significant differences Bonferroni-corrected for multiple comparison at: * 
= p < 0.05, *** = p < 0.0001. MSA, multiple system atrophy; PSP, progressive supranuclear palsy; 
PD, Parkinson’s disease; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive 
Assessment. 
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Table 3.3 Between-group differences for MMSE and MoCA scores 
 
MSA                                                                                                     
(n = 35) 
PSP                                                          
(n = 30) 
PD                                                 
(n = 65) 
 MSA 
vs.                                                                     
PSP 
PSP 
vs.
PD 
  Mean (SD) Mdn min max 
25           
−         
75P 
Mean 
(SD) Mdn min max 
25           
−         
75P 
Mean 
(SD) Mdn min max 
25           
−         
75P 
 
P value 
                   
MMSE  27.7              
(2.4) 
28.0 21 30 27            
−            
30 
26.0            
(2.9) 
26.0 19 29 24.8             
−               
28 
27.3               
(2.0) 
27.0 20 30 26         
−           
29 
 
* * 
MoCA 22.9                
(3.0) 
23.0 15 28 21             
−           
25 
18.2            
(3.9) 
18.0 11 27 16           
−                 
21.25 
22.3                 
(3.5) 
23.0 13 28 20           
−         
25 
 
*** *** 
MoCA                  
letter 
fluency 
10.5 
(4.8) 
10 3 22 7             
−           
14 
6.6 
(3.6) 
7 2 17 2             
−           
17 
10.1 
(4.5) 
12 3 21 9             
−           
14 
 
** *** 
 
Note. The p values were obtained by one-way analysis of variance. MSA, Multiple System Atrophy; PSP, Progressive 
Supranuclear Palsy; PD, Parkinson’s Disease; Mdn, median; Min, minimum score; Max, maximum score; 25-75P, 25-75th 
percentile; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment. 
Significant difference Bonferroni-corrected for multiple comparison at: * = p < 0.05, ** = p < 0.001,  *** = p < 0.0001. 
 
Results from backward linear regression analysis showed that in the PSP group 52 
percent of MMSE variance was explained by age, LEDD and education, and 34 percent of 
MoCA variance was explained by age and LEDD (Table 3.4).  
In MSA group, 15 percent of MMSE variance was explained by education, while 41 
percent of MoCA variance was explained by education associated with age. Instead, in the 
PD group the only factor that explained the variance in MMSE and MoCA scales was 
education, accounting for the 12 percent and 16 percent of variance, respectively. 
Overall, we noted that there was a tendency for a positive correlation between LEDD 
and MMSE (r = 0.373, p = 0.051), and LEDD and MoCA (r = 0.373, p = 0.05). 
Between-group comparisons showed that PSP patients had a mean MoCA score (18.2 ± 
3.9) lower than MSA and PD patients (22.9 ± 3.0, p < 0.00001; 22.3 ± 3.5, p < 0.00001, 
respectively). While this difference was less significant when comparing PSP mean MMSE 
score (27.7 ± 2.4) with MSA and PD performances (26.0 ± 2.0, p = 0.004; 27.3 ± 2.0, p = 
0.01, respectively). Further, since we found between-group differences in age (only between 
MSA and PSP group), disease duration, motor severity and LEDD, we used those variables 
as covariates. Results from ANCOVA confirmed that PSP had a significantly lower MoCA 
compared to MSA (p < 0.001) and PD (p < 0.011), while the difference for MMSE was no 
more significant when comparing PSP with MSA (p < 0.064) and PD (p < 0.079). 
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Figure 3.2 showed the results of the MMSE and MoCA subitems analyses. On the 
MMSE scale, PSP patients had a lower performance in the ‘copy of the pentagons’ 
compared to MSA and PD patients (p = 0.0223; p = 0.0121, respectively).  
While on the MoCA scale, the PSP group performed worse than MSA and PD patients 
in several subitems, respectively: in the ‘digit forward task’ (50% vs. 80%, p = 0.0223 and 
50% vs. 78%, p = 0.0121), ‘abstraction task’ (37% vs. 71%, p = 0.0125 and 37% vs. 62%, p 
= 0.0402) and ‘letter-fluency’ (13% vs. 43%, p=0.0173 and 13% vs. 62%, p = 0.00001). We 
also found additional differences between the three groups, which are reported in Table 
3.5. However, applying Bonferroni correction for multiple comparisons, the significant 
results were noted only on the following MoCA subitems: namely, in the ‘copy of the cube’ 
where PSP performed worse than MSA (corrected p = 0.047) and in the ‘letter fluency’ 
where PSP had a highly significant lower performance than PD (corrected p = 0.0012). 
 
Table 3.4 Impact of clinical and demographical variables in explaining MMSE and MoCA 
score variance 
   R2 R2-adjusted Independent            variables Coefficient Std. Error t p value 
                
MSA    (Constant) 25.204 1.021 24.682 < 0.0001 
 MMSE 0.172 0.147 Education 0.241 0.093 2.582 0.015 
         
    (Constant) 33.163 4.659 7.118 < 0.0001 
 MoCA 0.449 0.414 Age -0.219 0.071 -3.098 0.004 
       Education 0.381 0.097 3.931 < 0.0001 
          
PSP    (Constant) 36.758 5.542 6.632 < 0.0001 
 MMSE 0.587 0.518 Age -0.233 0.072 -3.214 0.005 
    Education 0.377 0.174 2.167 0.044 
    LEDD 0.004 0.001 2.836 0.011 
         
    (Constant) 37.316 7.618 4.898 < 0.0001 
 MoCA 0.404 0.342 Age -0.298 0.108 -2.756 0.013 
        LEDD 0.005 0.002 2.246 0.037 
         
PD    (Constant) 25.605 0.591 43.328 < 0.0001 
 MMSE 0.138 0.124 Education 0.179 0.057 3.174 0.002 
         
    (Constant) 19.038 1.007 18.912 < 0.0001 
  MoCA 0.168 0.155 Education 0.343 0.096 3.564 0.001 
 
Note. Backward regression analyses were run including Mini-Mental State Examination (MMSE) and Montreal Cognitive 
Assessment (MoCA) as dependent variable and as independent variables: age, education, disease duration, Movement 
Disorder Society Unified Parkinson’s Disease Rating Scale III (MDS-UPDRS III), Levodopa Equivalent Daily Dose 
(LEDD) and Dopamine Agonist Equivalent Daily Dose (DAED). 
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Figure 3.2 Between-group differences (obtained by Pearson’s Chi-squared analyses) in MMSE and 
MoCA subitems. In figure a) performance on MMSE and figure b) performance on MoCA. MSA, 
multiple system atrophy; PSP, progressive supranuclear palsy; PD, Parkinson’s disease; TMT-B, 
Trail Making Test (part B). * = p ≤ 0.05 ** = p ≤ 0.01, *** = p ≤ 0.001, # Significant after 
Bonferroni correction p < 0.05. 
 
 
Results of the ROC curve analyses for MMSE and MoCA total scores as well as the 
MoCA letter fluency subitems are reported in Table 3.6.  
MoCA total score and its fluency subitem were able to discriminate PSP from PD 
patients with AUC exceeding 0.80, as shown in Figure 3.3.  
In addition, a MoCA total score equal to 19 was able to differentiate PSP patients from 
MSA (AUC 0.83, specificity 0.89, sensitivity 0.70) as well as PSP from PD (AUC 0.78, 
specificity 0.80, sensitivity 0.70). While a cut-off score at the letter fluency subitem equal to 
7-words per minute was able to distinguish PSP from MSA patients (AUC 0.75, specificity 
0.71, sensitivity 0.70) as well as from PD (AUC 0.82, specificity 0.86, sensitivity 0.70). 
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Table 3.5. MMSE and MoCA subitems comparison between MSA, PSP and PD groups 
MMSE subitems          MoCA subitems         
  
MSA                   
vs.                    
PSP 
PSP                    
vs.                    
PD 
PD               
vs.            
MSA 
  
MSA                   
vs.                    
PSP 
PSP                    
vs.                     
PD 
PD                  
vs.               
MSA 
           
Temporal orientation  0.6627 0.7969 0.9690  TMT-B  0.4164 0.1385 0.7721 
Spatial orientation  0.8269 0.8799 0.6538  Cube  0.0039# 0.0905 0.1276 
3 words repetition  0.8269 0.4300 0.2921  Clock  0.0290 0.7157 0.0532 
Serial 7s  0.8269 0.2856 0.8781  Naming  0.8829 0.5239 0.7254 
Recall 3 words  0.5844 0.9652 0.5995  Digit forward  0.0223 0.0121 0.9816 
Naming  0.6453 0.8031 0.2921  Digit backward  0.3641 0.5725 0.7517 
Phrase repetition  0.7839 0.3521 0.2364  Sustained attention  0.5829 0.3892 0.0463 
3 stage command  0.8855 0.9407 0.9690  Serial 7s  0.2073 0.0294 0.7137 
Read & obey  0.8924 0.2253 0.6353  Phrases repetition  0.5082 0.3091 0.9835 
Writing  0.1806 0.1376 0.6172  Letter Fluency  0.0173 < 0.0001# 0.1069 
Pentagons   0.0223 0.0121 0.9816  Abstraction  0.0125 0.0402 0.4959 
          5 words recall  0.0943 0.2270 0.5734 
      Orientation   0.8655 0.7258 0.5389 
 
Note. P values are reported. Significant differences (p < 0.05) are reported in bold type.  #Significant values after 
Bonferroni correction for multiple comparisons (p <0.05). MMSE, Mini-Mental State Examination subitems; MSA, 
multiple system atrophy; PSP, progressive supranuclear palsy; PD, Parkinson’s disease; MoCA, Montreal Cognitive 
Assessment; TMT-B, Trail Making Test (part B). 
 
 
Table 3.6 Receiver operating characteristic for between-group comparisons 
       Cut-off Specificity (95% CI) Sensitivity (95% CI) PPV NPV 
       
PSP vs. MSA       
MMSE  26*  0.77 (0.60 to 0.90) 0.57 (0.37 to 0.75) 0.68 0.68 
MoCA  19*  0.89 (0.73 to 0.97) 0.70 (0.51 to 0.85) 0.84 0.78 
MoCA Fluency  7* 0.71 (0.54 to 0.85) 0.70 (0.51 to 0.85) 0.68 0.74 
       
PSP vs. PD       
MMSE  26*  0.74 (0.62 to 0.84) 0.57 (0.37 to 0.75) 0.50 0.79 
MoCA  19*  0.80 (0.68 to 0.89) 0.70 (0.51 to 0.85) 0.62 0.85 
MoCA Fluency  7* 0.86 (0.75 to 0.94) 0.70 (0.51 to 0.85) 0.70 0.86 
       
PD vs. MSA       
MMSE  28  0.46 (0.29 to 0.63) 0.72 (0.60 to 0.83) 0.71 0.47 
MoCA  20 0.77 (0.60 to 0.90) 0.32 (0.21 to 0.45) 0.72 0.38 
MoCA Fluency  10 0.54 (0.37 to 0.69) 0.61 (0.47 to 0.74) 0.66 0.49 
 
Note. MSA, multiple system atrophy; PSP, progressive supranuclear palsy; PD, Parkinson’s disease; MMSE, Mini-Mental 
State Examination; MoCA, Montreal Cognitive Assessment; PPV, positive predictive value; NPV, negative predictive 
value. * Tests that survived post-hoc DeLong test threshold p < 0.005 (DeLong et al. 1988), after Bonferroni correction. 
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Figure 3.3 Receiver operating characteristic (ROC) curves distinguishing between diagnostic 
groups using MoCA and its letter fluency subitem. Confidence intervals are shown for sensitivity 
and specificity. MSA, multiple system atrophy; PSP, progressive supranuclear palsy; PD, 
Parkinson’s disease; AUC, Area Under the Curve; MoCA, Montreal Cognitive Assessment.  
 
 
3.4 Discussion 
Our multicenter study showed that MoCA is more sensitive than the commonly used 
MMSE in detecting cognitive alterations in atypical parkinsonisms, especially in the PSP 
group. This is aligned with previous evidence showing that MMSE is relatively insensitive 
to the attentive and executive deficits, which are the most affected cognitive domains in 
MSA and PSP patients (Rittman et al., 2013; Siri et al., 2013). Indeed, previous studies 
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showed the superiority of other brief cognitive scales compared to MMSE, in detecting 
cognitive changes in MSA and PSP — namely, the ACE-R, the FAB and the DRS 
(Aarsland, 2003; Bak et al., 2005a; Paviour et al., 2005; Rittman et al., 2013; Siri et al., 2013). 
Our findings showed the presence of a ceiling effect in the performance of MMSE and this 
effect was noted in all the three groups, the 25th to 75th percentile in MSA was 27 to 30, in 
PSP 19 to 29, and 20 to 30 in the PD group. While MoCA did not show a ceiling effect, 
this was probably due to the fact that MoCA includes also the assessment of attentive and 
executive domains. Noteworthy, MoCA scores were distributed in a wider range than the 
MMSE scores, and did not show floor effect. This suggests that MoCA is more challenging 
than MMSE and overall clinically more meaningful and reliable in the assessment of 
general cognition in PSP as well as MSA. 
Dysfunctions on the executive and attention/working-memory domain are frequently 
reported in parkinsonian disorders, and characterize the neuropsychological profile of MSA 
and PSP (Auzou et al., 2015; Dujardin et al., 2003; Gerstenecker, 2017; Lange et al., 2003). 
Based on MoCA subitems analyses, overall, we found a tendency of PSP patients to 
perform worse than MSA and PD in tasks of the executive (i.e., ‘clock drawing, ‘letter 
fluency’ and ‘abstraction’ subitem), and attentive/working-memory domains (i.e., ‘sustained 
attention’, ‘digit forward’ and ‘calculation’ subitem). 
According to previous evidence, visuospatial dysfunctions have been reported in PSP 
patients (Borroni et al., 2008; Cordato, Halliday, Caine, & Morris, 2006; Nichelli & 
Magherini, 2005). This is in line with our findings, since we found a trend for PSP patients 
to have a worse performance than MSA and PD, in the MoCA ‘cube drawing’ task and in 
the MMSE subitem of the ‘bisecting pentagons’. Interestingly, Cordato and others (2006) 
noted that PSP patients were frequently impaired in the ‘copy of the bisecting pentagons,’ 
where the most common error was the incorrect positioning of the right pentagon.  
However, these findings should be considered cautiously, since in these visuospatial tasks, 
motor involvement as well as oculomotor scanning are required and thus, it is possible that 
specific clinical features of PSP (e.g., vertical gaze palsy) hamper the execution of these 
visuospatial tasks (Bak et al., 2006). 
Another important observation is that our study underlined the presence of prominent 
cognitive alterations, particularly in PSP patients. Interestingly, PSP were severely impaired 
on the letter fluency and we found that this task was able to differentiate PSP from PD 
patients with a high specificity and moderate sensitivity (Lange et al., 2003; Rittman et al., 
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2013; Soliveri, 2000). Letter fluency is impaired also in MSA (Pillon et al., 1995), and PD 
(Henry & Crawford, 2004; Lange et al., 2003), but their performance is not impaired as in 
PSP patients. The letter fluency task requires producing words beginning with a given letter 
in one minute; thus, it is a demanding task and its execution requires the involvement of a 
wide network, including the anterior–frontostriatal pathway to retrieve the words from the 
semantic network in the posterior regions (medial temporal and parietal cortex) (Koziol & 
Budding, 2009). The frontal cortex has a crucial role in the execution of letter fluency task. 
Indeed, previous evidence showed that patients with a brain lesion in the left dorsolateral 
and/or striatal region had an impaired fluency (Stuss et al., 1998). Hence, we hypothesize 
that the poor performance of PSP is possibly associated with a broader distribution of 
pathology, with a consistent involvement of cortical regions, compared to MSA and PD 
(Bak et al., 2005a). 
Our results provide additional support for superiority of MoCA over MMSE, and we 
recommend the use of MoCA, particularly of its letter fluency subitem, as seven or fewer 
F-words per minute would support a diagnosis of PSP, at least the Richardson’s syndrome 
subtype (Burrell et al., 2014; Rittman et al., 2013). Noteworthy, the same letter fluency cut-
off score is valid not only in the differential diagnosis with PD, but also between MSA and 
PSP. Thus, we recommend the use of MoCA in the clinical routine assessment of atypical 
parkinsonisms, as it could be a useful tool in the diagnostic process, especially in 
conjunction with other clinical features (Lee et al., 2012). 
Several studies highlighted the presence of cognitive deficits in MSA, which have a 
reduced magnitude compared to those in PD and PSP patients (Gerstenecker, 2017; Lee et 
al., 2012; Meco et al., 1996; Soliveri, 2000). However cognitive impairments are still 
considered as exclusion criteria on the current consensus criteria for the MSA diagnosis 
(Gilman et al., 2008). Further our results add to the view that MSA is associated with 
cognitive alterations and that current criteria need to be revised, considering the presence 
of cognitive alterations in MSA. 
Taken together our findings show MoCA is brief, easy to administer (requires about 10 
minutes) and provides important clinical information, particularly in the context of the 
differential diagnosis. General cognitive testing is crucial in the diagnostic work up of 
atypical parkinsonisms, even though in this study, our patients had no pathological 
confirmation and patients with probable diagnosis were included.  
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In addition, we found that age and education contribute to explain MMSE and MoCA 
performance, but this is not surprising as we used uncorrected data for both scales since 
age and education specific normative data were unavailable for the Romanian subsample. 
There are other limitations in our multicenter study: first, the sample size was relatively 
small, due to the rare nature of the investigated disorders. Then, the disease duration was 
not matched across the three diseases, as we preferred to match patients for age, sex and 
education. In addition, we included PSP patients in a moderate to advanced stage of the 
disease and patients of the more frequent phenotype (i.e., PSP-RS), which makes our 
results not generalizable to other PSP variants, like the parkinsonian variant. However, the 
features and the extent of the degenerative process are similar in all PSP manifestations, 
and possibly the underlying mechanisms of cognitive impairments of our population can be 
applied also to the other phenotypes. Lastly, we did not include other screening cognitive 
scales (i.e., ACE-R, DRS, and FAB) and further studies can be necessary to assess whether 
these tools would be better suited than MoCA in the assessment of cognitive changes in 
these disorders. Although our findings suggest that a simple, brief and easy to administer 
test – such as the letter fluency task − can be sufficient to differentiate PSP from MSA and 
PD. 
To conclude, in the present multicenter study we found that MoCA is a brief cognitive 
scale able to test cognitive abilities in atypical parkinsonisms. Further, we strongly suggest 
the use of phonemic fluency task since seven or fewer words per minute would support the 
PSP diagnosis. Additional studies are needed to assess the sensitivity of MoCA and of letter 
fluency in the early phases of the disease and to validate them in longitudinal studies. 
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CHAPTER 4 
PROSPECTIVE ASSESSMENT OF COGNITIVE DISFUNCTIONS IN 
PARKINSONIAN DISORDERS2 
 
 
4.1 Introduction  
Similar to PD, atypical parkinsonisms were primarily classified as motor disturbances; 
indeed, the hallmarks of MSA and PSP are characterized by a combination of motor, 
cognitive and behavioral symptoms (Gerstenecker, 2017). 
Cognitive deficits were initially categorized as ‘subcortical dementia’ (Albert et al., 1974; 
Brown & Marsden, 1988), as patients present mainly fronto-executive abnormalities 
(Brown et al., 2010) different from the Alzheimer’s-like pattern consisting of ‘genuine 
amnesia’ or abnormal instrumental functions (e.g., agnosia and apraxia) (Pillon et al., 1996). 
Although cognitive alterations are now recognized features in parkinsonian disorders, the 
specific neuropsychological profile for each disorder is poorly characterized as well as their 
neuropathological underpinnings. The different distribution of pathology could determine 
distinct neuropsychological profiles as well as specific characteristics of motor and clinical 
symptoms (Bak et al., 2005a; Pillon et al., 1996).  
Clinical neuropsychology can therefore contribute to better diagnostic accuracy among 
parkinsonian diseases (Hughes, Daniel, Ben-Shlomo, & Lees, 2002; Joutsa et al., 2014). 
In PD, cognitive impairment is characterized by heterogeneous manifestation during the 
disease’s course, ranging from normal cognition, through MCI to frank dementia (Biundo 
et al., 2016a). Impairment in fronto-executive functions has been described since the early 
stage of the disease, while deficits in visuospatial and semantic memory abilities seem to be 
highly sensitive in detecting transition to dementia (Kehagia et al., 2010; Williams-Gray et 
al., 2009). Prevalence of dementia in PD has been reported in approximately 80 percent 
after 15 to 20 years of disease (Halliday et al., 2008). 
                                                 
2 Part of this study has been published: Fiorenzato, E., Antonini, A., Wenning, G., & Biundo, R. (2017). 
Cognitive impairment in multiple system atrophy. Movement Disorders 32(9), 1338-1339. 
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Regarding atypical parkinsonisms, cognitive impairments are prominent and primary 
features of PSP patients. Overall cognitive dysfunctions and behavioral abnormalities are 
more frequent and severe in PSP than in MSA (Gerstenecker, 2017), and evidence suggests 
that this reflects a different distribution underlying pathology (Bak et al., 2005a). 
Interestingly, a previous study conducted with PSP, reported that the frequency of 
dementia, described as subcortical-frontal, increased greatly from 38 to 70 percent after a 
15-month follow-up (Dubois & Pillon, 2005). For MSA patients there are contradictory 
results: the current consensus criteria for MSA diagnosis consider dementia as non-
supporting feature, while a few studies reported dementia in some cases (Stankovic et al., 
2014). 
Although clinical and research experience suggests that cognitive impairments in 
parkinsonian disorders are progressive, there are only a few longitudinal studies in the 
literature, which investigated the progression in atypical parkinsonisms compared to PD 
(Dubois & Pillon, 2005; Rittman et al., 2013; Soliveri, 2000). Furthermore, these previous 
studies are based on screening scales or on brief neuropsychological assessments that did 
not extensively investigate the full spectrum of cognitive abilities (attention/working-
memory, executive, memory, visuospatial and language domains). 
 Although clinical criteria for MCI and dementia in PD have been formulated (Dubois 
et al., 2007; Litvan et al., 2012), it remains unclear whether similar criteria might be applied 
also for atypical parkinsonisms (Marras et al., 2014).  
 
Based on these considerations, the aims of the present study are: 
1) To assess the severity of cognitive dysfunctions in PSP and MSA patients using PD 
criteria for cognitive statuses; 
2) To investigate the sensitivity of two widely used cognitive screening instruments, the 
MMSE and prospectively MoCA, in differentiating MSA, PSP and PD global 
cognitive profile; 
3) To characterize the progression of cognitive decline on the five cognitive domains, 
behavioral features and to compare the 15-month follow-up profile across the 
parkinsonian diseases. 
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4.2 Materials and methods 
4.2.1 Study population 
Eighteen PSP and 12 MSA patients referred consecutively, and 30 PD patients matched 
for age, education and sex were evaluated at baseline and at a mean of 15-month follow-up 
(range 12−18 months). Patients were recruited at the Parkinson’s Disease and Movement 
Disorders Unit, San Camillo Hospital IRCCS, Venice, Italy, from June 2012 to August 
2017. All PD patients fulfilled the Queen Square Brain Bank criteria for a diagnosis of 
probable PD (Gelb et al., 1999), and standard diagnostic criteria were applied for the 
diagnosis of probable MSA and probable PSP patients (Gilman et al., 2008; Höglinger et 
al., 2017). PSP patients were all of Richardson’s syndrome phenotype. The exclusion 
criteria of this study were the presence of: 1) only one cognitive and motor evaluation at 
baseline, without a follow-up assessment, 2) deep brain stimulation, and 3) psychiatric or 
neurological comorbidity. Patients gave written informed consent (according to the 
Declaration of Helsinki) before study enrollment, and ethical approval was obtained from 
the Venice Research Ethics Committee, Venice, Italy.  
 
4.2.2 Clinical and neuropsychological assessment  
Demographic variables (i.e., age, education, and sex), and clinical characteristics (i.e., 
disease duration, age of onset, and motor symptoms) were collected by neurologists with 
experience in movement disorders.  
Motor function was assessed using the MDS-UPDRS: namely, motor aspects interfering 
with daily living were assessed by MDS-UPDRS II and motor symptoms by means of the 
motor section (MDS-UPDRS III). LEDD and DAED were calculated (Tomlinson et al., 
2010). 
With regard to cognitive evaluation, we selected a comprehensive neuropsychological 
battery specifically designed to target cognitive deficits in PD, according to Level II criteria 
(Dubois et al., 2007; Litvan et al., 2012; Marras et al., 2014) (see also Chapter 2 for further 
details). We also applied these criteria to MSA and PSP since there are no published criteria 
for atypical parkinsonisms.  
The neuropsychological tests were performed on two separate occasions within 5 to 7 
days and administered in the morning ON medication. 
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The cognitive battery included MMSE and MoCA to assess general cognitive functions, 
Attention and working memory domain was tested with the Trail Making Test part B-A 
(TMT B-A) (Giovagnoli et al., 1996) and Digit Span Sequencing (DSS) of Wechsler Adult 
Intelligence Scale–Fourth Edition (WAIS–IV) (Wechsler, 2008). Executive functions were 
evaluated with the Stroop Color and Word test, phonemic fluency, WAIS-IV similarities, 
and the Clock Drawing Test (CDT) (Caffarra et al., 2011; Caffarra, Vezzadini, Dieci, 
Zonato, & Venneri, 2002; Novelli, Papagno, Capitani, & Laiacona, 1986b; Wechsler, 2008). 
Memory was assessed with the delayed recall of Rey-Osterrieth complex figure test 
(ROCF)(Caffarra et al., 2002), word paired associated task, and prose memory tests 
(Novelli, Papagno, Capitani, & Laiacona, 1986a). Language was tested with the semantic 
fluency task, and Novelli's naming test (Novelli et al., 1986b). Visuospatial and 
visuoperceptive functions were assessed by Benton’s JLO (Gullett et al., 2013), VOSP 
incomplete letters recognition subtask (Warrington & James, 1991), and a copy of ROCF 
(Caffarra et al., 2002). 
We assessed the presence of depression, anxiety, apathy and quality of life using the 
Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory forms (STAI Y-1 to 
assess state anxiety, STAI Y-2 to assess trait anxiety), Starkstein Apathy Scale and an 8-item 
version of the Parkinson's Disease Questionnaire for quality of life (PDQ-8), respectively 
(Yamanishi et al., 2013). All the test scores were adjusted for age and education, according 
to the specific norm available. 
Subjective cognitive complaints and their impact on daily functioning were assessed 
during the clinical interview using the PD-CFRS (Kulisevsky et al., 2013), as well functional 
autonomy was evaluated with ADL and IADL scales (Katz, 1983). 
First, z-scores were calculated for each test and subject, based on standardized, 
published Italian normative data. We classified patients as having MCI if the z-score for a 
given test was at least -1.5 SD below appropriate norms on two tests within a single 
cognitive domain or at least one test in two or more cognitive domains (Litvan et al., 2012). 
Presence of dementia was assessed based on the MDS Task Force recommendations 
(Dubois et al., 2007), which included cognitive examination, functional autonomy and 
neuropsychiatric assessment. Patients without cognitive alterations were defined as having a 
‘normal cognition.’ 
Then, we defined the percentage of impaired subjects for each cognitive domain, when 
they had a performance below -1.5 SD. 
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Since our neuropsychological battery had more than two tests per cognitive domain, for 
diagnostic classification purpose (of cognitive statuses), we excluded the exceeding tests, 
and the tests whose performance could be hampered by motor deficits (i.e., ROCF and 
CDT) since atypical parkinsonisms usually showed severe motor impairment. Table 4.1 
shows the neuropsychological tests used and their associated norms for each cognitive 
domain. 
The outcomes of the clinical assessment and the extensive neuropsychological battery 
were compared at baseline as well as at follow-up.  
 
 
Table 4.1 Neuropsychological tests and their associated norms for each cognitive domain  
Cognitive Domains Neuropsychological tests and their associated norms 
Executive 
Stroop Color/ Word test (Caffarra et al., 2002) 
Similarities (WAIS-IV) (Wechsler, 2008) 
Attentive/ working 
memory 
Trail Making Test part B-A (TMT B-A) (Giovagnoli et al., 1996) 
Digit Span Sequencing (DSS) (WAIS–IV) (Wechsler, 2008) 
Memory 
Word paired associated task (WPAT) (Novelli et al., 1986a) 
Prose memory test (Delayed recall) (Novelli et al., 1986a) 
Visuospatial 
Incomplete letters subtask (VOSP) (Warrington & James, 1991) 
Benton’s Judgment of Line Orientation Test (Benton- JLO) (Gullett et al., 2013) 
Language 
Semantic fluency task (Novelli et al., 1986b) 
Novelli's Naming test (Novelli et al., 1986b) 
 
Note. WAIS IV, Wechsler Adult Intelligence Scale—Fourth Edition; VOSP, Visual Object and Space Perception. 
 
4.2.3 Statistical analyses 
All statistics were performed using SPSS version 20 (IBM SPSS, Chicago, IL) and 
statistical significance threshold was set at p < 0.05. 
Between-group comparisons were run with the non-parametric Kruskal-Wallis analysis 
of variance, ANOVA; and post hoc comparisons, followed by Bonferroni correction for 
multiple comparisons, were applied when appropriate. Within-group comparisons were 
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performed using the non-parametric Mann–Whitney U test and categorical variables were 
analyzed using Pearson’s Chi-squared test. 
To investigate changes over time on MMSE and MoCA performance, we calculated the 
percentage change of total score as well as of the subitems. Subitems scores were 
normalized, dividing the scores of each subitem by its maximum score. 
 
4.3  Results 
4.3.1  Demographic and clinical characteristics at baseline 
As reported in Table 4.2, the PD cohort was matched for age, sex and education with 
MSA and PSP groups. PD patients had longer disease duration than PSP and MSA, and a 
tendency to show less severe motor impairments (as assessed by MDS-UPDRS III), even 
though this difference was not significant after correction for multiple comparisons (PD vs. 
PSP, p = 0.064; PD vs. MSA p = 0.052). There were no differences in levodopa and 
dopamine-agonist dose. 
 
Table 4.2. Baseline demographic and clinical characteristics of PD, MSA and PSP groups  
  
PD                     
(n=30) 
MSA                        
(n=12) 
PSP                          
(n=18) 
p value 
Age, y 68.40 (7.02) 65.08 (4.85) 70.00 (6.82) 0.076 
Education, y 9.10 (4) 8.92 (4.58) 10.39 (4.79) 0.496 
Sex (m/f) 23/7 5/7 11/7 0.091 
C/P subtypes na 4/8 na na 
Disease Duration, y 8.63 (4.78)#§ 3.92 (2.02)# 5.11 (3.18)§ 0.001 
MDS-UPDRS II 13.43 (7.76) 19.00 (10) 19.33 (8.52) 0.101 
MDS-UPDRS III 25.30 (12.9) 40.64 (20.34) 38.53 (16.24) 0.018 
MDS-UPDRS Tot 57.93 (28.78) 61.36 (30.64) 57.93 (23.26) 0.937 
LEDD 798.41 (586.81) 625.85 (274.14) 518.58 (405.58) 0.248 
DAED 111.62 (115.04) 78.17 (100.73) 45.28 (71.05) 0.248 
 
Note. Values are means and SD. Post hoc comparison adjusted by the Bonferroni correction for multiple tests: p<0.05; 
#PD vs. MSA, §PD vs. PSP. PD, Parkinson’s disease; MSA, multiple system atrophy; PSP progressive supranuclear palsy; 
C, cerebellar subtypes; P, parkinsonian subtypes; na, not applicable; MDS-UPDRS, Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale; LEDD, levodopa equivalent daily dose; DAED, dopamine agonist equivalent dose. 
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4.3.2 Neuropsychological and behavioral assessment at baseline 
PSP group performed significantly worse than PD patients at the MoCA (p = 0.024), 
Stroop test (time), phonemic and category fluencies. We found no differences in the other 
cognitive tests (Table 4.3). The most impaired domain in PSP patients was the executive 
domain — 44 percent of patients had a performance below normality. Regarding the 
behavioral outcomes, the PSP group was characterized by reduced functional autonomy 
(ADL), more apathy and depression when compared to PD.  
 
Table 4.3 Between-group comparisons at baseline evaluation of behavioral and 
neuropsychological measures across PD, MSA and PSP groups 
  PD                                              MSA              PSP                           p value 
Behavioral measures     
ADL 5.67 (0.61) 5.00 (1.41) 4.47 (1.74) 0.017§ 
IADL 5.00 (1.74) 5.75 (1.96) 4.76 (2.11) 0.306 
PD-CFRS 2.96 (3.55) 2.38 (1.77) 4.54 (4.91) 0.333 
PDQ-8 9.07 (5.95) 13.00 (6.81) 11.07 (4.98) 0.220 
Apathy scale 14.91 (6.10) 16.14 (5.76) 21.82 (7.86) 0.048§ 
STAI Y-1 38.57 (11.60) 40.90 (8.17) 39.07 (7.34) 0.544 
STAI Y-2 41.04 (12.46) 44.91 (8.91) 45.73 (10.58) 0.514 
BDI-II 10.17 (7.21) 14.25 (7.30) 18.06 (10.35) 0.024§ 
Neuropsychological assessment     
MMSE 26.41 (2.20) 27.25 (1.89) 24.12 (4.18) 0.061 
MoCA 23.33 (3.73) 23.33 (2.64) 21.00 (3.14) 0.025§ 
ROCF- copy 29.27 (6.38) 31.14 (5.14) 24.69 (8.54) 0.052 
ROCF - delayed 12.60 (5.96) 15.77 (5.70) 11.09 (3.61) 0.100 
WPAT 8.88 (2.86) 10.54 (3.00) 10.00 (3.41) 0.265 
TMT B-A 206.80 (175.15) 183.17 (157.62) 235.69 (186.47) 0.759 
STROOP (Time) 31.21 (17.30) 27.94 (11.40) 53.08 (25.10) 0.013§ 
STROOP (Errors) 2.83 (4.87) 2.50 (3.66) 6.50 (5.33) 0.062 
Phonemic Fluency 29.41 (8.71) 28.83 (10.49) 19.18 (8.72) 0.003§ 
Semantic Fluency  33.17 (6.45) 37.92 (8.23) 26.94 (10.51) 0.021§ 
Similarities (WAIS-IV) 17.48 (4.37) 18.67 (3.55) 16.38 (3.69) 0.335 
DSS- SPAN (WAIS-IV) 4.72 (1.56) 5.58 (1.24) 5.07 (1.16) 0.250 
Prose Memory Test - immediate 9.77 (4.48) 10.83 (4.24) 9.88 (5.01) 0.730 
Prose Memory Test - delayed 12.55 (5.22) 12.75 (4.61) 11.50 (5.05) 0.724 
Clock- CDT 12.70(2.56) 13.58 (1.56) 11.31 (3.14) 0.095 
VOSP 17.13 (3.33) 18.75 (0.97) 17.00 (2.90) 0.168 
Benton - JLO 22.08 (5.36) 21.00 (7.01) 19.69 (6.87) 0.605 
Naming Task Novelli 30.13 (2.40) 30.89 (1.54) 30.08 (1.61) 0.406 
     
Subjects with an impaired performance per domain  
Attention/ working memory 13% 8% 25%  
Executive  33% 17% 44%  
Memory  17% 0% 19%  
Visuospatial 33% 8% 31%  
Language  10% 8% 12%  
 
Note. Significant values are in bold type. Post hoc comparison adjusted by the Bonferroni correction for multiple tests: p<0.05; §PD 
vs. PSP.  PD, Parkinson’s disease; PSP, progressive supranuclear palsy; MSA, multiple system atrophy; BDI-II, Beck Depression 
Inventory-II; State-Trait Anxiety Inventory (STAI Y-1, Y-2); MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive 
Assessment; ROCF, Rey–Osterrieth complex figure; WPAT, Word Paired associated task; TMT, Trail Making Test; DSS, Digit Span 
Sequencing; WAIS IV, Wechsler Adult Intelligence Scale—Fourth Edition; CDT, Clock Drawing task; VOSP, Visual Object and Space 
Perception; JLO, Judgment of Line Orientation Test. 
Chapter 4 
 106 
4.3.3 Clinical, behavioral and neuropsychological assessment at 15-month 
follow-up 
At the second assessment, the three groups differed significantly on disease severity (as 
assessed by MDS-UPDRS III), and the post hoc comparison analysis revealed that MSA 
and PSP were more impaired than PD (p = 0.012 and 0.007, respectively). Motor aspects 
also affect functional autonomy; indeed, MDS-UPDRS II was significantly different 
between MSA and PSP compared to the PD group (p = 0.002 and 0.017, respectively). 
This is in line also with the ADL and IADL score, where PSP patients showed a lower 
score in comparison to PD. 
 Interestingly, functional autonomy in PSP was not associated only with motor 
impairments but also with cognition deficits, since PSP patients showed a higher score at 
PD-CFRS compared to MSA patients (p = 0.032) and there was a trend also in comparison 
to PD (p =0.092), suggesting that cognitive alterations in PSP patients could interfere with 
their functional autonomy.  
These results agreed also with the PDQ-8 score, in which MSA and PSP (p = 0.029 and 
p = 0.051, respectively) reported a poor quality of life in comparison to PD. In addition, 
PSP patients reported more apathy and anxiety in comparison to PD. 
From a cognitive perspective, the between-group comparison showed again that PSP 
patients had a worse performance compared to PD on Stroop tests (error), phonemic and 
category fluencies (Table 4.4). As well, PSP had a lower score on MoCA scale when 
compared to PD and MSA (even though this difference did not reach significance after 
multiple comparisons, p = 0.079 and p = 0.060, respectively). The most impaired domain 
was the executive domain, with 65 percent of PSP patients below normality.
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Table 4.4 Between-group comparisons at 15-month follow-up of behavioral and 
neuropsychological measures across PD, MSA and PSP groups. 
  PD                                  MSA                        PSP                         p value 
Clinical measures     
MDS-UPDRS-II 12.52 (8.78) 26.77 (13.34) 24.82 (12.06) 0.002§,# 
MDS-UPDRS-III 25.90 (10.81) 48.89 (23.11)# 46.18 (16.91)§ 0.001§,# 
LEDD 818.74 (493.49) 698.52 (460.05) 542.84 (363.03) 0.143 
DAED 112.22 (96.18) 59.00 (79.83) 41.56 (60.32) 0.026§ 
     
Behavioral measures     
ADL 5.33 (0.88) 4.00 (2.14) 3.00 (2.00) <0.001§ 
IADL 4.53 (1.43) 3.91 (2.39) 3.17 (2.07) 0.041§ 
PD-CFRS 4.48 (4.31) 2.80 (2.90) 9.41 (7.95) 0.022* 
PDQ-8 8.62 (5.59) 14.00 (5.73) 13.44 (5.23) 0.009# 
Apathy scale 15.62 (5.04) 17.70 (6.60) 23.33 (6.52) 0.003§ 
STAI Y-1 35.24 (9.68) 37.36 (5.26) 39.25 (10.19) 0.289 
STAI Y-2 37.75 (10.41) 45.00 (11.36) 46.67 (7.51) 0.041§ 
BDI-II 9.90 (6.13) 15.82 (11.05) 13.53 (8.37) 0.167 
Neuropsychological assessment     
MMSE 25.46 (1.99) 26.10 (2.08) 23.71 (5.15) 0.445 
MoCA 22.57 (3.81) 23.55 (2.98) 18.78 (5.57) 0.031 
ROCF- copy 27.03 (5.68) 24.95 (4.70) 20.88 (11.38) 0.174 
ROCF - delayed 11.88 (6.58) 14.50 (4.47) 8.75 (6.61) 0.076 
WPAT 9.98 (4.74) 10.68 (3.93) 10.00 (3.91) 0.921 
TMT B-A 271.83 (195.46) 235.10 (197.18) 318.47 (211.87) 0.561 
STROOP (Time) 32.99 (16.31) 32.30 (15.46) 48.63 (28.45) 0.155 
STROOP (Errors) 3.48 (6.33) 2.80 (4.57) 10.97 (11.11) 0.039§ 
Phonemic Fluency 28.64 (9.16) 27.36 (10.13) 18.94 (10.38) 0.006§ 
Semantic Fluency  33.30 (9.45) 35.09 (10.52) 25.76 (11.33) 0.030§ 
Similarities (WAIS-IV) 16.38 (5.45) 19.00 (3.22) 17.12 (5.38) 0.281 
DSS- SPAN (WAIS-IV) 4.55 (1.27) 5.17 (1.19) 4.06 (1.39) 0.075 
Prose Memory Test - immediate 8.92 (4.52) 10.36 (3.20) 8.94 (5.78) 0.647 
Prose Memory Test - delayed 10.73 (5.77) 12.09 (3.48) 10.59 (6.22) 0.622 
Clock- FD 12.17 (2.21) 12.90 (1.60) 10.29 (3.31) 0.069 
VOSP 17.21 (3.23) 17.83 (1.90) 16.56 (3.85) 0.811 
Benton - JLO 20.00 (7.06) 19.60 (4.40) 16.38 (6.68) 0.304 
Naming Task Novelli 29.79 (2.57) 30.73 (0.79) 29.18 (3.00) 0.612 
     
Subjects with an impaired performance per domain 
Attention/ working memory 20% 25% 31%  
Executive  33% 18% 65%  
Memory  27% 9% 29%  
Visuospatial 37% 17% 38%  
Language  13% 0% 35%   
 
Note. Significant values are in bold type. Post hoc comparison and adjusted by the Bonferroni correction for multiple tests: p<0.05; §PD 
vs. PSP, #MSA vs. PSP, * PSP vs. MSA. PD, Parkinson’s disease; PSP, progressive supranuclear palsy; MSA, multiple system atrophy; 
MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; LEDD, levodopa equivalent daily dose; DAED, 
dopamine agonist equivalent dose; BDI-II, Beck Depression Inventory-II; State-Trait Anxiety Inventory (STAI Y-1, Y-2); MMSE, Mini-
Mental State Examination; MoCA, Montreal Cognitive Assessment; ROCF, Rey–Osterrieth complex figure; WPAT, Word Paired 
associated task; TMT, Trail Making Test; DSS, Digit Span Sequencing; WAIS IV, Wechsler Adult Intelligence Scale—Fourth Edition; 
CDT, Clock Drawing task; VOSP, Visual Object and Space Perception; JLO, Judgment of Line Orientation Test. 
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4.3.4 Sensitivity to motor and cognitive change after 15-month follow-up 
We further investigated which clinical and neuropsychological tests were the most 
sensitive in detecting a change at 15-month follow-up (Table 4.5). The within-group 
comparison analysis (follow-up vs. baseline) showed that the MDS-UPDRS-II was able to 
detect a change both in PSP and MSA group. MDS-UPDRS-III did not change 
significantly after 15 months, although there was a strong trend within the PSP group to 
show a higher motor severity (p = 0.050). ADL and IADL scores decreased significantly 
for each group: in addition, PD patients showed also a significant change in the PD-CFRS 
(2.96±3.55 vs. 4.48±4.31), only seen as a strong trend in the PSP group probably due to 
the small sample size (4.54±4.91 vs. 9.41±7.95; p = 0.052). 
With regard to the cognitive assessment, within the PD-group the most sensitive tests to 
detect cognitive change over time were the MMSE scale, the ROCF-copy, TMT B-A and 
the CDT. While in the MSA, the only test that was able to detect a change was the ROCF-
copy. Finally, in the PSP-group, MoCA was the most sensitive scale, together with the 
ROCF-delayed recall, TMT B-A, category fluency, DSS-span and Benton’s JLO.  
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Table 4.5 Neuropsychological, clinical and behavioral measures most sensitive to cognitive decline at 15-month follow-up for each group 
 
Note. Significant values are in bold type. MSA, multiple system atrophy; ns, not significant; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MMSE, 
Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; ROCF, Rey–Osterrieth complex figure; TMT, Trail Making Test; DSS, Digit Span Sequencing; WAIS IV, Wechsler 
Adult Intelligence Scale—Fourth Edition; CDT, Clock Drawing task; JLO, Judgment of Line Orientation Test. §PD vs. PSP. 
 
  
Mean score at baseline and follow-up 
 PD   MSA   PSP 
 Baseline Follow-up p value   Baseline Follow-up p value   Baseline Follow-up p value 
Clinical measures            
MDS-UPDRS-II 13.43 (7.76) 12.52 (8.78) ns  19.00 (10.00) 26.77 (13.34) 0.012  19.33 (8.52) 24.82 (12.06) 0.039 
MDS-UPDRS-III 25.30 (12.90) 25.90 (10.81) ns  40.64 (20.34) 48.89 (23.11) ns  38.53 (16.24) 46.18 (16.91) 0.050 
LEDD 798.41 (586.81) 818.74 (493.49) ns  625.85 (274.14) 698.52 (460.05) ns  518.58 (405.58) 542.84 (363.03) ns 
DAED 111.62 (115.04) 112.22 (96.18) ns  78.17 (100.73) 59.00 (79.83) ns  45.28 (71.05) 41.56 (60.32) ns 
            
Behavioral measures            
ADL 5.67 (0.61) 5.33 (0.88) 0.004  5.00 (1.41) 4.00 (2.14) 0.043  4.47 (1.74) 3.00 (2.00) 0.002 
IADL 5.00 (1.74) 4.53 (1.43) 0.038  5.75 (1.96) 3.91 (2.39) 0.011  4.76 (2.11) 3.17 (2.07) 0.002 
PD-CFRS 2.96 (3.55) 4.48 (4.31) 0.022  2.38 (1.77) 2.80 (2.90) ns  4.54 (4.91) 9.41 (7.95) ns 
Neuropsychological assessment            
MMSE 26.41 (2.20) 25.46 (1.99) 0.042  27.25 (1.89) 26.10 (2.08) ns  24.12 (4.18) 23.71 (5.15) ns 
MoCA 23.33 (3.73) 22.57 (3.81) ns  23.33 (2.64) 23.55 (2.98) ns  21.00 (3.14)§ 18.78 (5.57) 0.029 
ROCF- copy 29.27 (6.38) 27.03 (5.68) 0.042  31.14 (5.14) 24.95 (4.70) 0.008  24.69 (8.54) 20.88 (11.38) ns 
ROCF - recall 12.60 (5.96) 11.88 (6.58) ns  15.77 (5.70) 14.50 (4.47) ns  11.09 (3.61) 8.75 (6.61) 0.038 
TMT B-A 206.80 (175.15) 271.83 (195.46) 0.030  183.17 (157.62) 235.10 (197.18) ns  235.69 (186.47) 318.47 (211.87) 0.036 
Semantic Fluency  33.17 (6.45) 33.30 (9.45) ns  37.92 (8.23) 35.09 (10.52) ns  26.94 (10.51) 25.76 (11.33) 0.017 
DSS- SPAN (WAIS-IV) 4.72 (1.56) 4.55 (1.27) ns  5.58 (1.24) 5.17 (1.19) ns  5.07 (1.16) 4.06 (1.39) 0.005 
Clock- CDT 12.70 (2.56) 12.17 (2.21) 0.049  13.58 (1.56) 12.90 (1.60) ns  11.31 (3.14) 10.29 (3.31) ns 
Benton - JLO 22.08 (5.36) 20.00 (7.06) ns  21.00 (7.01) 19.60 (4.40) ns  19.69 (6.87) 16.38 (6.68) 0.035 
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4.3.5 Changes in cognitive profile at 15-month follow-up 
To investigate which cognitive domains were the most sensitive to detect cognitive 
decline over time (15-month), we calculated the difference of impaired subjects (as assessed 
by a cognitive performance below the normality, SD ≤ -1.5) at follow-up versus baseline 
(Figure 4.1). 
We observed significant changes in executive and language domain. Namely, compared 
to PD and MSA groups, which showed none or very little (0% and 2% respectively) 
variation in number of subjects with executive alterations. Up to 21 percent of PSP 
subjects further fell in these domains and the increment was significant compared to the 
PD group (p < 0.0098). 
With regard to the language domain, up to 24 percent of PSP patients further fell in this 
ability compared to the baseline evaluation; this percentage was significantly different in 
comparison to the PD (3%, p = 0.262) and MSA groups (-8%, p = 0.0071).  
 
Figure 4.1 Percentage of impaired subjects between follow-up and baseline (T1-T0) across the 
cognitive domain. Note. T1, follow-up; T0, baseline. 
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4.3.6 Cognitive statuses  
In the context of similar disease duration, MSA and PSP groups showed a different 
percentage of cognitive statuses at baseline (Figure 4.2). Namely, in the MSA group, 75 
percent showed normal cognition, 25 percent showed MCI, and no patient had diagnosis 
of dementia. While in the PSP group at baseline, 22 percent was classified as cognitively 
normal, 61 percent showed MCI and 17 percent had a diagnosis of dementia.  
 
 
Figure 4.2 Percentage of subjects (PD, MSA and PSP) across cognitive statuses. NC, normal 
cognition; MCI, mild cognitive impairment; D, dementia. 
 
 
At 15-month follow-up, thus approximately at six years of disease duration in both the 
diseases, 25 percent of MSA converted to MCI and no patients converted to dementia; 
while in the PSP group, 11 percent of patients with MCI improved and was classified as 
cognitively normal, and another subgroup (16%) converted to dementia.  
Of note, PSP patients who converted from MCI to normal cognition presented 
improved performance on one test of the attentive or executive domain (i.e., TMT B-A or 
Stroop test). 
Interestingly, in MSA and PSP, MCI patients at baseline evaluation all presented with 
multidomain deficits, but only some PSP patients converted to dementia.  
In PD, although the disease duration was longer compared with PSP and MSA patients, 
at baseline 40 percent was classified as PD-NC, 57 percent as PD-MCI (88% of whom 
showed multidomain deficits) and three percent as having dementia. Fifteen months later, 
10 percent of PD-NC converted to MCI and seven percent of PD-MCI to dementia.  
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4.3.7 MMSE versus MoCA change over time 
As reported in Table 4.3, both MMSE and MoCA scores declined after 15-month. At 
follow-up, the mean MMSE score was higher than the mean MoCA total score in all 
parkinsonian disorders. Namely, in PD (25.46 ± 1.99 vs. 22.57 ± 3.81, p < 0.0001), MSA 
(26.10 ± 2.08 vs. 23.55 ± 2.98, p < 0.013), and PSP group (23.71 ± 5.15 vs. 18.78 ± 5.57, p 
< 0.0001). Although a more comprehensive evaluation, by means of the full 
neuropsychological battery, showed a global decline over time at follow-up. We found 
MMSE scores of either 29 or 30 in 30 percent of the PD, 33 percent of MSA and 25 
percent of PSP patients. In contrast, a MoCA score over 28 was only present in one PD 
patient. This result suggests possibly the presence of a MMSE ceiling effect in the three 
groups. 
Exploratory analyses of the percentage changes on MMSE and MoCA between the 
follow-up and baseline revealed a greater decline of the PSP group on MoCA score (-11%) 
in comparison to the MSA and PD groups – namely, the score declined by 2.2 points in 15 
months (Figure 4.3). While on MMSE scale, MSA patients showed the greatest 
deterioration of performance, even though the change was relatively small (-4%), 
corresponding to a decline of 1.15 points. 
 
 
Figure 4.3 Percentage change (between follow-up and baseline) on MMSE and MoCA for 
patients with PD, PSP and MSA.  
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To investigate which subitems on MMSE and MoCA were more vulnerable to change 
over time, we calculated the ‘percentage change’ of the subitems and we considered a 
change as ‘clinically significant’ if greater than 30 percent, as reported previously (Soliveri, 
2000).  
Interestingly, in MMSE we found that PSP patients had a better performance in 
comparison to baseline in the ‘copy of the pentagons’, while MSA and PD groups showed 
a tendency to perform worse (Figure 4.4a).  
Regarding the analysis of MoCA subitems, PSP patients showed a significant greater 
decline in TMT-B and the ‘clock drawing,’ but they improved in ‘cube drawing.’ Instead, 
MSA and PD patients’ performance improved in the TMT-B task as well as in ‘clock 
drawing’ (Figure 4.4b).   
 
 
 
 
Figure 4.4 a) MMSE and b) MoCA subitems percentage change (between follow-up and baseline) 
for patients with PD, PSP and MSA. A percentage change greater than 30 percent was considered 
‘clinically significant’, as reported previously (Soliveri, 2000). 
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4.4 Discussion 
The main finding of our prospective study was that PSP patients have more severe 
cognitive decline than PD and MSA, matched for age and education. After 15-month 
follow-up, we found greater decline in the executive and language domains in PSP group 
compared to the others. This was the first study in which an extensive neuropsychological 
battery investigating the five cognitive domains was administered to atypical parkinsonisms 
as well as PD patients. Baseline and follow-up evaluations agreed, and showed that PSP 
patients had a worse performance than PD and MSA patients: especially, in the Stroop test, 
verbal fluencies (semantic and phonemic), and MoCA scale. These results are in line with 
previous findings that reported fronto-executive deficits as the predominant features of 
PSP neuropsychological profile (Brown et al., 2010; Gerstenecker et al., 2013) 
Verbal fluency tasks, and more specifically phonemic fluency, were particularly impaired 
in PSP and as previously reported they differentiated PSP from PD patients (Bak et al., 
2005a; Fiorenzato et al., 2016; Rittman et al., 2013). The consistent decline in verbal fluency 
is not exclusively related to motor problems (i.e., dysarthria), since this task requires 
minimal motor function (Rittman et al., 2013). Overall, PSP patients generated few words 
in the semantic fluency task, but even less in the phonemic task (at follow-up: 26 words vs. 
19 words in 3 minutes, respectively). This is aligned with previous evidence, showing that 
letter fluency was more impaired than category fluency across all parkinsonian syndromes, 
compared to healthy control or to AD performance (Bak et al., 2005a). Thus, it has been 
demonstrated that especially phonemic fluency is a ‘distinctive deficit’ of PSP, and a cut-off 
of 7-words per minute is able to differentiate PSP from PD patients, with a high specificity 
and sensitivity (0.92 and 0.87, respectively) (Rittman et al., 2013).  
Verbal fluency tasks probably reflect subcortical alterations. Indeed, patients with brain 
lesions in the frontal lobe were found to have altered verbal fluency, only if they had a 
concomitant or isolated striatal lesion (Stuss et al., 1998). And in turn, evidence from 
functional imaging studies, showed that frontal regions play a key role during the execution 
of verbal fluency tasks, namely Brodmann area (BA) 44 (pars opercularis of inferior frontal 
gyrus) seems to be involved in phonological processes while BA 45 (pars triangularis of 
inferior frontal gyrus) in semantic processes (Heim, Eickhoff, & Amunts, 2009). Hence, the 
more severe performance of PSP patients, compared to PD and MSA, could reflect a more 
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extensive frontal alteration, associated with cortical neuroglial tau pathology (Bigio et al., 
1999; Williams et al., 2007).  
 It is worth noting that PSP patients showed a decline also in their language domain. In 
our neuropsychological battery, language abilities were assessed by naming and semantic 
fluency tasks: namely, it has been shown that the latter has a stronger relationship with 
language functions rather than with the executive domain (Whiteside et al., 2016). 
Exploratory analyses of our sample indicate that a performance below normality in the 
language domain was driven by both the cognitive tests (naming and semantic fluency), and 
not by one in particular. Our finding is consistent with previous evidence, showing that the 
language domain was the second most impaired domain (after the executive) in PSP 
patients (Bak et al., 2005a). 
Assessing the severity of cognitive deficits, we found different percentages of cognitive 
statutes (i.e., normal cognition vs. MCI vs. dementia) among the three groups. Namely, in 
the MSA and PSP groups, in the context of similar disease duration (approximately six 
years at the follow-up) the percentage of patients with dementia was higher in the PSP 
group compared to MSA (33 percent vs. no patients with dementia). Noteworthy, MSA 
and PSP patients with MCI at baseline, all had multidomain deficits, but only patients with 
MCI in the PSP group converted to dementia. 
Another important observation is that although the disease duration was longer for PD 
patients compared with PSP, the percentage of patients who converted to dementia was 
still higher in the PSP group compared to PD (16 vs. 7 percent), despite both groups 
seeming to have similar severity of MCI status at baseline. Overall this suggests a more 
rapid and severe cognitive decline in PSP. Conversely, cognitive impairment in MSA is 
milder compared to the other two disease groups, suggesting a pattern of cognitive 
dysfunctions very similar but less pronounced, and this is in line with previous findings that 
tried to characterize the cognitive decline in MSA (Bak et al., 2005a; Soliveri, 2000). Our 
findings should be confirmed by longitudinal studies in larger cohorts and with longer 
follow-up. 
MSA and PSP have a different distribution of their pathology. In particular, MSA is 
characterized by alterations primarily in subcortical structures while cortical pathology is 
not considered as a predominant feature (Papp & Lantos, 1994). This notion is supported 
by a recent neuropathological study that failed to identify neuroanatomical regions 
associated with cognitive impairment in MSA (Koga et al., 2016), and is in line with also 
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our findings in a volumetric study, where we found only a focal atrophy in the frontal 
region associated with cognitive alterations, suggesting a marginal contribution of cortical 
pathology to cognitive defects in MSA (Fiorenzato et al., 2017) (see also Chapter 6 for 
further details). 
By contrast, in PSP, the pathological tau burden extends from the frontal cortex to the 
dentate nucleus of the cerebellum. Although the most severely affected regions are the 
subthalamic nucleus, substantia nigra, and globus pallidum (Hauw et al., 1994; Williams et 
al., 2007); several studies reported the association between cortical tau pathology and the 
severity of cognitive and behavioral dysfunctions (Bergeron, Pollanen, Weyer, & Lang, 
1997; Cordato et al., 2002). 
PD patients had longer disease duration in comparison to MSA and PSP. At follow-up 
60 percent was classified as MCI and 10 percent with dementia. However, the disease 
duration of patients with dementia was ranging between 11 to 21 years. Our findings 
suggest that PD patients deteriorate more slowly than MSA and PSP patients, and possibly 
longer follow-up is necessary to observe a sufficient decline in this disease (Soliveri, 2000). 
Interestingly, in this study we did not find MSA patients with dementia, and in the 
literature there are controversial results (Stankovic et al., 2014). A previous study, based on 
the Level II criteria showed that dementia was ranging between eight to 11 percent in a 
MSA sample (Auzou et al., 2015). Based on the MDS criteria as well as DSM-5 criteria for 
the diagnosis of dementia (APA, 2012; Dubois et al., 2007), cognitive impairment should 
be severe enough to impact daily functioning. The assessment of dementia in atypical 
parkinsonisms is challenging, as ADL and IADL are usually impaired due to motor 
dysfunctions from the first stages of the disease, and isolating the cognitive component of 
already impaired functional tasks is difficult (Marras et al., 2014). In order to address this 
clinical issue, we used for the first time the PD-CFRS scale with atypical parkinsonisms to 
measure the functional impact of cognitive impairments (Kulisevsky et al., 2013). We 
administered this scale to patient as well as caregiver to help the clinician in the diagnostic 
process. 
Results from the behavioral measures confirmed that neuropsychiatric features are more 
common in PSP patients than PD (Gerstenecker, 2017), especially apathy with 
accompanying low level of anxiety and depression. Also MSA patients usually reported 
numerous behavioral features, however in this study we found only a group difference 
between MSA and PD in the level of quality of life that was lower in the MSA group. Even 
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though we did not find other between group differences, level of apathy, anxiety and 
depression were always ‘higher’ compared to PD but ‘lower’ in respect to PSP. 
Another interesting finding from the analyses of the brief cognitive scales (MMSE and 
MoCA) was the higher sensitivity of MoCA in detecting cognitive changes, especially in 
PSP. This is possibly associated to the characteristics of MoCA’s subitems that evaluate 
executive and attentive abilities (Hoops et al., 2009). This finding is aligned with a previous 
study, where we demonstrated the superiority of MoCA (compared to MMSE) in detecting 
cognitive impairments in atypical parkinsonisms (Fiorenzato et al., 2016) (for further details 
please see Chapter 3). Interestingly, MoCA was less sensitive than MMSE in detecting 
cognitive decline at 15-month follow-up in PD patients, and this is consistent with 
previous evidence suggesting that MMSE was better for tracking cognitive changes in PD 
(Lessig, Nie, Xu, & Corey-Bloom, 2012). Analysis of subitems revealed that PSP patients 
had a ‘clinically significant’ worsening after 15-month in the attentive/executive subitems 
(TMT-B and the Clock drawing). However, it has been observed that some patients also 
improved in specific subtasks at the follow-up. This improvement could be related to a 
higher medications dose (although the difference was not significant when comparing the 
LEDD at baseline vs. follow-up). 
It is worth noting that alterations (>30% change) in performance have been seen for 
subitems sensitive to motor conditions (such as drawing figures and linking circles with a 
pen), which could have affected cognitive outcome leading to higher performance. These 
limits associated with MoCA and MMSE scale, already showed for PD patients (Biundo et 
al., 2016b; Hu et al., 2014), maybe exacerbate in atypical parkinsonisms.   
Significant differences between groups were also found in the disease severity 
assessment, where MSA and PSP showed more severe motor impairments compared to 
PD. For comparability purposes, we assessed the motor severity with the MDS-UPDRS, 
although we are conscious that this scale is tailored for PD patients rather than atypical 
parkinsonisms and possibly was unable to evaluate all the motor impairments of PSP and 
MSA. 
Our study has also other important limitations. First, the lack of pathological 
confirmation of the clinical diagnosis, although we used the most recent clinical consensus 
criteria published (Gilman et al., 2008; Höglinger et al., 2017), we are aware that there is a 
high risk of misdiagnosis across the atypical parkinsonisms (Hughes et al., 2002; Joutsa et 
al., 2014; Koga et al., 2015). However, the clinical diagnoses were made by movement 
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disorders specialists and the patients were monitored for at least three years, due to the 
longitudinal nature of this study. Second, another limitation is the small number of our 
sample size, which is due not only to the rare nature of these disorders but also to the high 
drop-out rate because patients died or were too disabled. So, ideally future longitudinal 
multicenter studies should be conducted in order to ameliorate this issue. Third, we focus 
only on PSP-RS phenotype and this makes our findings unapplicable to the other PSP 
subtypes (i.e., the PSP parkinsonian variant). Lastly, the disease duration of our PD sample 
was not matched with PSP and MSA, since we focus on matching the patients for age and 
education. 
In conclusion, the contribution of cognitive assessment can be useful in conjunction 
with other clinical information (e.g., disease progression, response to medication, motor 
and clinical features) to differentiate atypical parkinsonism and thus make an accurate 
clinical diagnosis (Lee et al., 2012).  
Taken together, our findings showed that PSP patients were markedly impaired in 
comparison to the other parkinsonian disorders (MSA and PD) and within six years from 
the first symptoms, 33 percent of patients develop dementia. This severe progression is 
possibly associated with the distribution of tau pathology that involves also cortical 
structures. By contrast, the pattern of cognitive impairment in MSA was less severe than in 
the PSP patients, suggesting a distribution of underlying pathology in MSA, mostly in 
subcortical structures with a cortical involvement only secondary to these abnormalities. 
However, our results demonstrated that cognitive dysfunctions are frequent in MSA and 
strongly suggest the need to revise the current consensus criteria for the diagnosis of MSA 
by including the presence of MCI in the diagnostic criteria. This would be useful also to 
minimize the risk of misdiagnosis, since patients with parkinsonisms plus cognitive 
impairment tend to be misdiagnosed with another neurodegenerative disease (Koga et al., 
2015). Thus, our findings recommend the use of cognitive assessment, as it could be useful 
to differentiate diagnosis across atypical parkinsonisms, and particularly to better 
understand the underlying pathology and its progression. 
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CHAPTER 5 
AMYLOID DEPOSITIONS AFFECT COGNITIVE AND MOTOR 
MANIFESTATIONS IN PARKINSON’S DISEASE3 
 
 
 
5.1 Introduction  
Cognitive dysfunction, particularly executive-attentive problems, can be present early 
in PD. Although very common, they are not universal and different cognitive profiles are 
associated with variable risk of progression rate of dementia (Aarsland et al., 2003a; 
Aarsland et al., 2009; Biundo et al., 2014; Kehagia et al., 2010). Prevalence of cognitive 
impairment in PD is about 30 percent and following the disease’s course, approximately 80 
percent of patients develop dementia (Emre et al., 2007; Halliday et al., 2008), with negative 
consequences on quality of life and survival (Levy et al., 2002). Several neuropathological, 
biochemical and anatomical changes may partially explain the heterogeneous profile of PD 
cognitive impairment and dementia (Irwin et al., 2013). In particular, presence of cortical 
and limbic LB (associated with synuclein), uneven dopamine loss across the basal ganglia 
circuitry (Lewis, Dove, Robbins, Barker, & Owen, 2003; Sawamoto et al., 2008), 
degeneration of basal forebrain cholinergic neurons, and AD like pathology (with amyloid-
β [Aβ 42] plaques and tau neurofibrillary tangles) have been identified (Irwin et al., 2013; 
Mattila et al., 2000). This is also associated with presence of specific metabolic and 
structural brain deficits (Biundo et al., 2013; Peppard et al., 1992; Song et al., 2011). Indeed, 
it has been suggested that amyloid pathology and synuclein may act in synergy, leading to a 
worse prognosis (Compta et al., 2011; Irwin et al., 2013). 
Dysfunction of the frontostriatal dopaminergic system may influence the presence of 
executive and attention problems in PD (Bruck et al., 2005), even though the evidence 
from dopamine transporter (DAT) imaging so far is inconsistent (Delgado-Alvarado et al., 
2016). Deficits in memory and visuospatial functioning, defined as posterior cortically 
                                                 
3 Published as: Fiorenzato, E., Biundo, R., Cecchin, D., Frigo, A.C., Kim, J., Strafella, A.P., Antonini, A. 
Amyloid deposition affects cognitive and motor manifestations in Parkinson disease: the PPMI dataset (under 
review). 
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based dysfunctions, have been related to non-dopaminergic alterations (i.e., cholinergic 
deficits) and the cortical LB (Williams-Gray et al., 2009). Furthermore, visuospatial deficits 
were also associated with amyloid depositions in the posterior and parietal cingulate 
cortices (Gomperts et al., 2008). Recent evidence from positron emission tomography 
(PET) imaging has suggested that in PD amyloid burden may contribute over time to 
cognitive, but not motor manifestations (Gomperts et al., 2013). Although in vivo evidence 
is still limited, particularly in early patients. 
The relationship between amyloid-β and synuclein pathology has been intensely debated 
and investigated. It has been suggested that synuclein facilitates deposition of other protein 
aggregates (Irvine, El-Agnaf, Shankar, & Walsh, 2008) — although this seems unlikely 
given the presence of findings from post-mortem studies showing presence of concomitant 
pathologies in only a small proportion of PD (Irwin et al., 2012; Mattila et al., 2000); 
besides, recently, it has been posited that the presence of amyloid depositions can possibly 
facilitate the spread of synuclein strains (Toledo et al., 2016). This hypothesis seems likely 
and is in line with recent evidence that in PD, synuclein pathology is mainly located in 
axons, resulting in synaptic axonal damage, and consequently dysfunction (Tagliaferro & 
Burke, 2016). Hence, in agreement with this model, amyloid deposition facilitates the 
spread of synuclein, increasing axonal vulnerability, and also leading to neuro-inflammation 
processes (Edison et al., 2013). 
To our knowledge, no study has previously combined PET-amyloid, DAT imaging and 
MRI-based measures of atrophy in order to investigate the relationship between amyloid 
depositions and synuclein pathology in the early phase of PD. 
In the present study, we investigated the extent to which amyloid depositions in 
frontostriatal circuit, striatal dopaminergic dysfunction and brain atrophy rates can interact 
and contribute to frontostriatal based cognitive impairment. Specifically, we hypothesized 
that amyloid depositions can possibly act synergistically with synuclein pathology, 
interfering with axonal transmission; and thus we expect that PD patients with amyloid 
burden will be more vulnerable to cognitive and motor alterations. 
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5.2 Methods 
5.2.1 Study design and participants 
We obtained approval to access the Parkinson’s Progression Markers Initiative (PPMI) 
database and to analyze the neuroimaging, cognitive and clinical data in early-PD (Marek et 
al., 2011). Briefly, the PPMI started in 2010 and is an ongoing international, multicenter, 
observational study of patients with PD and healthy controls in 33 sites in the USA, 
Europe, Israel and Australia; whose aim is to identify biomarkers of PD progression. Study 
aims, methodology, and details of the assessments have been published and are available on 
the PPMI website4. The Institutional Review Board of each participating institution 
approved the PPMI study. All participants gave their written informed consent to 
participate in the program.  
Participants selected from the PPMI dataset for the current study were all those with 
[18F]florbetaben PET images available and a diagnosis of PD. As of May 2017, these were 
33 patients who had been recruited at five institutions worldwide. For this study, 
assessment included single-photon emission computed tomography (SPECT) with [123I]FP-
CIT (DaTSCAN by GE Healthcare) imaging, MRI, clinical evaluation of motor and non-
motor features and cerebrospinal fluid (CSF) examination, as described previously (Kang et 
al., 2016). The [18F]florbetaben PET and the clinical evaluations were performed between 
visit 4 and 8, [123I]FP-CIT-SPECT between visit 6 and 10 (approximately within a year from 
the PET scanning). MRI scanning and CSF examination were collected at baseline 
(approximately within 2 or 3 years from the PET scanning). The participants of our sample 
have been evaluated between November 1, 2010 and August 1, 2016. Regarding the clinical 
evaluations, these subjects were monitored at least over three years.  
 
5.2.2 Motor and non-motor outcomes 
Demographic and clinical variables comprised age, sex, education, disease duration, 
LEDD, depression evaluated with the shorter 15 item Geriatric Depression Scale, disease 
severity assessed by means of the motor part of the Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale (in ON state), first motor symptoms at the onset and 
                                                 
4 http://www.ppmi-info.org/study-design 
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functional autonomy using the ADL. We also assessed CSF for Aβ42, synuclein, total tau 
and phosphorylated tau. 
Global cognition was evaluated by means of MoCA test scores assessed at the time of 
neuroimaging examination. Further, to evaluate fronto-executive abilities, we analyzed 
performance on the Letter Number Sequencing test (LNS) to evaluate working-memory 
and executive function and the Symbol Digit Modalities Test (SDTM), which measures 
attention and executive functions. The LNS requires one to recall strings of digits and 
letters and to re-organize them, while the SDTM requires one to pair a specific number 
with geometric figures based on a references key. 
 
5.2.3 Data acquisition and image processing: PET and SPECT 
 Images were acquired at PPMI institutions as specified in the imaging protocol for the 
PPMI scans5. Assessment of amyloid depositions was made using available, already 
processed data on the PPMI database. [18F]florbetaben PET images were imported to 
PMOD Biomedical Image Quantification Software (PMOD Technologies, Zurich, 
Switzerland) for processing and analysis, following scientific and technical quality control 
performed at an imaging core lab (Institute for Neurodegenerative Disorders, New Haven, 
Connecticut). Dynamic PET frames were assessed for motion and if necessary, motion 
correction was performed. These files were then averaged (time weighted mean) to create a 
single PET volume. The PET volume was normalized to standard Montreal Neurological 
Institute and Hospital (MNI) space, to have all scans in the same anatomical alignment. 
The normalized PET volume was then converted to standard uptake values (SUV). 
Volumes of Interest (VOIs) from the MNI modified Automated Anatomical Labeling 
template, including cortical and subcortical regions, were applied to the SUV PET volume 
and adjusted as needed for subject atrophy (Tzourio-Mazoyer et al., 2002). The VOI 
placement was saved specifically for each subject. Semi-quantitative measurements (average 
SUV per voxel) were extracted from the regions to calculate the regional SUV Ratios 
(SUVRs) using the cerebellar gray matter as reference. 
A composite SUVR for each subject was computed by calculating the mean SUVRs 
from six regions of interest, typically associated with increased tracer uptake (Rowe et al., 
2008): namely, frontal cortex, lateral temporal cortex, anterior cingulate cortex, posterior 
                                                 
5 http://www.ppmi-info.org/wp-content/uploads/2015/12/PPMI-AM10_protocol.pdf 
Amyloid depositions affect cognitive and motor manifestations in PD 
 125 
cingulate cortex, parietal cortex, and occipital cortex. Composite SUVR values ≥ 1.45 were 
considered positive, indicating presence of amyloid-β depositions in the range expected for 
AD (Jennings et al., 2015; Ong et al., 2013). Thus, we defined PD Aβ+ and Aβ- according 
to this SUVR cut-off.  
SPECT with the DAT tracer [123I]FP-CIT was obtained in all 33 participants, and the 
striatal binding ratio was calculated for the right and left caudate and putamen separately, 
using as a reference region the occipital lobe. Detailed explanations of data acquisition and 
processing have been described previously (Siepel et al., 2014), and this information is also 
available in the PPMI imaging protocol reported above.  
 
 5.2.4 Structural MRI acquisition 
Non-contrast enhanced 3D volumetric T1-weighted brain MRI scans were acquired 
using 1.5 or 3 Tesla scanners and were available for the majority of the sample (30 out of 
33 subjects), after excluding low quality scans on visual inspection. The majority of subjects 
were scanned using a 3 Tesla MR scanner (n = 24) and the remaining 6 with 1.5 Tesla MR 
scanner.  To minimize bias in data collection between different institutions, the PPMI 
optimized acquisition protocols across centers to maximize the data comparability. Hence, 
typical MRI parameters were as follows: repetition time 5 to 11 ms; echo time 2 to 6 ms; 
slice thickness 1 to 1.5 mm; inter slice gap 0 mm; voxel size 1*1*1.2 mm; matrix 256* 
minimum 160.6  
 
5.2.5 Pre-processing and statistical analysis for voxel-based morphometry 
Voxel-based morphometry analysis was performed using the DARTEL toolbox 
(Ashburner, 2007), as implemented in SPM12 as follows (Statistical Parametric Mapping; 
Wellcome Trust Centre for Neuroimaging, London, UK).7 i) The origin (coordinate x, y, z 
= 0, 0, 0) of all T1-weighted structural images were manually centered to the anterior 
commissure for normalization improvement. ii) An individual image was segmented into 
gray matter, white matter, and CSF tissue in native space using the New Segment 
procedure.  To improve automatic segmentation for subcortical structures, the new tissue 
                                                 
6 Further details at http://www.ppmi-info.org/wp-content/uploads/2010/07/Imaging-Manual.pdf 
7 http://www.fil.ion.ucl.ac.uk/spm/software/spm12/ 
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probability maps were used (Lorio et al., 2016). iii) The resulting segmented images were 
first spatially normalized to MNI space and used to acquire the study-specific template in 
DARTEL. The structural images were convolved using Jacobian determinant estimated 
during the previous step, so that the intensity of voxel in the image could reflect the 
volumes of the brain tissue class in the given voxel. iv) The images were eventually 
normalized to MNI space using affine spatial normalization. v) Gray matter images were 
smoothed by convoluting the Gaussian kernel with an 8 mm full width at half maximum. A 
final smoothed and spatially normalized GM image represents the regional volume of gray 
matter tissue and was used for statistical analysis. Total intracranial volume (TIV), the 
global volumes of individuals, were calculated by summing the value from the segmented 
gray matter, white matter, and CSF images using a ‘tissue volume’ utility implemented in 
SPM 12 (Malone et al., 2015), and used as covariate to control the head size difference 
across individuals. 
For statistical analysis to determine group differences of gray matter volumes, the 
normalized and smoothed gray matter images were analyzed with a two-sample t-test in 
SPM12. Age, TIV, manufacturer and scanner strength were included as nuisance covariates 
to reduce possible confounding effects, and absolute threshold masking was applied as 
0.15. The significance of statistical analysis was determined at an uncorrected voxel-wise 
level threshold of p < 0.005 with a cluster threshold of k > 1265, which corresponded to a 
cluster-level corrected familywise error rate of p < 0.05.  
The cluster extents for multiple comparisons correction were estimated via a Monte 
Carlo simulation via AFNI’s 3dClustSim-ACF option.8 
In addition, we later performed the additional non-parametric analysis using the 
statistical non-parametric mapping toolbox, SnPM13,9 to investigate the validity of the 
result performed in SPM. SnPM uses the general linear model to estimate the pseudo t-
statistics based on 5000 permutations testing without variance smoothing. The same 
statistical threshold criterion was applied as in the SPM analysis. 
 
 
 
                                                 
8 http://afni.nimh.nih.gov/pub/dist/doc/program_help/3dClustSim.html 
9 http://warwick.ac.uk/snpm 
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5.2.6 Statistical analysis 
Due to the non-normal distribution of the sample, descriptive and non-parametric 
statistics (Mann–Whitney U test) were run to analyze the demographic, clinical and imaging 
data. Further, the p-values of the cognitive and imaging data were adjusted for age. 
Categorical variables were compared using Fisher's exact test since in some variables, the 
number of observations was less than five. Then, Spearman’s rank correlations were 
performed to study the association between cognition (as assessed by MoCA, LNS and 
SDMT), dopaminergic deficiency and amyloid depositions in the frontostriatal circuit 
(caudate, putamen and frontal areas). Statistical analysis was performed using SAS 9.4 (SAS 
Institute Inc., Cary, NC, USA) for Windows. Statistical significance was set at a five percent 
level. 
 
5.3 Results 
5.3.1 Study cohort characteristics 
In total, we analyzed the data of 33 subjects enrolled in the PPMI study and with a 
diagnosis of idiopathic PD. Six PD (18%) were defined as PDAβ+ (SUVR≥1.45) and were 
compared to the PDAβ- group. The clinical and demographic data of the two groups are 
reported in Table 3.1.  
The groups did not differ in age, education or sex distribution; although there was a 
trend for the PDAβ+ group to be older (according to the median scores). No significant 
differences were noted in disease duration, motor impairments and functional autonomy 
— but LEDD was significantly higher in the PDAβ- group (p=0.04).  
From the cognitive point of view, we found no differences between these two groups, 
although there was a tendency for a lower MoCA score in the PDAβ+ vs. PDAβ- group 
(median scores: 25 vs. 27, respectively) as well as on executive functions performance (LNS 
and SDMT).  
This sample did not include PD with dementia, as all patients were independent in 
functional autonomy (as assessed by ADL score > 80/100).  
There were no between-groups differences in onset of motor symptoms as well as CSF 
markers at baseline. 
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Table 5.1 Demographic, clinical and cognitive features according to amyloid status 
  
   PD Aβ ̶                                                                    
   (n = 27) 
  
PD Aβ+                                                       
  (n = 6) 
  p-value  
Mean (SD) 
Median  
(min ̶  max) 
 Mean (SD) 
Median 
(min ̶  max) 
   
Age, y 64.26 (8.58) 61.00 (51 ̶  84)  66.00 (7.80) 68.50 (55 ̶  75)  0.69 
Sex (m/f) 20/7    6/0   0.30 
Education, y 15.74 (2.38) 16.00 (12 ̶  21)  16.33 (2.25) 16.50 (14 ̶  20)  0.52 
Disease duration, y 4.79 (1.44) 4.60 (3.20 ̶  9.00)  5.68 (1.51) 5.30 (3.60 ̶  7.90)  0.12 
LEDD 430.33 (252.08) 400 (0 ̶ 1000)  209.17 (139.16) 150 (100 ̶  450)  0.04 
MoCA score 26.93 (2.50) 27 (21 ̶  30)  25.33 (2.94) 25 (22 ̶  29)  0.20# 
LNS 10.78 (2.67) 10 (7 ̶  17)  8.83 (3.19) 9 (5 ̶  12)  0.14# 
SDMT 43.59 (8.44) 47 (30 ̶  59)  38.67 (12.86) 43 (21 ̶  51)  0.28# 
GDS score 5.04 (1.16) 5 (1 ̶ 7)  5.33 (1.37) 5 (4 ̶  7)  0.85 
MDS-UPDRS III 25.00 (9.75) 27 (8 ̶  41)  24.83 (12.00) 20 (17 ̶  48)  0.62 
ADL 85.93 (7.08) 80 (80 ̶  100)  87.50 (6.12) 90 (80 ̶  95)  0.49 
Motor symptoms at 
onset 
 
 
 
      Tremor  20 (74.1%)   5.0 (83.3%)   0.99 
      Rigidity  21 (77.8%)   4.5 (66.7%)   0.62 
      Bradykinesia  22 (81.5%)   4.0 (66.7%)   0.58 
CSF markers, pg/mL    
     Aβ42 386.33 (96.13) 368.00 (238 ̶  621)  353.33 (66.48) 335.50 (295 ̶  460)  0.41 
     α-synuclein 1717.19 (766.73) 1588.0 (333 ̶  3540)  1735.83 (318.87) 1805.5 (1344 ̶  2103)  0.67 
     Total tau 42.04 (17.38) 38 (22 ̶  92)  42.00 (10.37) 38 (33 ̶ 59)  0.62 
     Phosphorylated tau 16.00 (11.22) 11 (6 ̶  45)  11.17 (2.40) 11 (8 ̶ 15)  0.76 
    Aβ42:tau ratio 10.03 (3.02) 9.41 (4.95 ̶  16.79)   8.80 (2.61) 8.33 (5.90 ̶ 12.78)   0.29 
 
Note. PD, Parkinson’s disease; Aβ, Amyloid-β; FBB, [18F]florbetaben; SD, standard deviation; LEDD, levodopa 
equivalent daily dose; MoCA, Montreal Cognitive Assessment; LNS, Letter Number Sequencing test; SDMT, Symbol 
Digit Modalities Test; GDS, Geriatric Depression Scale; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s 
Disease Rating Scale; ADL, Activity of Daily Living; CSF, cerebrospinal fluid. #: Age adjusted p-value. Significant value is 
in bold type. 
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5.3.2 Regional amyloid depositions and DAT binding in PDAβ+ versus 
PDAβ- 
 [18F]florbetaben regional SUVRs and [123I]FP-CIT-SPECT SBRs as a function of the 
amyloid status (Aβ+ or Aβ-) with p-value adjusted for age are reported in Table 3.2.  
[18F]florbetaben regional SUVRs were consistently more elevated in PDAβ+ compared 
to the PDAβ- group. These differences were highly significant in several regions, 
particularly in cortical areas (i.e., frontal, orbitofrontal, temporal, mesial and lateral 
temporal, parietal, occipital regions, posterior and anterior cingulate cortex regions), 
subcortical nuclei (i.e., caudate, putamen, thalamus), pons, rectus, and cerebellar white 
matter regions.  
We found also that [123I]FP-CIT-SPECT binding differed between the two groups: 
namely, in the PDAβ- group DAT binding ratios were bilaterally lower in the caudate 
nucleus as well as in the right putamen compared to PDAβ+. Interestingly, after age 
correction, this difference was even more significant. This suggests the PDAβ+ group had 
a less prominent striatal dopaminergic deficit as expressed by higher DAT binding 
compared to the PDAβ- group, although it was characterized by a widespread distribution 
of amyloid-β depositions in cortical and subcortical regions. 
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Table 5.2 Between-group comparisons according to the amyloid status (PDAβ- vs. 
PDAβ+) on regional [18F]florbetaben SUVRs and [123I]FP-CIT-SPECT SBRs uptake  
Ligand Region 
 PDAβ ̶          
 (n = 27)   
         PDAβ+   
         (n = 6)   p-
value  
Age 
adjusted 
p-value Mean 
(SD) 
Median  
(min ̶  max)  
Mean 
(SD) 
Median  
(min ̶  max) 
  
[18F]florbetaben Mesial temporal cortex R 1.21 (0.07) 1.21 (1.08  ̶ 1.38)  1.39 (0.08) 1.38 (1.31  ̶ 1.49)  0.0006 0.0001 
Mesial temporal cortex L 1.21 (0.09) 1.19 (1.07  ̶ 1.48)  1.35 (0.06) 1.34 (1.28  ̶ 1.43)  0.0019 0.0020 
Pons 1.74 (0.18) 1.77 (1.30  ̶ 2.04)  1.96 (0.17) 1.91 (1.80  ̶ 2.22)  0.0320 0.0175 
Subcortical white matter 2.00 (0.18) 2.00 (1.63  ̶ 2.32)  2.40 (0.25) 2.36 (2.13  ̶ 2.81)  0.0011 0.0001 
Cerebellar white matter 2.08 (0.17) 2.11 (1.66  ̶ 2.39)  2.49 (0.22) 2.50 (2.18  ̶ 2.74)  0.0012 0.0001 
Rectus R 1.20 (0.11) 1.20 (0.94  ̶ 1.41)  1.49 (0.19) 1.45 (1.28  ̶ 1.82)  0.0008 0.0002 
Rectus L 1.24 (0.10) 1.24 (1.05  ̶ 1.47)  1.46 (0.14) 1.44 (1.34  ̶ 1.73)  0.0012 0.0002 
Cingulum anterior R 1.25 (0.10) 1.23 (1.04  ̶ 1.44)  1.54 (0.24) 1.46 (1.32  ̶ 1.93)  0.0015 0.0002 
Cingulum anterior L 1.30 (0.12) 1.30 (1.06  ̶ 1.52)  1.63 (0.22) 1.57 (1.40  ̶ 1.96)  0.0010 0.0001 
Cingulum posterior R 1.32 (0.14) 1.35 (1.08  ̶ 1.58)  1.71 (0.11) 1.73 (1.51  ̶ 1.83)  0.0002  <0.0001 
Cingulum posterior L 1.38 (0.13) 1.41 (1.10  ̶ 1.60)  1.77 (0.06) 1.78 (1.71  ̶ 1.87)  0.0002  <0.0001 
Caudate R 1.42 (0.10) 1.41 (1.29  ̶ 1.68)  1.65 (0.21) 1.61 (1.47  ̶ 2.05)  0.0028 0.0010 
Caudate L 1.36 (0.11) 1.34 (1.20  ̶ 1.61)  1.55 (0.22) 1.49 (1.36  ̶ 1.95)  0.0200 0.0074 
Putamen R 1.46 (0.10) 1.46 (1.19  ̶ 1.69)  1.75 (0.16) 1.82 (1.51  ̶ 1.89)  0.0010  <0.0001 
Putamen L 1.42 (0.08) 1.41 (1.22  ̶ 1.63)  1.65 (0.14) 1.70 (1.45  ̶ 1.80)  0.0012  <0.0001 
Thalamus R 1.47 (0.13) 1.44 (1.28  ̶ 1.87)  1.66 (0.08) 1.67 (1.52  ̶ 1.75)  0.0032 0.0042 
Thalamus L 1.56 (0.14) 1.56 (1.33  ̶ 1.96)  1.73 (0.13) 1.68 (1.60  ̶ 1.92)  0.0063 0.0129 
Occipital cortex R 1.30 (0.09) 1.30 (1.16  ̶ 1.52)  1.51 (0.09) 1.49 (1.41  ̶ 1.65)  0.0005 0.0001 
Occipital cortex L 1.32 (0.09) 1.31 (1.18  ̶ 1.52)  1.55 (0.09) 1.52 (1.44  ̶ 1.68)  0.0004  <0.0001 
Parietal cortex R 1.26 (0.09) 1.25 (1.09  ̶ 1.44)  1.56 (0.13) 1.53 (1.42  ̶ 1.77)  0.0002  <0.0001 
Parietal cortex L 1.26 (0.09) 1.25 (1.08  ̶ 1.43)  1.56 (0.15) 1.56 (1.38  ̶ 1.79)  0.0004  <0.0001 
Lateral temporal cortex R 1.24 (0.07) 1.23 (1.10  ̶ 1.38)  1.45 (0.10) 1.47 (1.33  ̶ 1.57)  0.0005  <0.0001 
Lateral temporal cortex L 1.23 (0.08) 1.22 (1.12  ̶ 1.45)  1.42 (0.08) 1.44 (1.30  ̶ 1.50)  0.0005 0.0002 
Orbitofrontal cortex R 1.23 (0.09) 1.23 (1.08  ̶ 1.44)  1.48 (0.18) 1.43 (1.32  ̶ 1.76)  0.0008 0.0002 
Orbitofrontal cortex L 1.24 (0.08) 1.22 (1.10  ̶ 1.43)  1.44 (0.15) 1.38 (1.32  ̶ 1.70)  0.0007 0.0003 
Frontal cortex R 1.29 (0.09) 1.28 (1.16  ̶ 1.49)  1.59 (0.14) 1.58 (1.43  ̶ 1.79)  0.0003  <0.0001 
Frontal cortex L 1.30 (0.08) 1.30 (1.16  ̶ 1.49)  1.58 (0.13) 1.58 (1.41  ̶ 1.75)  0.0004  <0.0001 
Temporal cortex R 1.23 (0.07) 1.23 (1.10  ̶ 1.38)  1.44 (0.09) 1.44 (1.33  ̶ 1.55)  0.0005  <0.0001 
Temporal cortex L 1.23 (0.08) 1.21 (1.11  ̶ 1.46)  1.40 (0.07) 1.41 (1.29  ̶ 1.48)  0.0009 0.0003 
[123I]FP-CIT-
SPECT 
(DaTSCAN) 
  
  
Caudate R 1.52 (0.44) 1.50 (0.78  ̶ 2.37)  2.34 (0.82) 2.28 (1.27  ̶ 3.33)  0.0180 0.0030 
Caudate L 1.49 (0.44) 1.57 (0.63  ̶ 2.16)  2.16 (0.43) 2.15 (1.62  ̶ 2.67)  0.0059 0.0038 
Putamen R 0.57 (0.23) 0.49 (0.28  ̶ 1.43)  1.09 (0.57) 1.01 (0.27  ̶ 1.91)  0.0240 0.0018 
Putamen L 0.54 (0.18) 0.53 (0.17 ̶  1.03)  0.75 (0.40) 0.65 (0.36 ̶  1.52)  0.1100 0.0536 
  
Note. SUVR, Standard Uptake Value ratio; PD, Parkinson’s disease; Aβ, Amyloid-β; SD, standard deviation; R, right; L, 
left. Highly significant results (p ≤ 0.0001) are reported in bold type. 
Amyloid depositions affect cognitive and motor manifestations in PD 
 131 
5.3.3 Cognition and its association with frontostriatal amyloid load and DAT 
binding  
In this analysis, we considered the whole PD cohort (PDAβ+ and PDAβ-) and tested 
the hypothesis that amyloid accumulations can possibly disrupt cognitive performance. 
Thus, we calculated the correlation between amyloid SUVRs in frontostriatal regions, the 
performance at MoCA scale and fronto-executive tests (LNS and SDMT). 
We found a moderate negative association between amyloid burden (in dorsal striatum 
and frontal areas) and MoCA. Similar correlation was noted also between amyloid 
accumulations in frontal regions and SDMT (Table 5.3). These correlations suggest greater 
amyloid load in the frontostriatal network is associated with a worse performance on global 
cognition and executive tasks.  
Further, we analyzed the relationship between cognitive tests and DAT binding, where 
we found an inverse correlation between DAT binding and cognitive performance. 
Namely, there was a negative correlation between the LNS test performance and dorsal 
striatum DAT binding, indicating better cognitive performance was associated with 
reduced DAT binding. We also observed a similar inverse association between MoCA scale 
and DAT binding in the right caudate nucleus. 
 
5.3.4 Model for cognition in PD: effect of amyloid depositions, age and DAT 
binding 
Stepwise regression analysis using MoCA score as the dependent variable showed that 
increasing amyloid depositions in frontal areas (i.e., [18F]florbetaben SUVR) accounted for 
23.1 percent of the variance of the cognitive scale. Instead, using LNS total score as the 
dependent variable, 33.3 percent of the variance was explained by striatal DAT binding 
(Table 3.4).  
In addition, using SDMT score as the dependent variable, 38.5 percent of the variance 
was accounted for by increasing age and amyloid depositions in frontal areas (as measured 
by [18F]florbetaben SUVR).  
Thus, in summary, the variance in some cognitive scales seems to be better explained by 
amyloid depositions rather than dopaminergic deficiency. 
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Table 5.3 Spearman’s rank correlation between cognitive tests versus amyloid burden and 
SBRs  
      
MoCA LNS SDMT 
[18F]florbetaben SUVR amyloid 
caudate nucleus 
(bilateral) 
rs -0.35 -0.11 -0.20 
p-value 0.0449 0.5354 0.2705 
SUVR amyloid 
putamen 
(bilateral) 
rs -0.35 -0.14 -0.17 
p-value 0.0459 0.4536 0.3566 
SUVR amyloid 
frontal area R 
rs -0.44 -0.05 -0.39 
p-value 0.0099 0.7763 0.0268 
SUVR amyloid 
frontal area L 
rs -0.39 -0.11 -0.41 
p-value 0.0230 0.5365 0.0177 
[123I]FP-CIT-SPECT 
(DaTSCAN) Caudate R 
rs -0.40 -0.55 -0.21 
p-value 0.0215 0.0009 0.2516 
Caudate L 
rs -0.28 -0.48 -0.28 
p-value 0.1121 0.0043 0.1180 
Putamen R 
rs -0.26 -0.39 -0.05 
p-value 0.1421 0.0269 0.7965 
Putamen L rs -0.01 -0.37 -0.09 
p-value 0.9390 0.0362 0.6179 
 
Note. SBRs, specific binding ratios; caudate, caudate nucleus, R, right; L, left; MoCA, Montreal Cognitive Assessment; 
LNS, Letter Number Sequencing test; SDMT, Symbol Digit Modalities Test; SUVR, standardize uptake value ratio. 
Significant values are in bold type.  
 
Table 5.4 Stepwise regression analyses for MoCA and fronto-executive tests (LNS and 
SDMT) 
Variable  Coefficient b SE (b) Beta t p-value 
MoCA 
     Constant 38.382 3.869  9.919  
     SUVR amyloid frontal area (bilateral) -8.693 2.848 -0.481 -3.052 0.005 
Letter Number Sequencing test 
     Constant 15.301 1.306  11.718  
     Mean striatal SBR -4.321 1.099 -0.577 -3.931 <0.0001 
Symbol Digit Modalities Test 
     Constant 103.864 14.347  7.239  
     SUVR amyloid frontal area (bilateral) -24.254 9.77 -0.374 -2.483 0.019 
     Age -0.44 0.169 -0.393 -2.606 0.014 
 
Note. MoCA model fit: F = 9.32; R2 = 0.231; excluded variables age and mean striatal SBR. LNS model fit: F = 15.45; R2 
= 0.333; excluded variables age and amyloid in frontal areas; SDMT model fit: F = 6.16; R2 = 0.385; excluded variable 
mean striatal SBR. The mean striatal SBR scores were calculated as the mean of the left and right caudate and putamen 
SBR scores. PD, Parkinson’s disease; MoCA, Montreal Cognitive Assessment; SBR, specific binding ratio; SUVR, 
standardized uptake value ratio; LNS, Letter Number Sequencing test; SDMT, Symbol Digit Modalities Test. 
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5.3.5 Effect of amyloid on gray matter volume 
As reported in Figure 3.1 and Table 3.5, whole brain direct comparison between 
PDAβ+ and PDAβ- reveals decreased gray matter volume in the PDAβ+ group in the 
middle cingulate cortex (MCC), including right medial superior frontal gyrus and right 
superior frontal gyrus, as well as the left fusiform gyrus extending to bilateral calcarine 
cortex. Notably, as the effect of age was controlled in this analysis, it is more probable the 
observed gray matter atrophies are related to the presence of amyloid in the PDAβ+, rather 
than age-related degeneration. 
 
 
 
Figure 5.1 Structural MRI analysis: regions of reduced gray matter in the amyloid positive group 
(cluster level corrected family-wise error p < 0.05). Aβ, Amyloid-β; FG, fusiform gyrus; CAL, 
calcarine cortex; MCC, middle cingulate cortex; mSFG, medial superior frontal gyrus. 
 
 
 
Table 5.5 Gray matter volume comparisons between PDAβ+ and PDAβ ̶  groups 
      MNI (mm)   
  Brain region (Brodmann area) 
Cluster 
size X Y Z 
T 
value 
 PDAβ+ < PDAβ ̶  Middle Cingulate (BA 24) 2293 0 9 42 4.99 
      R Superior Frontal (BA 9)  12 47 42 4.22 
      R Medial Superior Frontal (BA 32)  5 33 33 3.75 
 L Fusiform (BA 18) 2308 -26 -81 -15 4.91 
     R Calcarine (BA 18)  5 -89 -11 4.21 
      L Calcarine (BA 17)  -3 -98 -12 4.21 
 
Note. Reported clusters are corrected at cluster level p < 0.05 familywise error. PD, Parkinson’s disease; Aβ, Amyloid-β, L, 
left; R, right; MNI, Montreal Neurological Institute and Hospital, BA, Broadmann Area. 
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5.4 Discussion 
The neuropathology underlying cognitive impairment in PD is heterogeneous, and the 
contribution of β-amyloid to synuclein pathology is still under investigation (Irwin et al., 
2013). Even less is known about the contribution of these mechanisms in the early stages 
of PD. 
The underpinning hypothesis of this study was that amyloid depositions can possibly 
serve as a vulnerability factor to facilitate the spread of synuclein aggregates; hence, we 
focused particularly on frontostriatal circuit and executive dysfunctions, which are known 
to be altered since the early stages of the disease (Lewis et al., 2003).  
To the best of our knowledge, this is the first multimodal study in which dopamine 
SPECT imaging, PET-amyloid, and MRI-based measures of atrophy were used in 
conjunction to evaluate a cohort of early-PD. 
Two major findings characterize this study: first, high amyloid levels in early-PD, 
detected by [18F]florbetaben PET imaging, were associated with reduced striatal 
dopaminergic deficits (as expressed by higher DAT uptake); second, high amyloid levels 
were associated with a tendency to show more frequent cognitive dysfunctions and 
increased brain atrophy progression rates. 
These results add to the view that PD patients in the early phase of the disease, with 
concomitant amyloid pathology, have higher brain atrophy rates and can experience more 
cognitive deficits, but they are likely to show less prominent dopaminergic defects. While 
PD patients without amyloid pathology can possibly have less frequent cognitive 
impairment, lower brain atrophy rates, and can potentially show a greater dopaminergic 
deficit. 
Taken together, our findings support our initial hypothesis that amyloid depositions 
increase vulnerability to dopaminergic deficits in PD. Indeed, amyloid can possibly act in 
synergy with synuclein pathology in the dopaminergic circuit, leading to progressive 
cognitive alterations in patients with amyloid-β comorbidity.  
Our findings agree with a recent neuropathological hypothesis that considers synaptic 
axonal damage and dysfunction as PD’s key feature (Tagliaferro & Burke, 2016). Indeed, 
dopaminergic system neurons are particularly vulnerable to synuclein pathology due to 
their axonal features — long, thin and unmyelinated.  
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This is also aligned with evidence from human imaging with DAT-binding PET 
(Caminiti et al., 2017), FDG-PET (Eidelberg, 2009; Pappata et al., 2011), and animal 
models (Walsh & Selkoe, 2016); suggesting synuclein aggregations in PD can affect 
synaptic function, and thus signal transmission from very early stages.  
Further, it has been suggested an interaction between synuclein and the coincident 
amyloid pathology, wherein amyloid burden may facilitate the spread of synuclein (i.e., LB) 
(Toledo et al., 2016), and we speculate that this interaction can further contribute to axonal 
vulnerability. 
Noteworthy, axonal damage has also been suggested as a source of amyloid-β, as axonal 
damage may lead to protein accumulation (e.g., amyloid precursor protein), which can be 
cleaved to form amyloid-β (Johnson et al., 2010; Stokin et al., 2005), and in turn, if there is 
presence of amyloid facilitates synuclein spreading, this would further lead to additional 
synaptic axonal damage, leading to a vicious cycle. In addition, we think it also is 
conceivable a contribution from neuroinflammation, since amyloid depositions are 
surrounded by reactive microglia and in turn, synuclein aggregates attract microglia, then 
potentially resulting in neuronal death and disease progression (Edison et al., 2013; Zhang 
et al., 2005). 
To summarize, our results agree with a model of PD, where amyloid load amplifies 
dopaminergic dysfunction, leading to neuronal disconnection and consequently cognitive 
dysfunctions. Indeed, when both synuclein and amyloid pathologies coexist, brain 
functional and structural connectivity are maximally altered, leading to a breakdown of 
anatomical connections between brain areas (Jacquemont et al., 2017). Hence, the extent of 
cognitive alterations can be possibly due to the concomitance of dopaminergic pathology in 
conjunction to amyloid-β deposits; although amyloid seems to be the best predictor of 
cognitive defects. 
Indeed, a recent biomarker study reveals that in healthy subjects, the incidence of 
dementia is increased by 3-fold (between ages 65 and 85) in presence of neurodegenerative 
disease and an absence of amyloid aggregations; while this incidence increases up to 9-fold 
when both neurodegeneration and amyloidosis are present; and this again underlines the 
‘clinically malignant nature’ of this state (Jack et al., 2016). 
Our finding of an association between increased amyloid as well as brain atrophy rates 
in PD suggests that amyloid deposition can possibly lead to a progressive loss of gray 
matter over time. In this regard, we found a broader atrophy in occipital areas (calcarine 
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cortex and fusiform gyrus) as well as frontal regions (superior frontal gyrus and MCC). This 
is aligned with our amyloid-PET results, since these regions were also associated with a 
significantly elevated amyloid burden; even though evidence from patients with MCI 
showed that brain tissue loss is not necessarily overlapping with the areas of high amyloid 
distribution (Tosun, Joshi, & Weiner, 2013). Furthermore, metabolic studies in PD 
identified cingulate and visual association cortex as vulnerable regions to cognitive 
alterations and dementia (Bohnen et al., 2011), and in turn this agreed with our hypothesis 
that amyloid burden contributes to brain atrophy and cognitive dysfunction.  
It is worth noting that in the present study, MRI-imaging scans were performed at 
baseline (approximately 3-year before the PET-amyloid assessment), thus we can suppose 
that MRI-structural changes could possibly show an even broader distribution at time of 
PET scanning assessment. Indeed, our results are aligned with a recent study, based on the 
PPMI cohort, reporting that PD patients with lower CSF-amyloid levels showed a 
widespread cortical atrophy, especially in frontal regions, rather than in areas typically 
associated with AD (McMillan & Wolk, 2016). However, larger studies are required to 
confirm this pattern of atrophy, especially to better explain the possible relationship 
between amyloid pathology and brain atrophy rates in PD.  
Another important observation is that we did not observe differences in disease 
severity between PDAβ- and PDAβ+ groups, although the PDAβ- group showed more 
elevated dopaminergic loss. In other words, DAT binding was significantly lower in the 
right putamen and bilateral caudate nuclei. This finding supports our hypothesis that 
amyloid can possibly affect motor functions as well, since in presence of comorbid amyloid 
pathology, a minimal dopaminergic deficit is sufficient to trigger motor symptoms and thus 
PDAß+ patients would be also more vulnerable to motor impairments. Similarly, in AD, 
motor dysfunctions are reported even though there is no presence of dopaminergic 
degeneration (Thomas et al., 2017). 
We recognize that our PDAβ- group has a higher intake of dopaminergic medications 
(as assessed by LEDD) than the PDAβ+ patients; however, in our cohort we did not find 
an association between motor dysfunctions and LEDD (rs=-0.059, p=0.7458), and 
adjusting MDS-UPDRS motor score for LEDD, this difference remains not significant 
(p=0.7722). 
Another important finding of the present study is the correlation between high 
amyloid depositions in frontal regions, worse performance on global cognition and 
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attentive/executive functions. Results from the stepwise linear regression analysis showed 
that the 23 percent of MoCA variability was better explained by amyloid burden in frontal 
areas, while 39 percent of SDMT variance was explained mostly by age and amyloid 
depositions. Previous studies did not find these results in non-demented PD patients and 
this is possibly due to different cognitive scales being used (i.e., DRS-2 and MMSE) 
(Akhtar et al., 2017; Siderowf et al., 2014). Indeed, our finding is aligned with the recent 
literature where MoCA showed a high sensitivity in detecting early cognitive deficits in 
non-demented PD (Biundo et al., 2016a). 
Coversely, we obtained inconsistent correlations between cognitive measures and DAT 
binding. Namely, we found an inverse association between dorsal striatum uptake and 
executive/working-memory performance (i.e., LNS test), and between right caudate 
nucleus and MoCA scores. Our results are in disagreement with a recent study (based on 
the PPMI cohort), in which a positive correlation between DAT binding and executive 
functions was observed (Siepel et al., 2014); but notably, in that study the authors 
recognized the correlation was relatively weak, even in a very large cohort, suggesting that 
most of the variance in fronto-executive tasks cannot be attributed solely to dopamine 
dysfunction. In this regard, there are so far, discordant results in the literature about 
dopaminergic depletion and cognition, suggesting that dopaminergic deficiency, and hence 
synuclein, is not the only pathological determinant of cognitive alterations in PD (Delgado-
Alvarado et al., 2016). 
Amyloid deposits seem to have a crucial role in PD, and prevalence of concomitant AD 
pathology is up to 50 percent in postmortem cases (Irwin et al., 2012; Mattila et al., 2000). 
In the present study, we assessed amyloid aggregates by means of [18F]florbetaben imaging, 
a ligand widely used in AD,  and we observed that only 18 percent of our early-PD 
population was identified as amyloid positive. Previous evidence on PD patients found 
similar rates: 15 percent of amyloid positivity (i.e., using [11C] Pittsburgh compound B) 
(Petrou et al., 2012), and 16.5 percent (i.e., using CSF Aβ42) (McMillan & Wolk, 2016); 
suggesting different approaches have a high correspondence in detecting presence of 
amyloid aggregates. 
CSF Aβ42 has been recently identified as a reliable biomarker of cognitive decline (after 
two years) in PD patients (Fereshtehnejad, Zeighami, Dagher, & Postuma, 2017; Schrag, 
Weintraub, & Schott, 2017). However, we found no significant difference in the CSF Aβ42 
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level between our groups, and this is possibly because CSF Aβ42 was collected at the 
baseline visit (2 or 3 years before amyloid PET assessment). 
A main strength of our study is that we focused on PD in the early disease phase and 
without dementia, while the majority of previous PET-amyloid studies focused on patients 
with dementia and at advanced disease stage (Petrou et al., 2015). However, our study has 
also several limitations that should be considered. First, the small sample size, as only a 
minority of patients in the PPMI dataset had PET-amyloid imaging. In addition, PET-
imaging was analyzed only by SUVRs, while it is possible to use more sophisticated 
quantification methods (Cecchin et al., 2017). Then the cognitive battery used was limited, 
and not all executive functions were assessed. Lastly, the neuroimaging assessment and 
CSF measure were not assessed at the same time, but it is worth noting that all these data 
were collected from highly specialized movement disorders centers, and thus we expect a 
high reliability of these data. 
In summary, the present study suggests a possible synergy between synuclein and 
amyloid pathology in early-PD, and this is consistent with the hypothesis that presence of 
amyloid increases axonal vulnerability. 
Future longitudinal studies are necessary i) to elucidate the prognostic features of PD 
with comorbid amyloid pathology, as this could have key implications for patient care as 
well as life expectancy, and ii) to understand the disease’s underlying mechanisms and 
possibly translate these findings into new treatments. Further, targeting amyloid 
depositions early may represent a valuable strategy to slow the disease’s progression 
including cognitive decline and ideally to prevent dementia in PD. 
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CHAPTER 6 
BRAIN STRUCTURAL PROFILE OF MULTIPLE SYSTEM ATROPHY 
PATIENTS WITH COGNITIVE IMPAIRMENT10 
 
 
6.1 Introduction 
MSA is characterized by a variable combination of progressive parkinsonism, cerebellar 
ataxia, autonomic failure, and pyramidal symptoms (Gilman et al., 2008) (see also Chapter 1 
for further details). Regarding the pathological substrate of MSA, diagnosis is currently 
based on the presence of glial cytoplasmic inclusions, the hallmark of MSA, in the 
cerebellum, pontine nuclei, inferior olivary nucleus, striatum and substantia nigra (Quinn, 
1989). According to the clinical manifestations, MSA patients can be classified as MSA-P or 
MSA-C. However, during the course of the disease, the clinical and pahological features of 
MSA subtypes frequently overlap (Antonini et al., 1998; Ciolli, Krismer, Nicoletti, & 
Wenning, 2014; Colosimo et al., 2001; Wenning, Ben-Shlomo, Magalhaes, Daniel, & 
Quinn, 1995).  
In contrast to other synucleinopathies (e.g., PD and DLB), presence of dementia is 
considered a non-supporting feature for the MSA diagnosis (Gilman et al., 2008) — 
however, there is growing evidence that MSA patients can experience cognitive impairment 
ranging from executive dysfunctions to multiple-domain cognitive deficits (Gerstenecker, 
2017).  
In addition, a recent ‘Position statement by the Neuropsychology Task Force of the 
Movement Disorder Society MSA study group’ posited that cognitive alterations in MSA 
could be under-recognized (Stankovic et al., 2014); indeed, frequently, MSA patients 
presenting with parkinsonism and cognitive deficits tended to be misdiagnosed as other 
neurodegenerative diseases — namely, other synucleinopathies or PSP (PSP) (Koga et al., 
2015). The frequency of cognitive impairment differs according to applied methodologies 
                                                 
10 Published as: Fiorenzato, E., Weis, L., Seppi, K., Onofrj, M., Cortelli, P., Zanigni, S., . . . Imaging Study, G. 
(2017). Brain structural profile of multiple system atrophy patients with cognitive impairment. Journal of Neural 
Transmission (Vienna), 124(3), 293-302. 
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and sample size; however, it varies approximately between 14 percent and 37 percent 
(Koga & Dickson, 2017). 
Although, we demonstrated that MoCA is more sensitive than the commonly used 
MMSE in detecting cognitive impairment in MSA (for further details see Chapter 3); 
recently a large multicenter study has suggested using a cut-off score <27 of MMSE to 
increase its sensitivity in detecting cognitive dysfunctions in MSA (Auzou et al., 2015). 
The underlying mechanisms of cognitive impairment in MSA are still not understood, 
and in this regard evidence from MRI studies suggested a discrete cortical and subcortical 
contribution to explain cognitive deficits in MSA (Kim et al., 2015; Lee et al., 2016a), even 
though these studies were based on a relatively small number of patients at various disease 
stages as well as being single-center. 
The main objective of the present multicenter study was to better characterize structural 
abnormalities underpinning cognitive impairment in MSA. Thus, we investigated brain 
morphology changes using voxel-based morphometry (VBM) analysis of the gray and 
white-matter regions of a cohort of MSA with cognitive alterations, defined as MMSE < 
27. Further, since VBM analysis is not sensitive in detecting subcortical structures changes, 
we also applied a fully-automated segmentation of gray matter nuclei in conjunction to our 
VBM analysis. 
 
6.2 Methods 
6.2.1 Study population 
Seventy-two probable MSA patients were retrospectively collected from five 
international movement disorders institutions: namely, IRCCS San Camillo Hospital 
Foundation, Venice-Lido, Italy (n=34); Clinical Department of Neurology, Medical 
University of Innsbruck, Innsbruck, Austria (n = 8); IRCCS Institute of Neurological 
Sciences of Bologna, Bologna, Italy (n=7); Department of Neuroscience, Imaging and 
Clinical Sciences, Gabriele d’Annunzio University, Pescara, Italy (n=7); Dysautonomia 
Center, Department of Neurology, New York University School of Medicine, New York, 
USA (n=6). MRI and clinical data were compared with a control sample of 36 healthy 
controls (HC), collected at the institution in Venice, who volunteered to take part in this 
study. HC were matched for age and education to the MSA group. All participants were 
scanned between 2010 and 2015. This study received ethical approval from the Venice 
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Research Ethics Committee, Venice, Italy; and the research was completed in accordance 
with the Declaration of Helsinki.  All patients gave their written informed consent before 
study enrolment. 
 
6.2.2 Clinical and cognitive assessment 
Clinical, cognitive and MRI-data were available for all the participants. MSA patients 
fulfilled the MSA clinical established diagnostic criteria of a probable diagnosis, which was 
made by expert neurologists and based on clinical history as well as neurological 
examination (Gilman et al., 2008). Exclusion criteria were presence of: i) deep brain 
stimulation, ii) psychiatric or other neurological comorbidity, iii) motion artifacts, and iv) 
significant cortical or white matter vascular lesions of grades 2 and 3 (as seen on T2-
weighted axial and T2-weighted fluid attenuation inversion recovery) (Schmidt, Enzinger, 
Ropele, Schmidt, & Fazekas, 2003).  
The clinical features assessed were: age, sex, education, age at onset, disease duration, 
and motor severity, that was measured by means of the motor part of the MDS-UPDRS 
III. Global cognition was assessed using the MMSE (Folstein et al., 1975), performed 
within four weeks from the MRI assessment. According to the published MMSE threshold 
specific for MSA patients (Auzou et al., 2015), we defined MSA with cognitive impairment 
when the MMSE total score was below 27. Thus, we identified two subgroups: MSA with 
normal cognition (MSA-NC) and MSA cognitively impaired MSA-CI.  
Since our MSA sample consisted of patients in moderate to advanced disease stages, 
which at time of assessment showed a combination of clinical manifestations (i.e., 
parkinsonism and cerebellar features) in addition to autonomic failure, we did not analyze 
MSA-C and MSA-P separately. 
 
6.2.3 MRI imaging protocols 
In 66 MSA patients and 36 HC, brain MRI was acquired on a 1.5T scanner, while the 
remaining six MSA were assessed on a 3T scanner according to the routinely applied 
protocols at each institution. Further details on T1-weighted 3D volumetric parameters are 
reported in Table 6.1. 
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Table 6.1 Scanner characteristics and acquisition parameters at each institution 
Centers Manufac-turer Scanner Sequence 
Voxel size 
(mm3) FOV 
Pixel 
band 
width 
(Hz/Px) 
TR 
(ms) 
TE 
(ms) 
Inversion 
time (ms) 
Flip 
angle 
(°) 
                      
1 Philips Philips 
Achieva 
1.5T 
T1-TFE 0.9x0.9x0.9 288x288 173 8.3 4.2 974 8 
2 Siemens Avanto 
1.5T 
T1-
MPRAGE 
0.9x0.9x1.2 256x192  1600.0 3.4 800 15 
3 Siemens TrioTim 
3T 
T1-
MPRAGE 
1.0x1.0x1.0 256x256 238 2300.0 3.4 900  
4 GE Signa 
Horizon 
LX 
T1-FSPGR 1.0x1.0x1.0 256x256  1250.0 5.1 600 10 
5 Philips Philips 
Achieva 
1.5T 
T1-FFE 1.0x1.0x0.8 256x256  191 19.0 3.7  / 30 
 
Note. Centers: 1 = Venice, Italy; 2 = Innsbruck, Austria 3 = New York, USA; 4 = Bologna, Italy; 5 = Chieti, Italy; FOV, 
field-of-view; TR, repetition time; TE, echo time. 
 
 
6.2.4 Voxel-based morphometry analysis 
Structural data were analyzed with FSL-VBM pipeline, carried out with FSL tools 
(Jenkinson, Beckmann, Behrens, Woolrich, & Smith, 2012). First, structural images were 
brain-extracted using the Brain Extraction Tool, after cropping the image at the medulla 
level and after automatically removing hyperintense non-brain tissue (e.g., fat or muscle) by 
means of the MRIcro tool (Smith, 2002).11 Then, segmentation was performed using the 
FSL tool FAST. 
Both gray and white-matter partial volumes were aligned to MNI152 standard space 
using FSL tool FLIRT, followed by non-linear registration using FNIRT, which uses a b-
spline representation of registration warp field. The resulting images were averaged to 
create a specific template, based on a randomly selected subgroup of patients and then the 
original images were non-linearly re-recorded using the template. To minimize T1-sequence 
variability across institutions and scanners (i.e., 3T and 1.5T), spatial noise patterns 
associated with a field’s inhomogeneity were corrected by means of FSL-SUSAN pipeline, 
which reduces noise using nonlinear filtering (Smith & Brady, 1997). The recorded partial 
volume images were then modulated (to correct for local expansion or contraction), by 
                                                 
11 http://www.mricro.com 
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dividing by the Jacobian of the warp field. The modulated segmented images were then 
smoothed with an isotropic Gaussian kernel with a sigma of four mm. Sample 
homogeneity, implemented in CAT12 within SPM,12 was checked using covariance 
matrixes to identify potential outliers. Partial correlations analysis was run including age, 
sex and estimated total intracranial volume (eTIV) as nuisance variables. Participants were 
defined as outliers if the covariance was below two SD from the sample mean. 
In the following non-parametric analyses, the masks used were applied, but trying 
carefully to define the brainstem structure, and then avoiding gray and white-matter 
misassignment associated with the partial-volume effect. 
The gray-matter VBM mean-template was binarized using a threshold equal to 0.2 of the 
fractional intensity value to include gray-matter. Whereas, a white-matter VBM mask was 
obtained based on fractional anisotropy (FA) mean-template. Namely, in a subsample of 
MSA patients, FA was calculated with FreeSurfer’s dt_recon software tool, after motion 
and eddy current correction. Then a specific FA template was created, using the FA images 
from all participants (Abe et al., 2010). All participants' FA images were corecorded to the 
standard template, provided by FSL (FMRIB58_1mm), using an affine 12-parameter 
transformation followed by a non-linear transformation. The resulting normalized FA 
images were then smoothed with an eight mm isotropic Gaussian kernel, and a mean image 
was created. Individual participants' FA images were then recorded to the customized FA 
template, using the FSL registration tool (Tract-Based Spatial Statistics preprocessing). The 
FA mean-template was then binarized using a 0.3 FA value, as the conservative threshold 
for white-matter inclusion. 
 
6.2.5 Full-automated subcortical volumes segmentation 
Subcortical brain volumes were calculated from MRI T1-3D images using the software 
package FreeSurfer (version 6.00b)13 that has a specialized tool for automated parcellation 
of the neocortical gray-matter and subcortical volumes (Dale, Fischl, & Sereno, 1999; 
Fischl, Sereno, & Dale, 1999). Mapping between subjects and the atlas was executed using 
a non-rigid registration on the inflated surface. The outcome is the human cortex 
parcellation into 34 cortical regions of interest (in each hemisphere) and into 19 subcortical 
                                                 
12 http://dbm.neuro.uni-jena.de/cat/ 
13 http://surfer.nmr.mgh.harvard.edu/ 
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white-matter and deep gray matter volumetric structures (Desikan et al., 2006). 
Furthermore, the Bayesian based brainstem segmentation was used to obtain volumes of 
the superior cerebellum peduncles, pons, midbrain and medulla (Iglesias et al., 2015). For 
study purposes, only subcortical volumes were included. An overall mean of the left and 
right hemisphere indexes was calculated after pairwise t test, in order to verify the absence 
of significant between-hemisphere differences for each subcortical structure. 
 
6.2.6 Statistical analyses 
Chi-squared analyses were run to assess between-group differences in the distribution of 
categorical variables, namely to compare the whole MSA group and HC, as well as the 
MSA-NC group and MSA-CI. Instead, within-group comparisons of continuous variables 
(i.e., clinical and demographic data) were analyzed using the Mann–Whitney U test adjusted 
with bootstrap (1000 iterations to reduce false positives). 
VBM general linear model (GLM) analysis was run by means of FSL’s ‘randomize’ tool 
to compare MSA and HC using the following covariates: age, education, sex, and eTIV. 
While in the direct comparison of MSA-CI versus MSA-NC: age, education, MDS-UPDRS 
III, scanning sites and eTIV were used as covariates. Lastly, non-parametric statistics were 
performed using the FSL ‘randomize’ tool with 15,000 permutations, and then correcting 
for multiple comparisons across space using the threshold free cluster enhancement option 
either enabled or disabled (i.e., voxel-based thresholding are uncorrected for multiple 
comparisons), using previously calculated gray and white-matter masks. To obtain 
anatomical localization of statistical results of gray and white-matter, the Automated 
Anatomical Labeling template and the Johns Hopkins University white-matter tractography 
atlas were applied, respectively (Mori, Wakana, Van Zijl, & Nagae-Poetscher, 2005; Rolls, 
Joliot, & Tzourio-Mazoyer, 2015). 
Subcortical volumes obtained with full-automated segmentation were compared 
between groups (i.e., MSA vs. HC, and MSA-CI vs. MSA-NC) using GLM multivariate 
analyses, taking into account the same covariates of the previous analysis. The Partial Eta-
Squared (    ) value was calculated as an estimate of effect size. Statistical analyses were 
performed using SPSS 20, release version 20.0 (Armonk, NY). Statistical significance 
threshold was set at p < 0.05. 
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6.3 Results 
6.3.1 Demographic and clinical differences between groups 
Table 6.2 shows demographic and clinical details of MSA compared to HC, and MSA 
subgroups (MSA-NC and MSA-CI), while Table 6.3 reported the comparisons between 
MSA clinical variants (MSA-P vs. MSA-C). 
MSA and HC groups agreed in each variable, except for MMSE that was significantly 
lower in MSA patients. In the direct comparison between MSA-NC and MSA-CI group, 
the latter were older, had less education and showed a tendency to be older at age of onset. 
Regarding the comparisons between the two MSA clinical phenotypes, we found no 
significant difference between MSA-C and MSA-P variants in all the clinical variables, even 
though there was a trend for the MSA-P subgroup to be older than the MSA-C group (p = 
0.0605).  
Further, after checking the sample homogeneity, we did not exclude any participants 
from the analyses.  
 
6.3.2 Voxel-based morphometry  
Results from the VBM analysis revealed gray matter volume thinning in several cortical 
regions, when comparing the MSA group with HC, especially in the bilateral cerebellum, 
and bilaterally in cortical regions (i.e., frontal, parietal, and occipital lobes, middle cingulate 
gyrus, and partially in the temporal lobe). Gray matter volume reductions were found in 
subcortical regions (i.e., bilateral putamen). Further, we found volume increases bilaterally 
in the occipital gray matter (i.e., anterior lingual gyrus and calcarine cortex), in right 
amygdala, periaqueductal gray (PAG) and in the posterior thalamus, caudate nucleus, and 
olfactory cortex (Figure 6.1; Table 6.4a). White-matter volume thinning was observed 
mainly in the anterior thalamic radiation, cingulum, cerebellum, and corpus callosum 
(Figure 6.1; Table 6.4c).  
The direct comparison of MSA-CI versus MSA-NC groups showed a focal gray matter 
thinning only in the left dorsolateral prefrontal cortex (DLPFC) of the MSA-CI group 
(Figure 6.2, Table 6.4b). 
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 Table 6.2 Demographic and clinical features of HC and MSA, and their subgroups  
  MSA                           (n = 72) 
HC                                                                                    
(n = 36) 
  MSA-NC                                                                                       
(n = 50) 
MSA-CI                                                            
(n = 22) 
 MSA                
vs.                      
HC 
MSA-NC                         
vs.                                              
MSA-CI         
  
Mean                                             
(SD) Mdn 
 Mean                                          
(SD) Mdn 
 Mean                                         
(SD) Mdn 
Mean                                             
(SD) Mdn p p     
               
Age, y 63.8 (6.8) 64  61.6 (7.4) 62.0  62.6 (6.6) 62.0  66.4 (6.5) 67.5   * 
Education, y 11.2 (4.7) 11  12.5 (4.5) 13.0  12.4 (4.5) 12.0  8.4 (4.1) 8.0   ** 
Sex (m/f) 29/43   21/15   22/28     7/15     
Age of onset, y 59.0 (7.2) 60     58.0 (7.0) 58.0  61.3 (7.2) 62.0   * 
Disease duration, y 4.6 (3.0) 4     4.4 (2.9) 4.0  5.1 (3.3) 4.0    
MMSE 26.7 (3.1) 28  29.1 (1.0) 29.0  28.4 (1.1) 28.0  22.8 (2.7) 23.0  *** *** 
MDS-UPDRS III 41.3 (14.9) 41     39.7 (16.1) 41.0  44.9 (11.4) 42.0    
MSA-C/ MSA-P 25/47      18/32     7/15     
Center (1/2/3/4/5) 34/18/6/7/7   36/0/0/0/0   21/14/6/7/2   13/4/0/0/5   *** * 
eTIV 1463.7 
(160.0) 
1436.8   1439.8 (178.7) 
1441.4   1477.0 
(170.7) 
1447.3   1433.7 
(131.2) 
1423.6     
 
Note. Centers: 1 = Venice, Italy; 2 = Innsbruck, Austria 3 = New York, USA; 4 = Bologna, Italy; 5 = Chieti, Italy; MSA, 
multiple system atrophy; HC, healthy controls; MSA-NC, MSA with normal cognition; MSA-CI, MSA with cognitive 
impairment; SD, standard deviation; Mdn, median; y, year; MMSE, Mini-Mental State Examination; MDS- UPDRS III, 
Movement Disorder Society Unified Parkinson Disease Rating Scale; eTIV, estimated total intracranial volume. * = p < 
0.05; ** = p < 0.01; *** = p < 0.001 corrected for multiple comparisons. 
 
Table 6.3 Demographic and clinical features between MSA clinical subtypes 
  
MSA-C                                          
(n = 25) 
  MSA-P                                                                                    
(n = 47)     
 
Mean                                             
(SD) Mdn min max 
Mean                                             
(SD) Mdn min max 
 
  
                    
Age, y 
61.2 (7.3) 61 49 76  65.13 (6.1) 66 51 78  
Education, y 11.3 (4.3) 11 5 20  11.1 (5.0) 11 5 23  
Sex (m/f)  11/14     18/29     
MMSE 
26.7 (2.7) 28 21 30  26.7 (3.4) 29 27 30  
Center 
(1/2/3/4/5) 
9/7/5/2/2     25/11/1/5/5     
eTIV 1430.6 (161.5) 
        1481.4 
(158.1) 
        
 
Note. No significant differences in the MSA-P vs. MSA-C group comparison. Centers: 1 = Venice, Italy; 2 = Innsbruck, 
Austria 3 = New York, USA; 4 = Bologna, Italy; 5 = Chieti, Italy; MSA-C, multiple system atrophy of the cerebellar type; 
MSA-P, multiple system atrophy of the parkinsonian type; HC, healthy controls; SD, standard deviation; Mdn, median; y, 
year; MMSE, Mini-Mental State Examination; eTIV, estimated total intracranial volume. 
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Figure 6.1 Voxel-based morphometry comparison between MSA and HC group. (a): axial view; 
(b): 3D view. A statistical threshold Z<4 was used for visualization purpose. MSA: multiple system 
atrophy; HC: healthy control; GM: gray matter; WM: white matter; TFCE: Threshold-Free Cluster 
Enhancement. 
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Table 6.4 Voxel-based morphometry results of gray and white matter differences between 
MSA vs. HC and between MSA subgroups (MSA-CI vs. MSA-NC) 
GM VBM  AAL2 atlas Voxels§ Z Score P Value 
X 
(mm) 
(MNI) 
Y 
(mm) 
(MNI) 
Z 
(mm) 
(MNI) 
Side 
          a MSA < HC         
  Cerebellum VIII 5614 9.5 < 0.00001 -22 -54 -46 left 
  Cerebellum VIII  9.3  22 -58 -46 right 
  Cerebellum IX  7.7  -18 -50 -46 left 
  Cerebellum IX  5.3  18 -46 -46 right 
  Cerebellum VIIb  6.4  -14 -76 -46 left 
  Cerebellum VIIb  6.5  18 -74 -46 right 
  Cerebellum Crus II  6.3  -30 -74 -46 left 
  Cerebellum Crus II  5.5  30 -78 -42 right 
  Cerebellum VI  5.7  -30 -60 -26 left 
  Cerebellum VI  5.9  26 -60 -30 right 
  Cerebellum (Vermis)  6.8  0 -62 -26 midline 
  Fusiform  5.3  -30 -58 -8 left 
  Supramarginal 452 6.1 < 0.00001 -64 -20 38 left 
  Precentral 59 5.2 < 0.00001 -26 -20 68 left 
  Postcentral 55 5.0 < 0.00001 -58 -2 40 left 
  Middle Cingulate 33 5.5 < 0.00001 -14 -42 36 left 
  Putamen 40 6.2 < 0.00001 -26 2 12 left 
  Inferior Frontal  20 4.8 < 0.00001 -40 10 24 left 
  Middle Occipital  3 4.6 < 0.00001 -20 -90 -2 left 
  Lingual 1 4.6 < 0.00001 -16 -82 0 left 
  Inferior Occipital 1 4.6 < 0.00001 -24 -90 -6 left 
  Lingual 28 5.3 < 0.00001 20 -76 -2 right 
  Inferior Temporal  27 5.4 < 0.00001 50 -44 -14 right 
  Middle Temporal  25 5.0 < 0.00001 52 -30 -10 right 
  Putamen 112 6.0 < 0.00001 28 0 12 right 
  Middle Cingulate  67 5.4 < 0.00001 16 -34 38 right 
  Precentral 63 5.1 < 0.00001 56 2 42 right 
  Inferior Frontal  60 4.8 < 0.00001 52 14 26 right 
  Superior Frontal 17 4.9 < 0.00001 32 -8 66 right 
  Fusiform 9 4.9 < 0.00001 32 -66 -6 right 
   Angular 3 4.7 < 0.00001 44 -50 30 right 
                             MSA > HC         
  Thalamus  8.6 < 0.00001 -6 -28 0 left 
  Amygdala 10 4.9 < 0.00001 20 -2 -14 right 
  Thalamus 4081 11.7 < 0.00001 6 -24 16 right 
  Thalamus  6.9  -8 -18 10 left 
   Olfactory  8.3  6 10 -14 right 
  Olfactory  5.2  -8 16 -14 left 
  Periaqueductal Gray  4.3 < 0.00001 2 -22 -16 right 
  Calcarine 1173 6.7 < 0.00001 2 -70 10 right 
  Calcarine  6.0  -5 -72 10 left 
  Lingual  5.9  6 -60 2 right 
  Lingual 19 5.0 < 0.00001 -10 -40 -4 left 
          b MSA-CI < MSA-NC        
  Middle Frontal  572 3.80 0.00007 -32 26 44 left 
          
(continued on the next page) 
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Table 6.4 (continued) 
 
WM VBM JHU white-matter atlas Voxels§ Z score P Value 
X 
(mm) 
(MNI) 
Y 
(mm) 
(MNI) 
Z 
(mm) 
(MNI) 
Side 
          
c MSA < HC         
  Anterior thalamic radiation  10143 15.9 < 0.00001 -18 -2 0 left 
  Anterior thalamic radiation   16.3  18 -4 0 right 
  Cerebellum white matter  12.0  -4 -56 -16 left 
  Cerebellum white matter   13.4  4 -56 -16 right 
  Corticospinal tract   10.3  4 -30 -40 right 
  Superior longitudinal fasciculus   9.5  32 -8 6 right 
  Cingulum  1565 6.9 < 0.00001 -6 -38 30 left 
  Splenium of corpus callosum  6.0  -6 -40 24 left 
  Body of corpus callosum   4.8  -4 -28 18 left 
  Cingulum   6.2  14 -16 36 right 
  Cingulum (cingulate gyrus) 22 5.3 < 0.00001 -4 2 34 left 
  Inferior longitudinal fasciculus 12 3.9 0.00005 -48 -16 -16 left 
  Cingulum (hippocampus)  55 7.6 < 0.00001 24 -30 -12 right 
  Body of corpus callosum 40 5.0 < 0.00001 4 -16 28 right 
  Inferior fronto-occipital fasciculus  17 4.3 < 0.00001 18 34 -16 right 
  Uncinate fasciculus 2 4.5 < 0.00001 18 10 -14 right 
  Fornix 1 5.2 < 0.00001 4 -2 -8 left 
  Callosal body posterior pars 1 3.6 0.0002 -2 -24 20 left 
  Callosal body posterior pars 1 3.5 0.0002 2 -24 20 right 
                     
Note.  Images were overlaid into MNI 2x2x2 mm3 template. GM: gray matter; WM: white matter; VBM: voxel-based 
morphometry; MNI, Montreal Neurological Institute and Hospital; AAL2, new Anatomical Automatic Labeling; JHU, 
Johns Hopkins University; MSA, multiple system atrophy; HC, healthy controls; MSA-NC, MSA with normal cognition; 
MSA-CI, MSA with cognitive impairment. 
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Figure 6.2 Voxel-based morphometry comparison between MSA-CI and MSA-NC. (a) 
uncorrected (P value<0.005) maps; (b) axial and 3D views. MSA: multiple system atrophy; MSA-CI: 
MSA with cognitive impairment; MSA-NC: MSA with normal cognition; TFCE: Threshold-Free 
Cluster Enhancement; l-DLPFC: left dorsolateral prefrontal cortex. 
 
 
6.3.3 Subcortical volumetric segmentation 
Analysis of subcortical volumes segmentation showed numerous volume reductions in 
MSA versus HC comparison, particularly in medulla, superior cerebellar peduncles, pons, 
midbrain, middle posterior corpus callosum, cerebellar white and gray matter, putamen, 
globus pallidus, nucleus accumbens, thalamus and ventral diencephalon (Table 6.5). The 
direct comparison of MSA-CI versus MSA-NC groups showed no significant volumetric 
differences in subcortical structures. 
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Table 6.5 Full-automated subcortical segmentation analyses: significant volumes 
  
  
 
Subcortical regions 
  HC   MSA     
F p 
Effect 
size  Mean (SD) Mean (SD)  
         
MSA vs. HC Medulla  4759.3 (496.1) 4397.8 (644.3)  11.16 0.001 0.099 
 Pons  15378.4 (1884.1) 12296.2 (3080.0)  37.88 <0.0001 0.271 
 Superior cerebellum peduncle  247.2 (38.8) 220.1 (55.0)  8.56 0.004 0.077 
 Midbrain  6438.2 (666.7) 5894.7 (807.2)  16.70 <0.0001 0.141 
 Middle posterior corpus callosum  405.6 (89.9) 333.5 (87.2)  10.02 0.002 0.089 
 WM Cerebellum LH+RH  13791.2 (1880.9) 10243.2 (3765.5)  33.87 <0.0001 0.249 
 GM Cerebellum LH+RH  97527.8 (9972.3) 84899.9 (16706.4)  23.58 <0.0001 0.188 
 Putamen LH+RH  9637.5 (958.3) 7248.3 (1751.0)  59.78 <0.0001 0.370 
 Globus pallidus LH+RH  2947.1 (403.5) 2437.5 (547.1)  23.97 <0.0001 0.190 
 Nucleus accumbens LH+RH  992.5 (172.3) 804.8 (173.6)  20.26 <0.0001 0.166 
 Hippocampus LH+RH  7938.3 (702.2) 7365.2 (962.4)  9.16 0.003 0.082 
 Thalamus LH+RH  11251.3 (946.3) 10193.6 (1294.6)  21.28 <0.0001 0.173 
  Ventral Diencephalon LH+RH   7663.3 (739.6) 6862.9 (875.8)   24.14 <0.0001 0.191 
 
Note. MSA, multiple system atrophy; HC, healthy control; SD, standard deviation; WM, white matter; GM, gray matter; 
LH, left hemisphere; RH, right hemisphere.  
 
6.4 Discussion 
Patients with MSA showed a broader thinning in cortical brain regions (bilateral frontal, 
occipito-temporal and parietal areas), subcortical alterations, and white matter thinning 
compared to the HC group. Further, a focal reduction in the left DLPFC region was 
associated with the presence of cognitive alterations in MSA. 
This finding is aligned with previous evidence showing neuronal loss in the frontal 
region (Salvesen et al., 2015), as well as hypometabolism and hypoperfusion in MSA 
patients with cognitive impairment (Kawai et al., 2008; Kitayama et al., 2009; Lyoo et al., 
2008). In this regard, the focal alteration in the left DLPFC agrees also with the 
neuropsychological profile of MSA patients, wherein the fronto-executive domain is the 
most frequently altered (Gerstenecker, 2017; Stankovic et al., 2014).  
Overall, our results revealed a different pattern underlying cognitive manifestations in 
MSA as compared to the other synucleinopathies — in PD patients, cognitive deficits are 
associated with widespread cortical atrophies, involving not only frontal regions but also 
posterior regions (Biundo et al., 2016a); suggesting that MSA and PD cognitive 
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dysfunctions are related to distinct underpinning mechanisms. Indeed, MSA-CI patients are 
characterized by focal frontal alterations (i.e., DLPFC), probably secondary to striato-
pallido-thalamo-cortical circuits. This structural pattern underlying cognitive manifestation 
in MSA is possibly associated with the concept of ‘subcortical dementia’ that is 
characterized by executive dysfunctions, memory-retrieval type deficits, slow information 
processing as well as impairment in cognitive tasks based on frontal network functioning 
(Brown & Marsden, 1988; Cummings, 1986; Stankovic et al., 2014; Tekin & Cummings, 
2002).  
Noteworthy, our previous findings are aligned with these ‘subcortical alterations’ and 
support our observations regarding MSA performance on MMSE subitems (Fiorenzato et 
al., 2016). Particularly, the MSA-CI group showed a worse performance especially in the 
executive (i.e., calculation), memory retrieval (i.e., retrieval of three words) and 
visuoconstructive subitems (i.e., copy of pentagons). The ‘copy of pentagons’ activity 
should be interpreted as dependent on executive control, since previous evidence showed 
frontal involvement in the execution of this task (Filoteo, Reed, Litvan, & Harrington, 
2014).  
Another salient observation is that the natural motor course of MSA usually severely 
affects the functional independence of these patients; thus, it is challenging to identify if the 
‘subcortical cognitive dysfunctions’ are per se sufficient to significantly impact functional 
autonomy. For this reason, we propose to use the term ‘subcortical dementia’ with caution, 
since in this disease involving subcortical lesions, severe motor impairment is part of the 
clinical picture and may hamper cognitive assessment, leading to an overestimation of the 
cognitive deficits (Pillon et al., 1996). 
Another key finding is the widespread brain alteration in MSA patients compared to 
controls, which expand previous neuroimaging evidence especially due to the large sample 
size of our cohort (Brenneis et al., 2003; Chang et al., 2009; Minnerop et al., 2010; 
Minnerop et al., 2007; Shigemoto et al., 2013). In addition, we applied a fully-automated 
segmentation method, to more precisely segment the subcortical regions; and we found 
atrophies in the superior cerebellar peduncle, pons, medulla oblongata, and midbrain. We 
identified also significant volume reductions in the cerebellum and in the putamen — but 
interestingly not in the caudate nucleus (Messina et al., 2011; Scherfler et al., 2016). This 
result is aligned with recent neuropathological and neuroimaging studies, reporting that the 
degeneration in the caudate nucleus can possibly be absent or mild also in advanced disease 
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stages (Barbagallo et al., 2016; Wenning et al., 1997), and notably is less prominent 
compared to the putamen, whose role in motor functions is extensively recognized 
(Alexander, 1986).  
Regarding the white matter analyses, in agreement with previous studies, we noted 
reductions in the anterior thalamic radiation, cerebellum, corticospinal tract and corpus 
callosum (Minnerop et al., 2010; Shigemoto et al., 2013; Worker et al., 2014).  
Furthermore, volume increases in the bilateral occipital lobe (anterior lingual gyrus and 
calcarine cortex), posterior thalamus, nucleus caudate, olfactory cortex, right amygdala and 
PAG were found; and these probably reflect microstructural changes and remodeling, 
related to the pathological and neurodegenerative processes. Indeed, cortical and 
subcortical gray matter increases have been extensively described also in other 
neurodegenerative diseases (i.e., AD and HD); and previous studies posited that in the early 
phase of the disease, volume increases can possibly precede atrophies, which characterize 
more advanced patients (Fortea et al., 2011; Rosas et al., 2008). In this regard, volume 
increases can be related to local inflammation and/or neuronal hypertrophy (Fortea et al., 
2010).  
On the other hand, we found a conflicting result regarding the thalamus volume, as we 
observed a volume reduction in the full-segmented analysis, but a volume increase in the 
VBM analysis (namely, in the posterior region of thalamus). However, previous evidence 
showed that full-segmented analyses have higher accuracy than VBM analyses, whose 
accuracy is even lower in the subcortical structures located near the ventricles, as the 
thalamus (Schwarz et al., 2014). Thus, we support the finding of a volume reduction in the 
thalamus in MSA patients, compared to HC. 
The present retrospective multicenter study has some limitations: first, our MSA cohort 
was based on clinical diagnoses and not autopsy-based; however, the diagnoses were made 
by movement disorders specialists; second, we applied a MMSE threshold below 27 to 
identify the MSA subgroup with cognitive impairment. The MMSE cut-off score has been 
recently validated and is based on a neuropsychological extensive battery. However, to 
better identify the magnitude of cognitive impairments using a comprehensive 
neuropsychological battery is strongly recommended, and in the present study due to its 
retrospective design, we could only obtain the MMSE total score as the cognitive measure 
for the whole sample. Then, MRI data were collected with both 1.5T and 3T scanners and 
we could enroll the control group only at one institution (Venice, Italy). Although we 
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checked our sample homogeneity and found no outliers in both the subgroups, and in 
addition, we performed a field homogeneity correction including the institutions as 
covariates in the VBM analysis. 
In sum, our findings agree with previous evidence showing widespread cortical and 
subcortical alterations in MSA compared to healthy subjects, and in the present study we 
underlined also the crucial involvement of white matter in this disease. 
Indeed, clinicians should consider the heterogeneous nature of this pathology, 
characterized by neurodegenerative processes involving white and gray cortical matter as 
well as subcortical structures. 
Presence of significant cognitive alterations in MSA, as assessed by MMSE, is associated 
with focal volume reduction in the left DLPFC and suggests only a marginal contribution 
of cortical pathology to cognitive manifestations. The neuropathology underpinning MSA 
seems to be very different from other neurodegenerative diseases, such as PD, AD and 
PSP. 
Thus, we proposed that cognitive alterations in MSA could be possibly associated with 
the disruption of the striato-pallido-thalamo-cortical circuit, wherein cortical deficits are 
focal and only secondary to subcortical alterations. This again supports the evidence that 
cognitive impairment in MSA is less prominent than in other parkinsonian disorders. 
Further, our findings should encourage revising the consensus criteria for MSA diagnosis 
and listing the presence of specific frontostriatal cognitive deficits among the supporting 
features (Gilman et al., 2008), namely MSA patients with mild cognitive deficits should not 
be excluded in the differential diagnostic process in order to avoid possible misdiagnosis 
(Koga et al., 2015).  
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CHAPTER 7 
GENERAL CONCLUSIONS 
 
The experimental work included in the present thesis aims at characterizing the 
cognitive profile of patients with parkinsonian disorders as well as at investigating the 
neuroanatomical changes underlying cognitive impairment particularly in PD and MSA. 
The studies reported in the second part of the thesis have been designed to explore 
which one is the most sensitive cognitive screening instrument to detect cognitive 
alterations in atypical parkinsonisms (Chapter 3), and to assess prospectively cognitive 
deterioration (Chapter 4). 
Indeed, the results from the multicenter study presented in Chapter 3 provided evidence 
that MoCA is more sensitive than the commonly used MMSE in detecting cognitive 
dysfunctions, especially in patients with PSP. The superiority of MoCA was determined by 
subitems assessing attentive and executive domains, and also by the lack of ceiling effect 
compared to MMSE. In this regard, executive and attention/working-memory 
dysfunctions are common in MSA and PSP (Gerstenecker, 2017), but PSP patients were 
markedly impaired on phonemic fluency subitem compared to PD and MSA. Another 
compelling finding was that seven or fewer words per minute distinguish PSP with a high 
sensitivity and specificity, from both PD and MSA. In conclusion, MoCA is more sensitive 
than MMSE in detecting cognitive impairment in atypical parkinsonisms, and together with 
its verbal fluency subitem is a useful test to support PSP diagnosis. 
Interestingly, results of the longitudinal study in Chapter 4 strengthened these previous 
observations — PSP showed a more pronounced cognitive decline than MSA and PD 
particularly in the executive and language domains with more cases developing dementia. 
Verbal fluencies tasks and particularly phonemic fluency were severely impaired. 
MoCA was more sensitive in detecting cognitive changes in PSP, while MMSE was 
better in PD.  
Taken together these findings mirror the different distribution of the underlying 
pathology among the parkinsonian disorders. In PSP, tau-pathology involves both cortical 
and subcortical structures (from the frontal cortex to the dentate nucleus of the 
cerebellum) (Hauw et al., 1994; Williams et al., 2007). By contrast, MSA is characterized by 
alterations primarily in subcortical structures, and cortical pathology is not considered as a 
Chapter 7 
 
 156 
predominant feature (Papp & Lantos, 1994), indeed, the cortical involvement can possibly 
be secondary to subcortical abnormalities. 
Our findings show similar cognitive profiles in MSA and PD consistent with previous 
evidence (Lee et al., 2012). Our PD cohort had relatively short disease duration 
(approximately 8 years) and the proportion of PDD is in line with the literature (Hely et al., 
2008). In MSA, dementia is infrequent, and it is reported only in patients with disease 
duration longer than 13 years (Petrovic et al., 2012). 
In conclusion, the findings of the first two studies recommend the use of cognitive 
assessments to support differential diagnosis in atypical parkinsonisms, and to better 
understand the underlying pathology and its progression. 
In the third part of the thesis (chapters 5 and 6), I investigated structural changes in 
synucleinopathies and the relationship with cognitive impairment. Several neuroimaging 
studies investigated the basis of cognitive deficits in PD (see Section 2.3.1), but recent 
evidence suggests synergistic contribution of amyloid to synuclein pathology (see Section 
2.2.1). 
Hence, the study presented in Chapter 5 was driven by the hypothesis that amyloid 
depositions in PD is a vulnerability factor and may facilitate the spread of synuclein 
aggregates.  
Our analyses focused on the frontostriatal circuit and executive dysfunctions that are 
known to be altered since the disease’s early stages (Lewis et al., 2003). 
High amyloid levels in early-PD, measured by [18F]florbetaben PET, were associated 
with: a) reduced striatal dopaminergic deficits (as expressed by higher striatal DAT 
binding). b) a tendency to show more frequent cognitive dysfunctions and increased brain 
atrophy rates (i.e., in frontal and occipital regions). 
Notably, our results are consistent with recent neuropathological findings suggesting 
synaptic axonal damage and dysfunction in PD (Tagliaferro & Burke, 2016). Thus, we 
speculate that the interaction between synuclein and the coincident amyloid pathology, can 
further contribute to axonal vulnerability leading to a more ‘malignant prognosis’ (Irwin et 
al., 2013). 
A growing body of literature also suggests MSA − like the other synucleinopathies − 
frequently experience cognitive deficits, although dementia is still considered a non-
supporting feature for the diagnosis of MSA. Thus, the experimental study reported in 
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Chapter 6 was aimed at investigating the neuroanatomical basis underpinning cognitive 
dysfunction in MSA (see Section 2.3.2). 
Our results showed that in MSA, focal reduction in the left DLPFC region is associated 
with the presence of cognitive alterations. Interestingly, the pattern underlying cognitive 
dysfunctions is focal and in the frontal region, which is different from PD, where cognitive 
deficits are associated with widespread cortical atrophies involving both frontal and 
posterior regions (Biundo et al., 2016a). Taken together, these observations suggest only a 
marginal contribution of cortical pathology to cognitive dysfunctions in MSA, revealing 
that cognitive alterations are driven by focal frontostriatal degeneration in line with the 
concept of ‘subcortical cognitive impairment’. 
In conclusion, the findings of the last two-neuroimaging studies in the synucleinopathies 
suggest that cognitive dysfunctions in MSA and PD are related to distinct underlying 
mechanisms. Cognitive deficits in MSA are associated with focal frontal atrophy, probably 
secondary to striato-pallido-thalamo-cortical circuits, while in PD the broader involvement 
of the frontal as well as more posterior regions may reflect the synergistic effect between 
synuclein and amyloid pathology. 
In MSA, Kim and others (2013) showed limited contribution of amyloid pathology on 
cognition function — but further studies will be necessary to better investigate this issue.  
In summary, all the experiments proposed in the present thesis highlight that cognitive 
alterations have a distinct pattern among the parkinsonian disorders, and together with 
clinical and neuroimaging evaluation, provides an essential contribution in the diagnostic 
process and in predicting clinical outcome.  
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APPENDIX I Diagnostic criteria for Parkinson’s disease. From Gelb et al, 1999. 
 
Grouping of clinical features of Parkinson’s disease according to diagnostic utility 
GROUP A: Features characteristic of Parkinson’s disease 
Resting tremor 
Bradykinesia 
Rigidity 
Asymmetric onset 
 
GROUP B: Features suggestive of alternative diagnoses 
Features unusual early in the clinical course 
Prominent postural instability in the first 3 years after symptom onset 
Freezing phenomena in the first 3 years 
Hallucinations unrelated to medications in the first 3 years 
Dementia preceding motor symptoms or in the first year 
Supranuclear gaze palsy (other than restriction of upward gaze) or slowing of vertical saccades 
Severe, symptomatic dysautonomia unrelated to medications 
Documentation of a condition known to produce parkinsonism and plausibly connected to the patient’s symptoms (such as 
suitably located focal brain lesions or neuroleptic use within the past 6 months) 
 
 
Criteria for POSSIBLE diagnosis of Parkinson’s disease 
 
At least 2 of the 4 features in Group A are present; at least 1 of these is tremor or bradykinesia 
And either: 
None of the features in Group B is present 
or symptoms have been present for less than 3-year and none of the features in Group B is present to date 
And either: 
Substantial and sustained response to levodopa or a dopamine agonist has been documented 
or patient has not had an adequate trial of levodopa or dopamine agonist 
 
 
Criteria for PROBABLE diagnosis of Parkinson’s disease 
 
At least 3 of the 4 features in Group A are present 
and  
None of the features in Group B is present (note: symptom duration of at least 3 years is needed to meet this requirement) 
and  
Substantial and sustained response to levodopa or a dopamine agonist has been documented 
 
 
Criteria for DEFINITE diagnosis of Parkinson’s disease 
 
All criteria for POSSIBLE Parkinson’s disease are met 
and  
Histopathological confirmation of the diagnosis is obtained at autopsy 
 
 
Proposed criteria for histopathological confirmation of Parkinson disease 
 
• Substantial nerve cell depletion with accompanying gliosis in the substantia nigra 
• At least 1 Lewy body in the substantia nigra or in the locus coeruleus (note: it may be necessary to examine up to 4 non-
overlapping sections in each of these areas before concluding that Lewy bodies are absent) 
• No pathological evidence for other diseases that produce parkinsonism (progressive supranuclear palsy, multiple system 
atrophy, corticalbasal ganglionic degeneration) (Note: in excluding other diseases that produce Parkinsonism, published 
consensus criteria should be used when available) 
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APPENDIX II Diagnostic criteria for multiple system atrophy. From Gilman et al. 2008. 
 
 
 
Criteria for POSSIBLE MSA 
 
A sporadic, progressive, adult (>30 y)–onset disease characterized by: 
• Parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or 
• A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction) and 
• At least one feature suggesting autonomic dysfunction (otherwise unexplained urinary urgency, frequency or incomplete 
bladder emptying, erectile dysfunction in males, or significant orthostatic blood pressure decline that does not meet the level 
required in probable MSA) and 
• At least one of the additional features: 
 
 
Criteria for the diagnosis of PROBABLE MSA 
 
A sporadic, progressive, adult (>30 y)–onset disease characterized by: 
• Autonomic failure involving urinary incontinence (inability to control the release of urine from the bladder, with erectile 
dysfunction in males) or an orthostatic decrease of blood pressure within 3 min of standing by at least 30 mmHg systolic or 15 
mmHg diastolic and 
• Poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or 
• A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction) 
 
Additional features of POSSIBLE MSA 
 
Possible MSA-P or MSA-C 
● Babinski sign with hyperreflexia 
● Stridor 
Possible MSA-P 
● Rapidly progressive parkinsonism 
● Poor response to levodopa 
● Postural instability within 3 y of motor onset 
● Gait ataxia, cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction 
● Dysphagia within 5 y of motor onset 
● Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum 
● Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum 
Possible MSA-C 
● Parkinsonism (bradykinesia and rigidity) 
● Atrophy on MRI of putamen, middle cerebellar peduncle, or pons 
● Hypometabolism on FDG-PET in putamen 
● Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET 
 
 
Criteria for DEFINITE MSA 
 
Neuropathologic findings of widespread and abundant CNS synuclein–positive glial cytoplasmic inclusions (Papp– Lantos 
inclusions) in association with neurodegenerative changes in striatonigral or olivopontocerebellar structures 
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APPENDIX III Diagnostic criteria for Progressive supranuclear palsy. From Höglinger et 
al. 2017. 
 
Basic features 
B1: Mandatory 
inclusion criteria 
 
1. Sporadic occurrence 
2. Age 40 or older at onset of first PSP-related symptom 
3. Gradual progression of PSP-related symptoms 
B2: Mandatory 
exclusion criteria 
 
Clinical findings 
1. Predominant, otherwise unexplained impairment of episodic memory, suggestive of AD 
2. Predominant, otherwise unexplained autonomic failure, e.g., orthostatic hypotension (orthostatic 
reduction in blood pressure after 3 minutes standing 30mmHg systolic or 15mmHg diastolic), 
suggestive of multiple system atrophy or Lewy body disease 
3. Predominant, otherwise unexplained visual hallucinations or fluctuations in alertness, suggestive of 
dementia with Lewy bodies 
4. Predominant, otherwise unexplained multisegmental upper and lower motor neuron signs, 
suggestive of motor neuron disease (pure upper motor neuron signs are not an exclusion criterion) 
5. Sudden onset or step-wise or rapid progression of symptoms, in conjunction with corresponding 
imaging or laboratory findings, suggestive of vascular etiology, autoimmune encephalitis, metabolic 
encephalopathies, or prion disease 
6. History of encephalitis 
7. Prominent appendicular ataxia 
8. Identifiable cause of postural instability, e.g., primary sensory deficit, vestibular dysfunction, severe 
spasticity, or lower motor neuron syndrome  
Imaging findings 
1. Severe leukoencephalopathy, evidenced by cerebral imaging 
2. Relevant structural abnormality, e.g., normal pressure or obstructive hydrocephalus; basal ganglia, 
diencephalic, mesencephalic, pontine or medullary infarctions, hemorrhages, hypoxic-ischemic 
lesions, tumors, or malformations 
B3: Context dependent 
exclusion criteria 
 
Imaging findings 
1. In syndromes with sudden onset or step-wise progression, exclude stroke, cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) or severe 
cerebral amyloid angiopathy, evidenced by diffusion-weighted imaging (DWI), fluid attenuated 
inversion recovery, or T2*-MRI 
2. In cases with very rapid progression, exclude cortical and subcortical hyperintensities on DWI-MRI 
suggestive of prion disease  
Laboratory findings 
1. In patients with PSP-CBS, exclude primary AD pathology (typical CSF constellation [i.e., both 
elevated total tau/phospho-tau protein and reduced beta-amyloid 42] or pathological beta-amyloid PET 
imaging) 
2. In patients aged<45 years, exclude 
a. Wilson’s disease (e.g., reduced serum ceruloplasmin, reduced total serum copper, increased copper 
in 24-hour urine, and Kayser-Fleischer corneal ring) 
b. Niemann-Pick disease, type C (e.g., plasma cholestan-3ß,5a,6ß-triol level, filipin test on skin 
ibroblasts) 
c. Hypoparathyroidism 
d. Neuroacanthocytosis (e.g., Bassen-Kornzweig, Levine Critchley, McLeod disease) 
e. Neurosyphilis 
3. In rapidly progressive patients, exclude 
a. Prion disease (e.g., elevated 14-3-3, neuron-specific enolase, very high total tau protein [>1,200 
g/mL], or positive real-time quaking-induced conversion in CSF) 
b. Paraneoplastic encephalitis (e.g., anti-Ma1, Ma2 antibodies) 
4. In patients with suggestive features (i.e., gastrointestinal symptoms, arthralgias, fever, younger age, 
and atypical neurological features such as myorhythmia), exclude Whipple’s disease (e.g., T. Whipplei 
DNA polymerase chain reaction in CSF) 
Genetic findings 
1. MAPT rare variants (mutations) are no exclusion criterion, but their presence defines inherited, as 
opposed to sporadic PSP. 
2. MAPT H2 haplotype homozygosity is not an exclusion criterion, but renders the diagnosis unlikely. 
3. LRRK2 and Parkin rare variants have been observed in patients with autopsy confirmed PSP, but 
their causal relationship is unclear so far. 
4. Known rare variants in other genes are exclusion criteria, because they may mimic aspects of PSP 
clinically, but differ neuropathologically; these include: 
a. Non-MAPT associated frontotemporal dementia (e.g., C9orf72, GRN, FUS, TARDBP, VCP, 
CHMP2B); b. PD (e.g., SYNJ1, GBA); c. AD (APP, PSEN1, PSEN2); d. Niemann-Pick disease, type 
C (NPC1, NPC2); e. Kufor-Rakeb syndrome (ATP13A2); f. Perry syndrome (DCTN1); g. 
Mitochondrial diseases (POLG, mitochondrial rare variants); h. Dentatorubral pallidoluysian atrophy 
(ATN1); i. Prion-related diseases (PRNP); j. Huntington’s disease (HTT); k. Spinocerebellar ataxia 
(ATXN1, 2, 3, 7, 17). 
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Core clinical features 
Functional Domain 
Levels of 
Certainty 
Ocular Motor 
Dysfunction Postural Instability Akinesia 
Cognitive 
Dysfunction 
Level 1 
O1: 
Vertical supranuclear 
gaze palsy 
P1: 
Repeated unprovoked 
falls within 3 years 
A1: 
Progressive gait 
freezing within 3 years 
C1: 
Speech/language 
disorder, i.e., 
nonfluent/agrammatic 
variant of primary 
progressive aphasia or 
progressive apraxia of 
speech 
Level 2 
O2: 
Slow velocity of 
vertical saccades 
P2: 
Tendency to fall on the 
pull-test within 3 years 
A2: 
Parkinsonism, akinetic-
rigid, predominantly 
axial, and levodopa 
resistant 
C2: 
Frontal 
cognitive/behavioral 
presentation 
Level 3 
O3: 
Frequent macro square 
wave jerks or ‘eyelid 
opening apraxia’ 
P3: 
More than two steps 
backward on the pull-
test within 3 years 
A3: 
Parkinsonism, with 
tremor and/or 
symmetric and/or 
levodopa responsive 
C3: 
Corticobasal syndrome 
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Operationalized definitions of core clinical features, supportive clinical clues, and supportive imaging findings 
Ocular motor dysfunction 
O1 Vertical supranuclear gaze palsy A clear limitation of the range of voluntary gaze in the vertical more than 
in the horizontal plane, affecting both up- and downgaze, more than 
expected for age, which is overcome by activation with the vestibulo-
ocular reflex; at later stages, the vestibulo-ocular reflex may be lost, or 
the maneuver prevented by nuchal rigidity. 
 
O2 Slow velocity of vertical saccades Decreased velocity (and amplitude) of vertical greater than horizontal 
saccadic eye movements; this may be established by quantitative 
measurements of saccades, such as infrared oculography, or by bedside 
testing; gaze should be assessed by command (‘Look at the flicking 
finger’) rather than by pursuit (‘Follow my finger’), with the target >20 
degrees from the position of primary gaze; to be diagnostic, saccadic 
movements are slow enough for the examiner to see their movement (eye 
rotation), rather than just initial and final eye positions in normal 
subjects; a delay in saccade initiation is not considered slowing; findings 
are supported by slowed or absent fast components of vertical 
optokinetic nystagmus (i.e., only the slow following component may be 
retained). 
 
O3 Frequent macro square wave jerks 
or ‘eyelid opening apraxia’ 
 
Macro square wave jerks are rapid involuntary saccadic intrusions during 
fixation, displacing the eye horizontally from the primary position, and 
returning it to the target after 200 to 300 milliseconds; most square wave 
jerks are <1 degree in amplitude and rare in healthy controls, but up to 3 
to 4 degrees and more frequent (>10/min) in PSP. ‘Eyelid opening 
apraxia’ is an inability to voluntarily initiate eyelid opening after a 
period of lid closure in the absence of involuntary forced 
eyelid closure (i.e., blepharospasm); the term is written in quotation 
marks because the inability to initiate eyelid opening is often attributed 
to activation of the pretarsal component of the orbicularis oculi (i.e., 
pretarsal blepharospasm) rather than failure to activate the levator 
lpebrae. 
 
Postural instability 
P1 Repeated unprovoked falls within 
3 years 
 
Spontaneous loss of balance while standing, or history of more than one 
unprovoked fall, within 3 years after onset of PSP-related features. 
 
P2 Tendency to fall on the pull-test 
within 3 years 
 
Tendency to fall on the pull-test if not caught by examiner, within 3 
years after onset of PSP-related features. The test examines the response 
to a quick, forceful pull on the shoulders with the examiner standing 
behind the patient and the patient standing erect with eyes open and feet 
comfortably apart and parallel, as described in the MDS-UPDRS item 
3.12. 
 
P3 More than two steps backward on 
the pull-test within 3 years 
 
More than two steps backward, but unaided recovery, on the pull-test, 
within 3 years after onset of PSP-related features. 
 
Akinesia 
A1 Progressive gait freezing within 
3 years 
 
Sudden and transient motor blocks or start hesitation are predominant 
within 3 years after onset of PSP-related symptoms, progressive and not 
responsive to levodopa; in the early disease course, akinesia may be 
present, but limb rigidity, tremor, and dementia are absent or mild. 
 
A2 Parkinsonism, akinetic-rigid, 
predominantly axial and 
levodopa resistant 
Bradykinesia and rigidity with axial predominance, and levodopa 
resistance (see in next page, Clinical Clue CC1 for operationalized 
definition). 
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Cognitive dysfunction 
 
C1 Speech/language disorder Defined as at least one of the following features, which has to be 
persistent (rather than transient): 
1. Nonfluent/agrammatic variant of primary progressive aphasia 
(nfaPPA) or Loss of grammar and/or telegraphic speech or writing 
2. Progressive apraxia of speech (AOS) Effortful, halting speech with 
inconsistent speech sound errors and distortions or slow syllabically 
segmented prosodic speech patterns with spared single-word 
comprehension, object knowledge, and word retrieval during sentence 
repetition. 
 
C2 Frontal cognitive/behavioral 
presentation 
 
Defined as at least three of the following features, which have to be 
persistent (rather than transient): 
1. Apathy Reduced level of interest, initiative, and spontaneous 
activity; clearly apparent to informant or patient. 
2. Bradyphrenia Slowed thinking; clearly apparent to informant or 
patient. 
3. Dysexecutive syndrome E.g., reverse digit span, Trails B or Stroop 
test, Luria sequence (at least 1.5 standard deviations below mean of age- 
and education-adjusted norms). 
4. Reduced phonemic verbal fluency E.g., ‘D, F, A, or S’ words per 
minute (at least 1.5 standard deviations below mean of 
age- and education-adjusted norms). 
5. Impulsivity, disinhibition, or perseveration E.g., socially inappropriate 
behaviors, overstuffing 
the mouth when eating, motor recklessness, 
applause sign, palilalia, echolalia. 
 
C2 CBS Defined as at least one sign each from the following two groups (may be 
asymmetric or symmetric): 
1. Cortical signs  
a. Orobuccal or limb apraxia. 
b. Cortical sensory deficit. 
c. Alien limb phenomena. 
(more than simple levitation). 
2. Movement disorder signs  
a. Limb rigidity. 
b. Limb akinesia. 
c. Limb myoclonus. 
 
Clinical clues 
CC1 Levodopa resistance Levodopa resistance is defined as improvement of the MDS-UPDRS 
motor scale by _30%; to fulfill this criterion patients should be assessed 
having been given at least 1,000 mg (if tolerated) at least 1 month OR 
once patients have received this treatment they could be formally 
assessed following a challenge dose of at least 200 mg. 
 
CC2 Hypokinetic, spastic dysarthria Slow, low volume and pitch, harsh voice. 
 
CC3 Dysphagia Otherwise unexplained difficulty in swallowing, severe enough to 
request dietary adaptations. 
 
CC4 Photophobia Intolerance to visual perception of light attributed to adaptative 
dysfunction. 
 
Imaging findings 
IF1 Predominant midbrain atrophy or 
hypometabolism 
Atrophy or hypometabolism predominant in midbrain relative to pons, as 
demonstrated, e.g., by MRI or [18F]DG-PET. 
 
IF2 Postsynaptic striatal dopaminergic 
degeneration 
Postsynaptic striatal dopaminergic degeneration, as demonstrated, e.g., 
by [123I]IBZM-SPECT or [18F]-DMFP-PET. 
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Degrees of diagnostic certainty, obtained by combinations of clinical features and clinical clues 
Diagnostic Certainty Definition Combinations Predominance Type Abbreviation 
Definite PSP Gold standard defining 
the disease entity 
 
Neuropathological 
diagnosis 
 
Any clinical presentation def. PSP 
 
Probable PSP Highly specific, but not 
very sensitive for PSP 
Suitable for therapeutic 
and biological studies 
(O1 or O2) + (P1 or P2) PSP with Richardson’s 
Syndrome 
 
prob. PSP-RS 
 
(O1 or O2) + A1 PSP with progressive 
gait freezing 
 
prob. PSP-PGF 
 
(O1 or O2) + (A2 or A3)  
 PSP with predominant 
parkinsonism 
 
prob. PSP-P 
 
(O1 or O2) + C2 PSP with predominant 
frontal presentation 
 
prob. PSP-F 
 
Possible PSP Substantially more 
sensitive, but less 
specific for PSP 
Suitable for descriptive 
epidemiological studies 
and clinical care 
 
O1 PSP with predominant 
ocular motor dysfunction 
 
poss. PSP-OM 
 
O2 + P3 PSP with Richardson’s 
syndrome 
 
poss. PSP-RS 
 
A1 PSP with progressive 
gait freezing 
 
poss. PSP-PGF 
 
(O1 or O2) + C1 PSP with predominant 
speech/ language 
disorders 
poss. PSP-SL 
 
(O1 or O2) + C3 PSP with predominant 
CBS 
poss. PSP-CBS 
 
Suggestive of PSP Suggestive of PSP, but 
not passing the threshold 
for possible or probable 
PSP 
Suitable for early 
identification 
 
O2 or O3 PSP with predominant 
ocular motor dysfunction 
s.o. PSP-OM 
 
P1 or P2 PSP with predominant 
postural 
instability 
 
s.o. PSP-PI 
 
O3 + (P2 or P3) PSP with Richardson’s 
syndrome 
s.o. PSP-RS 
 
(A2 or A3) + (O3, P1, 
P2, C1, C2, CC1, CC2, 
CC3, or CC4) 
 
PSP with predominant 
parkinsonism 
 
s.o. PSP-P 
 
C1 PSP with predominant 
speech/ 
language disorder 
 
s.o. PSP-SL 
 
C2 + (O3 or P3) PSP with predominant 
frontal 
presentation 
 
s.o. PSP-F 
 
C3 PSP with predominant 
CBS 
s.o. PSP-CBS 
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APPENDIX IV Criteria for the Diagnosis of PD-MCI. From (Litvan et al., 2012) 
 
 
I. Inclusion criteria 
• Diagnosis of Parkinson’s disease as based on the UK PD Brain Bank Criteria 
• Gradual decline, in the context of established PD, in cognitive ability reported by either the patient or informant, or 
observed by the clinician 
• Cognitive deficits on either formal neuropsychological testing or a scale of global cognitive abilities (detailed in section III) 
• Cognitive deficits are not sufficient to interfere significantly with functional independence, although subtle difficulties on 
complex functional tasks may be present 
 
II. Exclusion criteria 
• Diagnosis of PD dementia based on MDS Task Force proposed criteria18 
• Other primary explanations for cognitive impairment (e.g., delirium, stroke, major depression, metabolic abnormalities, 
adverse effects of medication, or head trauma) 
• Other PD-associated comorbid conditions (e.g., motor impairment or severe anxiety, depression, excessive daytime 
sleepiness, or psychosis) that, in the opinion of the clinician, significantly influence cognitive testing 
 
III. Specific guidelines for PD-MCI Level I and Level II categories 
 
A. Level I (abbreviated assessment) 
• Impairment on a scale of global cognitive abilities validated for use in PD or 
• Impairment on at least two tests, when a limited battery of neuropsychological tests is performed (i.e., the battery includes 
less than two tests within each of the five cognitive domains, or less than five cognitive domains are assessed) 
 
B. Level II (comprehensive assessment) 
• Neuropsychological testing that includes two tests within each of the five cognitive domains (i.e., attention and working 
memory, executive, language, memory, and visuospatial) 
• Impairment on at least two neuropsychological tests, represented by either two impaired tests in one cognitive domain or one 
impaired test in two different cognitive domains 
• Impairment on neuropsychological tests may be demonstrated by: 
o Performance approximately 1 to 2 SDs below appropriate norms or 
o Significant decline demonstrated on serial cognitive testing or 
o Significant decline from estimated premorbid levels 
 
IV. Subtype classification for PD-MCI (optional, requires two tests for each of the five cognitive domains assessed and is 
strongly suggested for research purposes) 
 
• PD-MCI single-domain—abnormalities on two tests within a single cognitive domain (specify the domain), with other 
domains unimpaired or 
• PD-MCI multiple-domain—abnormalities on at least one test in two or more cognitive domains (specify the domains) 
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APPENDIX V Criteria for the Diagnosis of PDD. Emre at al. 2007 
 
 
 
Features of dementia associated with Parkinson’s disease 
I. Core features 
1. Diagnosis of Parkinson’s disease according to Queen Square Brain Bank criteria 
2. A dementia syndrome with insidious onset and slow progression, developing within the context of established Parkinson’s 
disease and diagnosed by history, clinical, and mental examination, defined as: 
• Impairment in more than one cognitive domain 
• Representing a decline from premorbid level 
• Deficits severe enough to impair daily life (social, occupational, or personal care), independent of the impairment ascribable 
to motor or autonomic symptoms 
II. Associated clinical features 
1. Cognitive features: 
• Attention: Impaired. Impairment in spontaneous and focused attention, poor performance in attentional tasks; performance 
may fluctuate during the day and from day to day 
• Executive functions: Impaired. Impairment in tasks requiring initiation, planning, concept formation, rule finding, set shifting 
or set maintenance; impaired mental speed (bradyphrenia) 
• Visuo-spatial functions: Impaired. Impairment in tasks requiring visual-spatial orientation, perception, or construction 
• Memory: Impaired. Impairment in free recall of recent events or in tasks requiring learning new material, memory usually 
improves with cueing, recognition is usually better than free recall 
• Language: Core functions largely preserved. Word finding difficulties and impaired comprehension of complex sentences 
may be present 
2. Behavioral features: 
• Apathy: decreased spontaneity; loss of motivation, interest, and effortful behavior 
• Changes in personality and mood including depressive features and anxiety 
• Hallucinations: mostly visual, usually complex, formed visions of people, animals or objects 
• Delusions: usually paranoid, such as infidelity, or phantom boarder (unwelcome guests living in the home) delusions 
• Excessive daytime sleepiness 
III. Features which do not exclude PD-D, but make the diagnosis uncertain 
• Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause of 
dementia, e.g. presence of relevant vascular disease in imaging 
• Time interval between the development of motor and cognitive symptoms not known 
IV. Features suggesting other conditions or diseases as cause of mental impairment, which, when present make it 
impossible to reliably diagnose PD-D 
• Cognitive and behavioral symptoms appearing solely in the context of other conditions such as: 
Acute confusion due to 
a. Systemic diseases or abnormalities 
b. Drug intoxication 
Major Depression according to DSM IV 
• Features compatible with ‘Probable Vascular dementia’ criteria according to NINDS-AIREN (dementia in the context of 
cerebrovascular disease as indicated by focal signs in neurological exam such as hemiparesis, sensory deficits, and evidence 
of relevant cerebrovascular disease by brain imaging AND a relationship between the two as indicated by the presence of 
one or more of the following: onset of dementia within 3 months after a recognized stroke, abrupt deterioration in cognitive 
functions, and fluctuating, stepwise progression of cognitive deficits) 
 
Criteria for the diagnosis of probable and possible PDD 
Probable PDD 
A. Core features: Both must be present 
B. Associated clinical features: 
• Typical profile of cognitive deficits including impairment in at least two of the four core cognitive domains (impaired 
attention which may fluctuate, impaired executive functions, impairment in visuo-spatial functions, and impaired free 
recall memory which usually improves with cueing) 
• The presence of at least one behavioral symptom (apathy, depressed or anxious mood, hallucinations, delusions, 
excessive daytime sleepiness) supports the diagnosis of Probable PD-D, lack of behavioral symptoms, however, does not 
exclude the diagnosis 
C. None of the group III features present 
D. None of the group IV features present 
Possible PD-D 
A. Core features: Both must be present 
B. Associated clinical features: 
• Atypical profile of cognitive impairment in one or more domains, such as prominent or receptive-type (fluent) aphasia, 
or pure storage-failure type amnesia (memory does not improve with cueing or in recognition tasks) with preserved attention 
• Behavioral symptoms may or may not be present 
OR 
C. One or more of the group III features present 
D. None of the group IV features present 
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APPENDIX VI Algorithm for diagnosing PDD at Level I. From Dubois et al., 2007 
 
 
 
1      A diagnosis of Parkinson’s disease based on the Queen’s Square Brain Bank     
        criteria for PD 
2      PD developed prior to the onset of dementia 
3      MMSE below 26 
4      Cognitive deficits severe enough to impact daily living 
        (Caregiver interview or Pill Questionnaire) 
5      Impairment in at least two of the following tests: 
        - Months reversed or Seven backward 
        - Lexical fluency or Clock drawing 
        - MMSE Pentagons 
        - 3-Word recall 
The presence of one of the following behavioral symptoms: apathy or depressed mood or elusions16 
or excessive daytime sleepiness may support the diagnosis of probable PD-D. 
The presence of major depression or delirium or any other abnormality, which may by itself cause 
significant cognitive impairment makes the diagnosis uncertain. 
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